
<html lang="en"     class="pb-page"  data-request-id="0b78f827-653f-4717-bcfb-c032ed278560"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b01578;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2017.60.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase" /></meta><meta name="dc.Creator" content="Alessio  De Simone" /></meta><meta name="dc.Creator" content="Debora  Russo" /></meta><meta name="dc.Creator" content="Gian Filippo  Ruda" /></meta><meta name="dc.Creator" content="Alessandra  Micoli" /></meta><meta name="dc.Creator" content="Mariarosaria  Ferraro" /></meta><meta name="dc.Creator" content="Rita Maria Concetta  Di Martino" /></meta><meta name="dc.Creator" content="Giuliana  Ottonello" /></meta><meta name="dc.Creator" content="Maria  Summa" /></meta><meta name="dc.Creator" content="Andrea  Armirotti" /></meta><meta name="dc.Creator" content="Tiziano  Bandiera" /></meta><meta name="dc.Creator" content="Andrea  Cavalli" /></meta><meta name="dc.Creator" content="Giovanni  Bottegoni" /></meta><meta name="dc.Description" content="We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 ..." /></meta><meta name="Description" content="We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 2, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01578" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01578" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01578" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01578" /></link>
        
    
    

<title>Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01578" /></meta><meta property="og:title" content="Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0013.jpeg" /></meta><meta property="og:description" content="We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH–D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1. To understand the unexpected affinity for the CB1 receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound 33 was selected for PK studies because it displayed balanced affinities for the main targets and clear selectivity over the two off-targets. 33 has good stability and oral bioavailability and can cross the blood–brain barrier." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01578"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01578">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01578&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01578&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01578&amp;href=/doi/10.1021/acs.jmedchem.6b01578" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2287-2304</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01478" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01568" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of <i>O</i>-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessio++De+Simone">Alessio De Simone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Debora++Russo">Debora Russo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gian+Filippo++Ruda">Gian Filippo Ruda</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessandra++Micoli">Alessandra Micoli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mariarosaria++Ferraro">Mariarosaria Ferraro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rita+Maria+Concetta++Di+Martino">Rita Maria Concetta Di Martino</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giuliana++Ottonello">Giuliana Ottonello</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Summa">Maria Summa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Armirotti">Andrea Armirotti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tiziano++Bandiera">Tiziano Bandiera</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2496-2701" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Cavalli">Andrea Cavalli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giovanni++Bottegoni">Giovanni Bottegoni</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>○</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-1251-583X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1.0"><span class="aff-text"><sup>†</sup>CompuNet, and <sup>‡</sup>PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">FaBit, Università di Bologna, 40127 Bologna, Italy</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">BiKi Technologies, 16163 Genova, Italy</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#a7c0cec8d1c6c9c9ce89c5c8d3d3c2c0c8c9cee7cfc2d7d3c6d5c2d489c4c8ca"><span class="__cf_email__" data-cfemail="5b3c32342d3a3535327539342f2f3e3c3435321b333e2b2f3a293e2875383436">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01578&amp;href=/doi/10.1021%2Facs.jmedchem.6b01578" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2287–2304</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 9, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 October 2016</li><li><span class="item_label"><b>Published</b> online</span>2 March 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 March 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01578" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01578</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2287%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlessio%2BDe%2BSimone%252C%2BDebora%2BRusso%252C%2BGian%2BFilippo%2BRuda%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D6%26contentID%3Dacs.jmedchem.6b01578%26title%3DDesign%252C%2BSynthesis%252C%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%252C%2Band%2BThree-Dimensional%2BQuantitative%2BStructure%25E2%2580%2593Activity%2BRelationship%2B%25283D-QSAR%2529%2BModeling%2Bof%2Ba%2BSeries%2Bof%2BO-Biphenyl%2BCarbamates%2Bas%2BDual%2BModulators%2Bof%2BDopamine%2BD3%2BReceptor%2Band%2BFatty%2BAcid%2BAmide%2BHydrolase%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2304%26publicationDate%3DMarch%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01578"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1982</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01578" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, Structure–Activity Relationship Studies, and Three-Dimensional Quantitative Structure–Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alessio&quot;,&quot;last_name&quot;:&quot;De Simone&quot;},{&quot;first_name&quot;:&quot;Debora&quot;,&quot;last_name&quot;:&quot;Russo&quot;},{&quot;first_name&quot;:&quot;Gian&quot;,&quot;last_name&quot;:&quot;Filippo Ruda&quot;},{&quot;first_name&quot;:&quot;Alessandra&quot;,&quot;last_name&quot;:&quot;Micoli&quot;},{&quot;first_name&quot;:&quot;Mariarosaria&quot;,&quot;last_name&quot;:&quot;Ferraro&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Maria Concetta Di Martino&quot;},{&quot;first_name&quot;:&quot;Giuliana&quot;,&quot;last_name&quot;:&quot;Ottonello&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Summa&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Armirotti&quot;},{&quot;first_name&quot;:&quot;Tiziano&quot;,&quot;last_name&quot;:&quot;Bandiera&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Cavalli&quot;},{&quot;first_name&quot;:&quot;Giovanni&quot;,&quot;last_name&quot;:&quot;Bottegoni&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;2287-2304&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01578&quot;},&quot;abstract&quot;:&quot;We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH–D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1. To understand the unexpected affinity for the CB1 receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound 33 was selected for PK studies because it displayed balanced affinities for the main targets and clear se&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01578&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01578" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01578&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01578" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01578&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01578" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01578&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01578&amp;href=/doi/10.1021/acs.jmedchem.6b01578" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01578" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01578" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01578%26sid%3Dliteratum%253Aachs%26pmid%3D28182408%26genre%3Darticle%26aulast%3DDe%2BSimone%26date%3D2017%26atitle%3DDesign%252C%2BSynthesis%252C%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%252C%2Band%2BThree-Dimensional%2BQuantitative%2BStructure%25E2%2580%2593Activity%2BRelationship%2B%25283D-QSAR%2529%2BModeling%2Bof%2Ba%2BSeries%2Bof%2BO-Biphenyl%2BCarbamates%2Bas%2BDual%2BModulators%2Bof%2BDopamine%2BD3%2BReceptor%2Band%2BFatty%2BAcid%2BAmide%2BHydrolase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D6%26spage%3D2287%26epage%3D2304%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/jmcmar.2017.60.issue-6/20170323/jmcmar.2017.60.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-<i>N</i>-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH–D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB<sub>1.</sub> To understand the unexpected affinity for the CB<sub>1</sub> receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound <b>33</b> was selected for PK studies because it displayed balanced affinities for the main targets and clear selectivity over the two off-targets. <b>33</b> has good stability and oral bioavailability and can cross the blood–brain barrier.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multitarget-directed ligands (MTDLs) are small organic molecules purposely designed to interact with multiple biological targets.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Developed within the framework of polypharmacology, the basic concept behind this relatively novel but already consolidated approach is quite simple: when a single molecule modulates multiple selected targets, it can have synergistic efficacy, milder side effects, and a lower probability of triggering resistance or drug–drug interactions. MTDLs may thus overcome the limitations of the traditional “one drug, one target” approach.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> MTDLs can be seen as a straightforward way to put into practice the insights of network medicine, which approaches the etiology and, possibly, the treatment of diseases as perturbations of complex and interconnected signaling pathways.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Thus, research on MTDLs has traditionally focused on treating complex and multifaceted conditions such as neurodegeneration,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> cancer,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> and infectious diseases.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">We recently began investigating the possibility of developing MTDLs to treat tobacco addiction. Responsible for over five million deaths every year, tobacco smoking is the single most common cause of avoidable death in Western countries.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Tobacco contains harmful chemicals that are directly connected to about 33% of all cancer deaths, including about 90% of all cases of lung cancer, the most deadly form of cancer.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, the actual addiction to tobacco is caused by the alkaloid nicotine.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Nicotine elevates the dopaminergic tone in specific areas of the brain, including the ventral tegmental area (VTA) and the nucleus accumbens (NAc). These areas belong to the mesocorticolimbic system, a brain circuit that is critical in natural and drug-induced reward and motivated behavior. This is nicotine’s best understood effect, and it is mediated by interaction with nicotinic acetylcholine receptors (nAChRs) in the brain.</div><div class="NLM_p">Nicotine’s effects have also been associated with alterations in most of the main neurotransmitter systems, including biogenic amines, amino acid transmitters such as glutamate and γ-aminobutyric acid (GABA), opioids, and endocannabinoids.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> For example, the activity of dopamine neurons in the VTA is regulated by nAChR-expressing glutamatergic and GABAergic neurons. In this circuit, the balance between the stimulating and repressing actions of the two neurotransmitters is crucial for modulating dopamine levels in the NAc. Moreover, presynaptic CB<sub>1</sub> receptors located on GABAergic fibers or on glutamatergic interneurons have been shown to abolish GABA-dependent tonic inhibition of dopamine neurons, facilitating nicotine actions.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> This profound and widespread modification of multiple neurotransmitter levels is conducive to a complex behavioral condition dominated by withdrawal symptoms, craving, drug-seeking, and reinforcing effects. This complexity may explain why none of the currently proposed pharmacological treatments for nicotine addiction have long-lasting efficacy.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Varenicline, a nicotine receptor partial agonist, and bupropion, a norepinephrine-dopamine reuptake inhibitor and nicotine receptor antagonist, are marketed drugs for the treatment of nicotine addiction.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> These molecules have shown promising results in counteracting nicotine cravings and withdrawal symptoms. However, as mentioned, their effectiveness in promoting long-term abstinence avoiding relapse is quite limited. Furthermore, their mechanism of action, based on directly interfering with the cholinergic transmission in various brain areas connected to reward and gratification, is likely responsible for the mild to intense severity of the side effects (e.g., eating disorders, suicidal thoughts) associated with treatments based on these molecules.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> For these reasons, nicotine addiction remains a largely unmet medical need, hence, our idea of tackling nicotine addiction by means of MTDLs that can concurrently modulate the dopamine receptor subtype D3 (D3R) and the human fatty acid amide hydrolase (FAAH), likely eliciting enduring effects. D3R is a G-protein-coupled receptor that is predominantly expressed in the mesocorticolimbic system. For many years, D3R has been the focus of synthetic chemistry campaigns to develop drugs to treat addiction and compulsive behaviors.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Specific overexpression of D3R has been observed in nicotine-exposed brains and is a common feature of drug addictions.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Earlier studies focused on developing antagonists, while more recent investigations have sought to develop potent and selective partial agonists.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Pharmacologically, partial agonists are more appealing because they provide a functional response, which depends on dopamine levels in the mesolimbic area. In the absence of dopamine (after withdrawal), a partial agonist would act as a functional agonist with lower intrinsic efficacy. In the presence of the natural substrate, it would functionally antagonize dopamine binding to D3R, preventing the reinstatement of nicotine-induced signaling circuits. In contrast, pure D3R antagonists are of limited use in alleviating withdrawal symptoms, but they are more effective in reducing craving, drug-seeking, relapse, and reinforcement effects.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> FAAH inhibition has only recently been considered as a potential strategy for treating addiction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> FAAH’s physiological role is to terminate the endocannabinoid (EC) signaling by cleaving anandamide (AEA), one of the agonists of the endogenous CB<sub>1</sub> receptor (CB<sub>1</sub> R).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Interestingly, while considerable evidence has emerged that directly links the endocannabinoid system to nicotine addiction, FAAH’s role is likely to be mediated by non-cannabinoid signaling pathways.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> FAAH is also responsible for cleaving two more substrates: oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), which are endogenous agonists of the nuclear receptor PPAR-α. Activating PPAR-α stimulates the activation of tyrosine kinases, which in turn leads to the phosphorylation and negative regulation of neuronal nAChR. Inhibiting FAAH in order to maintain artificially high levels of OEA and PEA thus appears to be a reasonable strategy for pharmacologically counteracting the effects of nicotine.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Furthermore, region-specific FAAH inhibition leads to increased levels of EC, with the potential of modulating in a more effective way nicotine-related behaviors as compared to effects observed after ubiquitous activation of CB<sub>1</sub>Rs by direct agonists, suggesting that selective alterations of FAAH activity in limbic regions of the brain could have a key role in the development of addictive behaviors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Increased AEA levels due to FAAH inhibition can likely activate CB<sub>1</sub> receptors on glutamatergic neurons that, in turn, negatively modulate dopamine release in NAc, interfering with the creation of the addiction cycle. Last, the activation of CB<sub>1</sub>R has been associated with anxiolytic effects, which can be useful in the treatment of negative emotional states during withdrawal.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Inhibition by FAAH inhibitor URB597 was recently reported to prevent self-administration and cue- and substance-induced reinstatement in animal models of nicotine addiction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In 2014, we reported the first set of rationally designed compounds endowed with potent in vitro activities against these two targets. Our compounds turned out to be potent FAAH inhibitors and D3R partial agonists.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> While the <i>O</i>-naphthyl carbamate series of compounds, exemplified by <b>1</b> (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), was fairly selective with respect to the investigated off-targets, the biphenyl-bearing molecules <b>2</b> and <b>3</b> displayed unexpected and potent activity at CB<sub>1</sub> R (EC<sub>50</sub> of 0.3 nM and 0.9 nM, respectively). Here, we report on an extensive SAR exploration of a series of biphenyl <i>N</i>-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, which helped identify the structural drivers for the desired activities at the two targets. This study also helped rationalize activities at the investigated off-targets, pointing to potential strategies for designing more selective compounds.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported <i>O</i>-biphenyl carbamates with dual D3R and FAAH activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of the compounds are largely based on well-described reactions. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> reports the synthetic pathway used to prepare the final carbamate derivatives. Amines with general structure <b>7</b> were obtained by alkylation of arylpiperazine derivatives <b>5</b> with different commercially available bromoalkylphthalimides <b>6</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>; see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Supporting Information</a> for details). The obtained phthalimides were deprotected by treatment with hydrazine. In the final step, the obtained amines were activated as isocyanates by reaction with a slight excess of Boc anhydride and 4-dimethylaminopyridine (DMAP) in acetonitrile. These were then reacted with the appropriate phenol derivatives to produce the various final carbamates. An alternative procedure involved activating the amine derivative with <i>p</i>-nitrophenyl chloroformate and then reacting with the phenolic derivatives.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Compounds <b>16</b>–<b>29</b>, <b>32</b>–<b>37</b>, and <b>40</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub>, reflux, 6 h. Yields: 83–99%. (b) Hydrazine monohydrate, MeOH, 80 °C, 2 h, then 2 N HCl, 1 h. Yields: 53–88%. (c) ArOH, (Boc)<sub>2</sub>O, DMAP, CH<sub>3</sub>CN, rt, 23 h. Yields: 7–50%. (d) ArOH, <i>p</i>-nitrophenyl chloroformate, DIPEA, DMA/DCM 1:1, rt, overnight. Yields: 10–26%.</p></p></figure><div class="NLM_p">For the synthesis of the noncommercially available phenolic derivatives, different procedures were applied and are outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Biphenyl alcohols of general formula <b>10</b> were prepared with a modified Suzuki cross-coupling reaction<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> between commercially available aryl halides and boronic acid derivatives <b>8</b> and <b>9</b>, in the presence of a catalytic amount of palladium acetate in a medium of water and ethylene glycol monomethyl ether (EGME). This procedure provided the desired products in high yield and with good reproducibility. When R<sub>3</sub> is a methoxy group, this procedure is ineffective for the steric hindrance of this group on the halogen atom. In these attempts, PdCl<sub>2</sub>(dppf) was used as a catalyst (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>; see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Noncommercially Available Phenolic Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, EGME/H<sub>2</sub>O, rt, 5 min. Yields: 58–97%. (b) PdCl<sub>2</sub>(dppf), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/water 3:1, 90 °C, 3 h. Yield: 48% (average of two attempts).</p></p></figure><div class="NLM_p">To synthesize analogues bearing an alkene in the linker (<b>30</b>, <b>31</b>), the synthesis started from <i>trans</i>-1,4-dichloroalkene <b>12</b> and potassium phthalimide <b>11</b> to yield intermediate <b>13</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Then, reaction with arylpiperazine <b>5</b> and deprotection with hydrazine afforded the desired amine <b>15</b> in good yields. The amine was used in a reaction with biphenolic derivatives <b>10b</b>,<b>c</b> (prepared using the same conditions reported in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) in the presence of Boc<sub>2</sub>O and DMAP to obtain the carbamate derivative <b>30</b> and <b>31</b>, as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to Alkenyl Derivatives <b>30</b> and <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, rt, under nitrogen atmosphere, overnight. Yield: 67%. (b) 1-(2,3-dichlorophenyl)piperazine, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 6 h. Yield: 83%. (c) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, MeOH, then 2 N HCl, reflux, 3 h. Yield: 88%. (d) Boc<sub>2</sub>O, DMAP, MeCN, rt, 20–25 h. Yields: <b>30</b>, 16%; <b>31</b>, 22%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The newly synthesized compounds fit into the general structure reported in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure of the newly synthesized dual D3R FAAH modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We sought to characterize the SAR for this class of compounds by introducing different substituents on the aromatic ring of the arylpiperazine and investigating both meta (<i>m</i>-) biphenyl-bearing and para (<i>p</i>-) biphenyl-bearing compounds. We also considered the role of the carboxamide in the distal ring of the <i>O-</i>biphenyl moiety. Finally, we studied a limited set of variants by exploring substituents of the proximal ring in the biphenyl group as well as the role of the alkyl spacer. We evaluated the biological activities of the reported compounds as FAAH inhibitors and D3R modulators by means of a fluorescent assay and a cellular functional assay, respectively. To manage our resources, we only assessed compounds for selectivity for D2R and CB<sub>1</sub>R if they were also characterized by reasonable activities at the main targets (FAAH IC<sub>50</sub> < 60 nM, D3R EC<sub>50</sub> < 100 nM, and no more than 2 orders of magnitude less potent than <b>4</b>; D3R efficacy of <75% as compared to 300 nM dopamine, as we were interested in developing D3R partial agonists). Considering our starting point in the biphenyl series, we sought an initial selectivity ratio with respect to the investigated off-targets of at least 1 order of magnitude. The results are reported in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Results of the SAR Studies</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">As of 300 nM dopamine.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Activity (FAAH, D3R, CB<sub>1</sub>) and efficacy (D3R) data as reported in ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Antagonist.</p></div></div><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR Studies</h3><div class="NLM_p">We further investigated the properties of the <i>m</i>-biphenyl series by introducing the classic 2-methoxy substituent in the arylpiperazine in the presence of three- (<b>16</b>) and four-methylene-unit (<b>17</b>) linkers.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> With respect to <b>2</b> and <b>3</b>, their 2,3-di-Cl-substituted counterparts, both derivatives maintained potent activities at the main targets (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), with the 2-methoxy substituent being only slightly detrimental for D3R activity. In line with results reported for <b>2</b> and <b>3</b>, <b>16</b> and <b>17</b> were also potent CB<sub>1</sub>R agonists with 1.4 nM and 2.3 nM EC<sub>50</sub> values, respectively. Derivatives <b>18</b> and <b>19</b>, displaying a naked pendent aromatic ring, maintained potent and balanced activities at both targets, but their D3R activation profile switched significantly toward a full agonist effect. Eliminating the carboxamide in the distal <i>m</i>-biphenyl ring in <b>20</b> severely reduced the activity against D3R.</div><div class="NLM_p">The results for <b>4</b> suggested that a potent dual modulator profile devoid of selectivity problems could be achieved by introducing a <i>p</i>-biphenyl group at the O-side of the carbamate. We therefore turned our attention to derivatives bearing this moiety. Reducing the length of the linker of <b>4</b> to three methylene units (<b>21</b>) was not detrimental for activities at the main targets (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, while over 50-fold selectivity over D2R could be obtained, <b>21</b> displayed 6.1 nM EC<sub>50</sub> at CB<sub>1</sub>R. Studying the effect of substituents in the aromatic ring of the arylpiperazine, we observed that when we introduced a 2-methoxy group in combination with a three-methylene-unit linker, compound <b>22</b> maintained potent activities at FAAH and D3R but did not achieve selectivity toward both off-targets. When the same substitution was coupled with a longer linker (<b>23</b>), activity at D3R was maintained and activity at FAAH was only slightly affected. Notably, activity at CB<sub>1</sub>R decreased by up to 320 nM. Introducing smaller substituents at position 2, as with the 2-methyl-bearing (<b>24</b>) and 2-trifluoromethyl-bearing (<b>25</b>) derivatives, did not affect activity at the two targets but did lead to increased efficacy at D3R, shifting activity closer to a full agonist profile. Compound <b>24</b> had moderate 18-fold selectivity toward D2R and acceptable selectivity with respect to CB<sub>1</sub>R (4.0 nM EC<sub>50</sub> at D3R and 52 nM EC<sub>50</sub> at CB<sub>1</sub>R). Consistently and in line with the results obtained with the <i>m</i>-biphenyl derivatives, compound <b>26</b>, bearing a naked phenyl ring, behaved almost like a full agonist (88% efficacy).</div><div class="NLM_p">We also introduced some substituents in the proximal ring of the biphenyl moiety. To address possible solubility issues, we introduced a fluorine atom, which endowed <b>27</b> with subnanomolar inhibitory potency against FAAH. However, activity at D3R (18 nM EC<sub>50</sub>) was almost 20 times less than that observed for <b>4</b>. Most importantly, this derivative displayed no selectivity with respect to the off-targets. As previously reported by Moreno-Sanz and co-workers, a methoxyl group introduced in the proximal ring of the biphenyl should further improve inhibitory potency at FAAH without compromising brain penetration.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Indeed, <b>28</b> turned out to be a potent FAAH inhibitor (2.7 nM IC<sub>50</sub>), but its efficacy at D3R shifted toward pure agonism. Conversely, when this substitution was coupled with a 2-methoxyl substituent in the arylpiperazine (<b>29</b>), the partial D3R agonist profile was restored but inhibitory activity at FAAH decreased quite substantially (63 nM IC<sub>50</sub>). Introducing an unsaturation in the linker (<b>30</b>) decreased activity at D3R (EC<sub>50</sub> 37.8 nM) while maintaining activity at FAAH (IC<sub>50</sub> = 1.2 nM). Introducing a fluorine group in the proximal biphenyl ring (<b>31</b>) restored activity at D3R in the single digit nanomolar range. Interestingly, <b>30</b> and <b>31</b> behaved as D3R antagonists. As expected in light of classic studies of D3R modulators,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the presence of a central trans double-bond in the linker lowered the affinity for D2R, which decreased with respect to the saturated analogues from 23 nM (<b>4</b>) to 147 nM (<b>30</b>) and from 13.7 nM (<b>27</b>) to 66.2 nM (<b>31</b>). However, neither <b>30</b> nor <b>31</b>, with EC<sub>50</sub> values of 20 nM and 9.2 nM, respectively, displayed selectivity toward CB<sub>1</sub>R.</div><div class="NLM_p">To assess the effects of the carboxamide in the distal ring of the biphenyl region, we synthesized and tested several compounds lacking this substituent. Activity data are reported in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and systematically compared to those of the carboxamide-bearing analogues. 2,3-Di-Cl-substituted arylpiperazine compounds <b>32</b> and <b>33</b> were characterized by potent activities at FAAH in line with those of <b>21</b> and <b>4</b>. In <b>32</b>, activity at D3R decreased with respect to <b>21</b> (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>); consistently, in <b>33</b>, D3R EC<sub>50</sub> increased from 1.0 nM to 18 nM. In terms of selectivity, an acceptable ratio could be achieved for D2R. Remarkably, activity at CB<sub>1</sub>R dropped substantially in <b>32</b> (EC<sub>50</sub> = 70 nM) with respect to <b>21</b> and decreased in <b>33</b> by over 2 orders of magnitude (EC<sub>50</sub> = 1500 nM) with respect to <b>4</b>. The 2-methoxy substituted compound <b>34</b> preserved potent and balanced activities at both main targets, but its efficacy shifted toward an agonist profile (D3R efficacy 82%). In the four-methylene-unit linker analog <b>35</b>, activities decreased at both targets, with FAAH IC<sub>50</sub> equal to 39 nM and D3R EC<sub>50</sub> equal to 330 nM (efficacy 85%). In agreement with the behavior of <b>35</b>, introducing a 2-methyl (<b>36</b>) or a 2-trifluoromethyl (<b>37</b>) group in the pendent aromatic ring of the carboxamide-lacking derivatives led to a significant drop in D3R activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p">In light of these results, we propose a first rationale for the chemical features required for a balanced and potent activity at FAAH and D3R. Substitutions on the pendent aromatic ring of the arylpiperazine were required for a partial agonist profile against D3R. In the presence of a saturated linker, bulkier substituents shifted the efficacy profile toward antagonism. Regarding the linker, the four-methylene-unit linker resulted in lower activation of D3R than the three-methylene-unit linker and was thus preferred in order to have partial agonist derivatives. By introducing a central trans double-bond to increase the system’s rigidity, we obtained D3R antagonists. These results are in qualitative agreement with previous studies by Newman and colleagues on how substitutions at the terminal aromatic ring, in combination with different linkers, can affect efficacy.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Regarding FAAH, a longer linker, especially when combined with a bulkier substituent in position 2, led to a drop in activity. This may be due to a more constrained fit in the binding pocket region known as the acyl chain binding channel. At the O-side of the carbamate, the distal phenyl ring could be placed in both the <i>m-</i> and <i>p-</i>positions of the proximal ring without affecting the potencies against the two main targets. For the <i>p-</i>biphenyl derivatives, a substituent in the meta position of the proximal phenyl ring could be inserted without dramatically altering activities. The carboxamide substituent on the distal ring revealed a beneficial role in the affinity for D3R, possibly because of an H-bond interaction with Thr92, which was consistently suggested by our previous docking experiments.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, while consistent across the series, the loss in D3R affinity due to the deletion of the carboxamide was less severe for compounds with the 2,3-di-Cl-substitution in the arylpiperazine. In FAAH, the activity of our derivatives was only marginally affected by the presence of the carboxamide, although the reported activities of known inhibitors URB524 (naked biphenyl group in the O-side of the carbamate, FAAH IC<sub>50</sub> = 63 nM)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and URB597 (carboxamide substituted biphenyl ring, FAAH IC<sub>50</sub> = 4.6 nM)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> had suggested this would not be the case. This was probably due to the presence of an elongated substituent at the N-side of the carbamate, which is here the key structural driver for the FAAH inhibitory effect.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> These SAR considerations are summarized in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of the results of SAR studies performed on different regions of the synthesized derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Selectivity at the Off-Targets</h3><div class="NLM_p">Twelve derivatives that showed a promising activity profile for the main targets were assessed for selectivity for D2R and CB<sub>1</sub>R. For D2R, some general considerations can be outlined. With the sole exception of <b>27</b>, in which affinities for D3R and D2R were almost equivalent, our compounds had greater affinity for D3R than for D2R. This is not surprising, given that the original concept for these compounds was to introduce a carbamate as a conservative variation of a classic D3R-selective pharmacophore.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The aryl carbamate protrudes outside the orthosteric binding site in a region defined by the extracellular loop 3 and transmembrane helices I, II, and VII (secondary binding site). Selectivity can be obtained by exploiting subtle differences in both side chain and backbone rearrangements in this region.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Selectivity over D2R decreased (i) in <i>p</i>-biphenyl derivatives with respect to their <i>m</i>-biphenyl counterparts, (ii) in molecules bearing a shorter linker, and (iii) in 2-methoxy substituted molecules (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Again, this is consistent with previously reported studies indicating that selectivity for D3R over D2R is affected by the nature and (most importantly) orientation of the portion of the molecule in contact with the secondary binding site.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In turn, this orientation varies in the two receptor subtypes depending on the substituents **in the arylpiperazine and the linker length. While the present study did not match the remarkable D2R/D3R selectivity ratio that characterized our previously described derivatives <b>2</b> and <b>3</b>, as well as classic arylamide-based D3R modulators reported in the literature,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> several compounds obtained did display sufficient selectivity.</div><div class="NLM_p">From a structural perspective, the CB<sub>1</sub>R activity data was more puzzling. A three-unit linker usually led to increased activity at CB<sub>1</sub>R so long as it was coupled to the carboxamide substituent in the distal phenyl ring. The presence of this substituent was the structural feature exerting the more evident effect, as suggested by activity data on <b>32</b> and <b>33</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). We hypothesized that these results could be interpreted within the framework of the classic SAR of CB<sub>1</sub>R agonists.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> reports the structures of four prototypical CB<sub>1</sub>R agonists, namely Δ<sup>9</sup>-THC (<b>38</b>, CB<sub>1</sub>R EC<sub>50</sub> 10.2 nM), HU-210 (<b>39</b>, CB<sub>1</sub>R EC<sub>50</sub> 0.73 nM), JWH-051 (<b>40</b>, CB<sub>1</sub>R EC<sub>50</sub> 1.2 nM), and JWH-133 (<b>41</b>, CB<sub>1</sub>R EC<sub>50</sub> 667 nM).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of four CB<sub>1</sub>R agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">No crystal structure of an agonist-bound CB<sub>1</sub>R was available when we conducted our study; however, several reports have suggested that the aliphatic chain of classic CB<sub>1</sub>R agonists lays perpendicular to the plane of the tricyclic system.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> This is also consistent with the pose adopted by Δ<sup>9</sup>-THC docking studies carried out at the recently reported crystal structure of antagonist-bound CB<sub>1</sub>R.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Using as a template a conformation of the subnanomolar agonist <b>39</b> that reflected this arrangement, we performed an APF-based structural alignment (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>) and generated an overlapping conformation of <b>4</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The resulting structural alignment, with the biphenyl group matching the tricyclic system, is particularly evocative, as the classic SAR of THC analogs could be applied to our molecules. First, the presence of a hydroxyl group in position 1 (<b>38</b>) is very important for eliciting potent activity. Another hydrogen bond donor/acceptor group in position 11 can further increase activity (<b>39</b>) or can maintain activity if the hydroxyl group in 1 is removed (<b>40</b>). The removal of both hydrogen bond donor groups is detrimental for activity, as exemplified by <b>41</b>. This would explain the strong effect of the carboxamide substituent. Second, the aliphatic chain of CB<sub>1</sub>R agonists can be modified quite substantially without compromising activity, even if elongated or decorated with bulky pendants. Hence, it stands to reason that linker and arylpiperazine could be lodged in the corresponding region without compromising activity. Finally, it has been reported that CB<sub>1</sub>R activity is modulated by the planarity of the tricyclic system, with more planar systems being less active and more susceptible to the effect of the substitutions in positions 1 and 11, respectively. To further test the hypothesis that CB<sub>1</sub>R activity can be explained by the classic SAR of THC analogs, we synthesized three novel compounds (<b>42</b>–<b>44</b>), introducing a flat aromatic group at the O-side of the carbamate. Potent and selective D3R modulators displaying rigid tricyclic systems have already been reported.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Computational studies to rationalize activity at CB<sub>1</sub>R: (A) APF-based superimposition of <b>4</b> and <b>39</b>, using the putative receptor-bound conformation of the latter as a rigid template; (B) 3D alignment of the 18 molecules included in the training set; (C) equipotential contours of the H-bond acceptor (red) and H-bond donor (blue) APF components; (D) equipotential contours of the sp<sup>2</sup> carbon atom hybridization APF component (white); (E) equipotential contours of the lipophilicity APF component (green); (F) correlation plot between pIC<sub>50exp</sub> and pIC<sub>50pred</sub>. The structures of the predicted compounds (red dots) are reported explicitly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As expected, CB<sub>1</sub>R activity was significantly reduced in all three derivatives (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>): <b>42</b>, EC<sub>50</sub> = 380 nM; <b>43</b>, EC<sub>50</sub> = 370 nM; and <b>44</b>, EC<sub>50</sub> = 2300 nM. However, <b>42</b> and <b>43</b> displayed reduced activity at D3R (D3R EC<sub>50</sub> of 150 nM and 120 nM, respectively), and <b>44</b> coupled an only mild selectivity over D2R (D2R/D3R selectivity ratio equal to 4.8) with a reduced activity against FAAH (FAAH IC<sub>50</sub> = 37 nM). Therefore, we did not investigate further carbazole-bearing derivatives.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activity Data of the Carbazole-Based Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">As of 300 nM dopamine.</p></div></div><div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> 3D-QSAR Studies</h3><div class="NLM_p">At this point, we attempted a 3D-QSAR analysis to systematically describe, at the structural level, the CB<sub>1</sub> R activity in our series and to prospectively test our hypothesis. This 3D-QSAR analysis was carried out by means of the atom property fields (APF) methods originally developed by Totrov (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A set of 18 molecules, encompassing <b>2</b>–<b>4</b>, <b>16</b>, <b>17</b>, <b>21</b>–<b>24</b>, <b>27</b>, <b>29</b>–<b>33</b>, and <b>42</b>–<b>44</b>, namely, all molecules which had been tested for CB<sub>1</sub>R activity, were automatically aligned to the previously generated conformation of <b>4</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). For each molecule, we generated a set of seven three-dimensional continuous potentials, representative of seven molecular properties (namely, presence of a hydrogen bond donor, presence of a hydrogen bond acceptor, sp<sup>2</sup> carbon atom hybridization, charge, lipophilicity, size, and electropositivity/negativity), approximated on a set of regularly spaced grids. Each molecule could thus be expressed by 126 descriptors: the pseudoenergy values generated by the molecule’s fit in each of the 7 property fields of the 18 compounds in the training set. Each descriptor was assigned a weight by means of a partial least-squares (PLS) fitting procedure in order to reproduce experimental activity data. Eventually, we selected 4 latent vectors (see <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Squared Correlation Coefficients (<i>R</i><sup>2</sup>) and Leave-One-out Squared Correlation Coefficients (<i>Q</i><sup>2</sup>) According to the Number of Latent Vectors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no. of latent vectors</th><th class="colsep0 rowsep0" align="center" char="."><i>R</i><sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">RMSE<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>Q</i><sup>2</sup><sub>LOO</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">RMSE<sub>LOO</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">1.04</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.87</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="char" char=".">0.48\</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Root mean squared error.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Leave-one-out.</p></div></div></div><div class="NLM_p">According to best practice, selecting roughly one latent vector for every five compounds in the training set is a good heuristic ratio for building the model in order to avoid overfitting and to achieve external validity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Furthermore, in this specific case, including more latent vectors would not have substantially increased our model’s predictive power within the set (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). By combining the activity-weighted maps from individual compounds, we can identify two key features conducive to CB<sub>1</sub>R activity: (i) the presence of a hydrogen bond donor/acceptor in the distal phenyl ring of the biphenyl group (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C) and (ii) an extended and not completely flat ring system (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D). This is consistent with our previously reported findings that compounds bearing a naphthyl group at the O-side of the carbamate display much lower CB<sub>1</sub>R activities. Given the structural homogeneity of the training set, other features (such as the hydrogen bond donor/acceptor signal in carbamate region or the strong lipophilic signal generated by the arylpiperazine tail (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E)) are consistent with the data but not very informative. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> reports the experimental (pEC<sub>50ex</sub>), predicted (pEC<sub>50pred</sub>), and leave-one-out cross-validated (pEC<sub>50l.o.o.</sub>) pEC<sub>50</sub> values for the training set.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Experimental, Predicted, and Leave-One-Out Cross-Validated pEC<sub>50</sub> Values for the Training Set Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">pEC<sub>50exp</sub></th><th class="colsep0 rowsep0" align="center" char=".">pEC<sub>50pred</sub></th><th class="colsep0 rowsep0" align="center" char=".">pEC<sub>50LOO</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">9.04</td><td class="colsep0 rowsep0" align="char" char=".">8.90</td><td class="colsep0 rowsep0" align="char" char=".">8.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">9.52</td><td class="colsep0 rowsep0" align="char" char=".">9.50</td><td class="colsep0 rowsep0" align="char" char=".">9.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">7.85</td><td class="colsep0 rowsep0" align="char" char=".">7.73</td><td class="colsep0 rowsep0" align="char" char=".">7.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">8.85</td><td class="colsep0 rowsep0" align="char" char=".">9.06</td><td class="colsep0 rowsep0" align="char" char=".">9.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">8.64</td><td class="colsep0 rowsep0" align="char" char=".">8.40</td><td class="colsep0 rowsep0" align="char" char=".">8.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">8.21</td><td class="colsep0 rowsep0" align="char" char=".">8.51</td><td class="colsep0 rowsep0" align="char" char=".">8.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">8.58</td><td class="colsep0 rowsep0" align="char" char=".">7.98</td><td class="colsep0 rowsep0" align="char" char=".">7.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">7.17</td><td class="colsep0 rowsep0" align="char" char=".">7.30</td><td class="colsep0 rowsep0" align="char" char=".">7.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">7.28</td><td class="colsep0 rowsep0" align="char" char=".">7.63</td><td class="colsep0 rowsep0" align="char" char=".">7.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">7.82</td><td class="colsep0 rowsep0" align="char" char=".">7.76</td><td class="colsep0 rowsep0" align="char" char=".">7.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">6.96</td><td class="colsep0 rowsep0" align="char" char=".">7.19</td><td class="colsep0 rowsep0" align="char" char=".">7.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">7.70</td><td class="colsep0 rowsep0" align="char" char=".">7.74</td><td class="colsep0 rowsep0" align="char" char=".">7.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">8.04</td><td class="colsep0 rowsep0" align="char" char=".">7.74</td><td class="colsep0 rowsep0" align="char" char=".">7.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">7.15</td><td class="colsep0 rowsep0" align="char" char=".">7.12</td><td class="colsep0 rowsep0" align="char" char=".">6.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">5.82</td><td class="colsep0 rowsep0" align="char" char=".">6.48</td><td class="colsep0 rowsep0" align="char" char=".">6.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">6.42</td><td class="colsep0 rowsep0" align="char" char=".">6.73</td><td class="colsep0 rowsep0" align="char" char=".">7.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">6.43</td><td class="colsep0 rowsep0" align="char" char=".">6.02</td><td class="colsep0 rowsep0" align="char" char=".">5.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">5.63</td><td class="colsep0 rowsep0" align="char" char=".">5.33</td><td class="colsep0 rowsep0" align="char" char=".">5.10</td></tr></tbody></table></div></div><div class="NLM_p last">The model was internally very consistent with a <i>R</i><sup>2</sup> equal to 0.92 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>F) and a root mean squared error (RMSE) of 0.30. No compound emerged as a clear outlier. The leave-one-out (LOO) procedure for cross-validation returned a still predictive <i>Q</i><sup>2</sup> of 0.79 (RMSE = 0.51, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Again, no predicted activity departed by more than 1 order of magnitude from the experimental value.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Prospective Validation of the 3D-QSAR Model</h3><div class="NLM_p">Finally, in order to prospectively challenge our hypothesis and confirm that the SAR for classic CB<sub>1</sub>R agonists applies to our molecules, we designed three novel compounds and used the APF-based 3D-QSAR model to predict their activities at the CB<sub>1</sub>R receptor. This is particularly relevant because our model was generated from a limited number of molecules. Our design concept for compounds <b>45</b>–<b>47</b> was to introduce small structural variations of <b>33</b> in order to retain its selectivity against CB<sub>1</sub>R, avoiding hydrogen bond donor/acceptor groups in the distal biphenyl ring while introducing substitutions in the proximal one (see <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biological Data of 3D-QSAR Predicted and Synthesized Molecules</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0012.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">As of 300 nM dopamine.</p></div></div><div></div></div><div class="NLM_p last">Substitutions in the proximal ring (i) are generally well-tolerated in FAAH and help improve the solubility profile<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and (ii) are detrimental for CB<sub>1</sub>R activity when coupled with a lack of hydrogen bond donor/acceptor groups (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>F reports the fitting of <b>45</b>–<b>47</b> in the global APF maps generated by the molecules of the training set. We then synthesized and tested these compounds. Predictions were generally in good agreement with the experimental data (red circles in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>F). For <b>45</b> and <b>46</b>, the experimental activities matched the predictions remarkably well. Furthermore, these two molecules were endowed with potent and balanced activities at the main targets with a clear partial agonist profile at D3R. Although their affinity for CB<sub>1</sub>R increased with respect to <b>33</b>, the selectivity profile remained acceptable because of these potency values and actually improved in <b>46</b>. In <b>47</b>, while still rather accurate, the model suggested a slightly less potent molecule (pEC<sub>50pred</sub> = 6.50) than the experimental result (pEC<sub>50pred</sub> = 7.03, <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Here, the selectivity with respect to CB<sub>1</sub>R was also compromised by decreased potency at the main targets.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Preliminary Pharmacokinetics Characterization and Selectivity Profiling of <b>33</b></h3><div class="NLM_p">Given its promising activity at the main targets, its physicochemical profile (molecular weight, 498; polar surface area, 46.1; calculated log <i>P</i>, 5.48), and its selectivity profile at off-targets known from previous studies, we selected <b>33</b> as the new lead compound for further pharmacokinetics (PK) studies and selectivity profile characterization. First, we assessed how <b>33</b> remained stable in rat plasma for over an hour with an average <i>t</i><sub>1/2</sub> of 97 ± 13 min (<i>n</i> = 3). The compound was also stable in rat liver microsomes (<i>t</i><sub>1/2</sub> > 60 min, <i>n</i> = 3). PK analyses in rats showed that <b>33</b> possessed good oral bioavailability and blood–brain barrier (BBB) penetration. After dosing <b>33</b> intravenously and orally, we monitored plasma concentrations for 8 h. After intravenous dosing (3 mg kg<sup>–1</sup>), we measured a maximal plasma concentration of 500 ng mL<sup>–1</sup> (5 min time point). The half-life of <b>33</b> for the elimination phase was 145 min. Compound <b>33</b> showed a volume of distribution of 23.7 l kg<sup>–1</sup> and disappeared from the systemic circulation with a clearance of 0.11 l min<sup>–1</sup> kg<sup>–1</sup>. After oral administration (10 mg kg<sup>–1</sup>), the maximal plasma concentration of <b>33</b> (54 ng mL<sup>–1</sup>) was observed 120 min after dosing. The oral bioavailability of <b>33</b> was 21%. BBB penetration of this compound was also measured for the per os arm of the study (10 mg mL<sup>–1</sup>): <b>33</b> reached a maximum concentration of 37 ng mL<sup>–1</sup> of brain homogenate, 4 h after oral administration; the total brain exposure (AUC) was quantified in 84.5 ng min mL<sup>–1</sup> (see also <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Figure S1 in the Supporting Information</a>). It can be calculated that <b>33</b> reaches a total brain concentration of approximately 391 nM, more than adequate to effectively engage the target (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><div class="NLM_p last">In terms of selectivity, we reasoned that CB<sub>1</sub>R and D2R were off-targets selected based on the compound’s alleged mechanism of action. Next, we decided to begin expanding the polypharmacological profile of <b>33</b> investigating its activity at off-targets selected based on the compound structure. Displaying an arylpiperazine, which is a privileged moiety for interacting with aminergic receptors,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> we tested the activity of <b>33</b> at this class of GPCRs starting from β adrenergic receptors subtypes β<sub>1</sub> and β<sub>2</sub> and serotonergic receptor subtypes 5-HT<sub>1A</sub> and 5-HT<sub>1b</sub>. In binding experiments, <b>33</b> turned out to be selective with respect to both β adrenergic receptor subtypes and 5-HT<sub>1b</sub>. Interestingly a moderate affinity for 5-HT<sub>1A</sub> could be detected (60.4% inhibition of the binding of a labeled radioligand at 100 nM; see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Supporting Information</a> for details). On the same line, as <b>33</b> bears an aryl carbamate, which is a warhead exploited by several compounds to interact with hydrolases, we tested <b>33</b> for activity at monoacylglycerol lipase (MAGL). We selected this classic serine hydrolase, since it is responsible for over 80% of the degradation of 2-arachidonoylglycerol (2-AG), another key mediator together with AEA in the cannabinoid transmission.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> On the basis of high-resolution mass spectrometry data, we were able to conclude that <b>33</b> exerts irreversible covalent inhibition at FAAH but not at MAGL. Experimental details are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">Supporting Information</a>. While further studies will be necessary to describe the complete pharmacological fingerprint of <b>33</b>, and possibly other members of this series, it is tempting to speculate that this class of compounds could share some common features with the structurally related antipsychotic drug aripiprazole, which has been recently investigated for the treatment of addiction.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we conducted the first exploration of the SAR of a series of biphenyl <i>N</i>-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates. Within the MTDL framework, these molecules were purposely designed to exert a combined activity at the FAAH enzyme and the D3 receptor. Ideally, the concurrent modulation of these two targets should produce an enhanced therapeutic profile for treating addiction (in particular, nicotine addiction) and compulsive behaviors in general. We have rationalized the structural features conducive to activities at the main targets and we have investigated activities at two off-targets, D2R and CB<sub>1</sub>R. In light of structural insights previously reported by other authors, it was quite straightforward to explain activity at (and selectivity over) D2R. In contrast, concerted modeling and synthetic efforts were required to understand the remarkable affinity for CB<sub>1</sub>R displayed by our first set of biphenyl derivatives. Using a prospectively validated 3D-QSAR model, we proposed that our molecules behave like classic THC-based CB<sub>1</sub>R agonists. This knowledge could be used to design out unwanted affinity at CB<sub>1</sub>R. One derivative, <b>33</b>, was endowed with quite balanced affinities for the two targets and was fairly selective over the two off-targets. This molecule was stable in plasma and in the presence of rat liver microsomes. Upon oral administration, <b>33</b> showed moderate oral bioavailability and crossed the blood–brain barrier. In light of these results, we conclude that this class of compounds has potential for further development. Future efforts will be devoted to (i) assessing the effects of more radical structural variations on the original scaffold, (ii) carrying out a much broader characterization of off-target activities,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> including other dopamine receptor subtypes, monoamine receptors and transporters, and hERG, and (iii) testing the efficacy of these compounds in in vivo models of nicotine addiction and other compulsive behaviors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">a Chemistry. Chemicals, Materials, and Methods</h3><div class="NLM_p">Abbreviations used in the description of the examples that follow are the following: acetonitrile (MeCN); ammonium chloride (NH<sub>4</sub>Cl); BnBr (benzyl bromide); carbonyldiimidazole (CDI); cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>); cyclohexane (Cy); chloroform (CHCl<sub>3</sub>); deuterated chloroform (CDCl<sub>3</sub> or chloroform-<i>d</i>); deuterated dimethylsulfoxide (DMSO-<i>d</i><sub>6</sub>); dichloromethane (DCM); dimethylsulfoxide (DMSO); <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA); dimethylacetamide (DMA); di-<i>tert</i>-butyl dicarbonate (Boc<sub>2</sub>O); 4-(dimethylamino)pyridine (DMAP); ethylene glycol monomethyl ether (EGME); ethanol (EtOH); electrospray (ES); ethyl acetate (EtOAc); hydrochloric acid (HCl); mass spectrometry (MS); microwave (MW); sulfuric acid (H<sub>2</sub>SO<sub>4</sub>); iodomethane (MeI); <i>N</i>,<i>N</i>-dimethylformamide (DMF); lithium hydroxide (LiOH); magnesium sulfate (MgSO<sub>4</sub>); methanol (MeOH); nuclear magnetic resonance (NMR); room temperature (rt); palladium acetate (Pd(OAc)<sub>2</sub>); potassium carbonate (K<sub>2</sub>CO<sub>3</sub>); sodium bicarbonate (NaHCO<sub>3</sub>); tetrabutylammonium iodide (TBAI); triethylsilane (TES); tetrahydrofuran (THF); thin layer chromatography (TLC); triethylamine (Et<sub>3</sub>N); and trifluoroacetic acid (TFA).</div><div class="NLM_p">Automated column chromatography purifications were conducted using a Teledyne ISCO apparatus (CombiFlashTM Rf) with prepacked silica gel columns of different sizes (from 4 g to 120 g). Mixtures of increasing polarity of cyclohexane and ethyl acetate or dichloromethane and methanol were used as eluents. Preparative TLCs were performed using Macherey-Nagel precoated 0.05 mm TLC plates (SIL G-50 UV254). Hydrogenation reactions were performed using H-Cube continuous hydrogenation equipment (SS-reaction line version), using disposable catalyst cartridges (CatCart) preloaded with the required heterogeneous catalyst. Microwave heating was performed using Explorer-48 positions instrument (CEM). NMR experiments were run on a Bruker Avance III 400 system (400.13 MHz for <sup>1</sup>H, and 100.62 MHz for <sup>13</sup>C), equipped with a BBI probe and Z-gradients. Spectra were acquired at 300 K, using deuterated dimethylsulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterated chloroform (CDCl<sub>3</sub>) as solvents. Chemical shifts for <sup>1</sup>H and <sup>13</sup>C spectra were recorded in parts per million using the residual nondeuterated solvent as the internal standard (for CDCl3: 7.26 ppm, <sup>1</sup>H and 77.16 ppm, <sup>13</sup>C; for DMSO-<i>d6</i>: 2.50 ppm, <sup>1</sup>H; 39.52 ppm, <sup>13</sup>C).</div><div class="NLM_p">UPLC/MS analyses were run on a Waters ACQUITY UPLC/MS system consisting of a SQD (single quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. PDA range was 210–400 nm. Electrospray ionization was applied in positive and negative modes. UPLC mobile phases were (A) 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O, pH 5, and (B) 10 mM NH<sub>4</sub>OAc in MeCN/H<sub>2</sub>O (95:5), pH 5. Analyses were performed with method A, B, or C as reported below.</div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Method A (Generic)</h4><div class="NLM_p last">Gradient: 5–95% B over 3 min. Flow rate 0.5 mL/min. Temp 40 °C. Precolumn: Vanguard BEH C18 (1.7 μm, 2.1 mm × 5 mm). Column: BEH C18 (1.7 μm. 2.1 mm × 50 mm).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Method B (Polar)</h4><div class="NLM_p last">Gradient: 0–50% B over 3 min. Flow rate 0.5 mL/min. Temp 40 °C. Precolumn: VanGuard HSS T3 C18 (1.7 μm, 2.1 mm × 5 mm). Column HSS T3 (1.8 μm, 2.1 mm × 50 mm)</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Method C (Apolar)</h4><div class="NLM_p">Gradient: 50–100% B over 3 min. Flow rate 0.5 mL/min. Temp 40 °C. Precolumn: Vanguard BEH C18 (1.7 μm, 2.1 mm × 5 mm). Column: BEH C18 (1.7 μm, 2.1 mm × 50 mm)</div><div class="NLM_p last">Purifications by preparative HPLC/MS were run on a Waters autopurification system consisting of a 3100 single quadrupole mass spectrometer equipped with an electrospray ionization interface and a 2998 photodiode array detector. The HPLC system included a 2747 sample manager, 2545 binary gradient module, system fluidic organizer, and 515 HPLC pump. PDA range was 210–400 nm. Purifications were performed on an XBridgeTM Prep C18 OBD column (100 mm × 19 mm i.d., particle size 5 μm) with an XBridgeTM Prep C18 (10 mm × 19 mm i.d., particle size 5 μm) guard cartridge. Mobile phases were 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in MeCN–H<sub>2</sub>O (95:5) at pH 5 (B). Electrospray ionization was used in positive and negative modes. Analyses by chiral HPLC were run on a Waters Alliance HPLC instrument consisting of an e2695 separation module and a 2998 photodiode array detector. PDA range was 210–400 nm. Analyses were performed isocratically on a Daicel ChiralPak AD column (250 mm × 4.6 mm i.d., particle size 10 μm). Mobile phase was 0.1% TFA heptane–2-propanol (75:25). Separations by preparative chiral HPLC were run on a Waters Alliance HPLC instrument consisting of a 1525 binary HPLC pump, Waters fraction collector III, and a 2998 photodiode array detector. UV detection was at 240 nm. Purifications were performed isocratically on a Daicel ChiralPak AD column (250 ,, × 10 mm i.d., particle size 10 μm). Mobile phase was 0.1% TFA heptane–2-propanol (75:25).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure 1 for the Synthesis of the Arylpiperazine Amine Derivatives <b>7a</b>–<b>j</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h3><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step A</h4><div class="NLM_p last">A mixture of arylpiperazine·HCl (1 equiv), <i>N</i>-(bromoalkyl)phthalimide (1.1 equiv), and base (K<sub>2</sub>CO<sub>3</sub> or triethylamine, 3 equiv) in acetonitrile was heated to reflux for 6 h. The hot suspension was filtered and the residue washed with acetone several times. The filtrates were concentrated under reduced pressure to give the phthalimide intermediates.</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step B</h4><div class="NLM_p last">The phthalimide derivative (1 equiv) and hydrazine hydrate (1.2 equiv) in methanol were heated to reflux for 2 h. To the hot solution was added 2 N HCl, and reflux was continued for one more hour. After cooling to ambient temperature, the mixture was filtered, the residue washed with methanol, and the filtrate evaporated to dryness. This residue was suspended in water and neutralized with 2 N NaOH. Extraction with EtOAc afforded an oily product, which was pure enough for the next step.</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure 2 for the Synthesis of Phenolic Derivatives <b>9a</b>–<b>h</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h3><div class="NLM_p last">Commercially available arylboronic acid derivative (1.2 equiv) was added to a solution of the appropriate aryl halide (1 equiv) in EGME/water 3:1, followed by the addition of Pd(OAc)<sub>2</sub> (0.01 equiv) and K<sub>2</sub>CO<sub>3</sub> (2.5 equiv). After a few minutes, the yellowish suspension turned dark-black and the reaction reached full conversion. The mixture was stirred for a further 5 min, then diluted with water, acidified with 2 N HCl, and extracted with DCM. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude residue was adsorbed on silica and purified by flash chromatography (eluent: 5% MeOH in DCM).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure 3 for the Synthesis of the Final Carbamate Derivatives (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h3><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Method A</h4><div class="NLM_p last">To a solution of di-<i>tert</i>-butyl dicarbonate (1.4 equiv) in acetonitrile were added in sequence a solution of DMAP (1 equiv) in acetonitrile and a solution of the appropriate amine (1 equiv) in acetonitrile. After stirring for 10 min at room temperature, the alcohol derivative (1.2–1.4 equiv) was added. The reaction mixture was stirred for 23 h at room temperature, after which the solvent was evaporated under reduced pressure. The crude residue was solubilized in ethyl acetate and washed with a saturated solution of NaHCO<sub>3</sub>. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified by flash chromatography (eluent: 5% MeOH in DCM).</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Method B</h4><div class="NLM_p last">The amine derivative (1.0 equiv) was treated with <i>p</i>-nitrophenyl chloroformate (1.1 equiv) and DIPEA (1.1 equiv) in a 1:1 mixture of DMA/DCM. The reaction mixture was stirred at ambient temperature for 30 min. To the resulting <i>p</i>-nitrophenyl carbamate solution were added the alcohol derivative (1.25 equiv) and DIPEA (1.1 equiv, 2.2 total), and the resultant mixture was stirred at room temperature overnight. The desired carbamate was isolated by removal of the undesired <i>p</i>-nitrophenol byproduct and DMA by washing several times with brine and water, collection and concentration of the organic phase, and purification by flash chromatography (eluent: 5% MeOH in DCM).</div></div></div><div id="sec5_1_4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> [3-(3-Carbamoylphenyl)phenyl] <i>N</i>-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl]carbamate (<b>16</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (115 mg, 0.53 mmol), 4-dimethylaminopyridine (64 mg, 0.53 mmol), 3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-amine (120 mg, 0.48 mmol), and 3-(3-hydroxyphenyl)benzamide (112 mg, 0.53 mmol) in acetonitrile (4 mL). White solid 70 mg (30%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.88 min, <i>m</i>/<i>z</i> 489 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18–8.14 (m, 1H), 8.14–8.07 (m, 1H), 7.90–7.85 (m, 1H), 7.85–7.79 (m, 2H), 7.61–7.46 (m, 4H), 7.45–7.38 (m, 1H), 7.17–7.11 (m, 1H), 6.96–6.83 (m, 4H), 3.76 (s, 3H), 3.14 (q, <i>J</i> = 6.8 Hz, 2H), 2.96 (s, 4H), 2.55–2.46 (m, 4H), 2.39 (t, <i>J</i> = 7.0 Hz, 2H), 1.68 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.79, 157.87, 154.31, 151.96, 141.27, 140.26, 139.20, 134.97, 129.26, 128.83, 126.96, 126.52, 125.60, 123.35, 122.30, 121.16, 120.83, 120.16, 117.87, 111.91, 55.62, 55.30, 53.03 (2C), 50.05 (2C), 39.01, 26.47. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub> 489.2475; found, 489.2494 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> [3-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate (<b>17</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (153 mg, 0.70 mmol), 4-dimethylaminopyridine (61 mg, 0.50 mmol) 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (132 mg, 0.50 mmol), and 3-(3-hydroxyphenyl)benzamide (150 mg, 0.70 mmol) in acetonitrile (4 mL). White solid 51 mg (20%). Mp: 90–94 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.90 min; <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19–8.14 (m, 1H), 8.12 (br s, 1H), 7.90–7.79 (m, 3H), 7.60–7.46 (m, 4H), 7.42 (br s, 1H), 7.16–7.10 (m, 1H), 6.96–6.83 (m, 4H), 3.76 (s, 3H), 3.18–3.06 (m, 2H), 3.04–2.88 (m, 4H), 2.57–2.44 (m, 4H), 2.39–2.26 (m, 2H), 1.62–1.42 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 157.54, 152.44, 150.49, 140.92, 140.68, 140.07, 132.79, 129.74, 128.83, 128.75, 126.62, 126.12, 122.44, 122.36, 119.69, 118.35, 117.71, 114.35, 56.72, 56.42, 52.27, 49.82, 40.36, 27.50, 25.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub> 503.2658; found 503.2667 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> [3-(3-Carbamoylphenyl)phenyl] <i>N</i>-[3-(4-Phenylpiperazin-1-yl)propyl]carbamate (<b>18</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (167 mg, 0.77 mmol), 4-dimethylaminopyridine (67 mg, 0.55 mmol), 3-(4-phenylpiperazin-1-yl)propan-1-amine (120 mg, 0.55 mmol), and 3-(3-hydroxyphenyl)benzamide (140 mg, 0.66 mmol) in acetonitrile (4 mL). White solid 40 mg (16%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.94 min; <i>m</i>/<i>z</i> 459 [M – H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19–8.14 (m, 1H), 8.12 (br s, 1H), 7.91–7.85 (m, 1H), 7.85–7.78 (m, 2H), 7.61–7.46 (m, 4H), 7.42 (br s, 1H), 7.23–7.16 (m, 2H), 7.16–7.10 (m, 1H), 6.95–6.88 (m, 2H), 6.80–6.73 (m, 1H), 3.19–3.09 (m, 6H), 2.54–2.51 (m, 4H), 2.39 (t, <i>J</i> = 7.1 Hz, 2H), 1.69 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.67, 154.28, 151.68, 151.01, 140.77, 139.18, 134.96, 129.78, 129.40, 128.97, 128.85 (2C), 126.94, 125.59, 123.33, 121.13, 120.14, 118.68, 115.26 (2C), 55.25, 52.73 (2C), 48.20 (2C), 39.32, 26.46. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> 459.2396; found 459.2409 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> [3-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-(4-Phenylpiperazin-1-yl)butyl]carbamate (<b>19</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (550 mg, 2.52 mmol), DMAP (264 mg, 2.16 mmol), 4-(4-phenylpiperazin-1-yl)butan-1-amine (420 mg, 1.8 mmol), and 3-(3-hydroxyphenyl)benzamide (460 mg, 2.16 mmol) in CH<sub>3</sub>CN (4 mL). White solid 504 mg (59%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.77 min; <i>m</i>/<i>z</i> 473 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16 (t, <i>J</i> = 1.8 Hz, 1H), 8.13 (br s, 1H), 7.90–7.84 (m, 2H), 7.82 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.60–7.52 (m, 2H), 7.51–7.46 (m, 2H), 7.44 (br s, 1H), 7.22–7.17 (m, 2H), 7.12 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.2 Hz, 2H), 6.76 (t, <i>J</i> = 7.2 Hz, 1H), 3.16–3.08 (m, 6H), 2.56–2.49 (m, 4H), 2.37–2.30 (m, 2H), 1.56–1.48 (m, 4H). <sup>13</sup>C NMR (151 MHz, DMSO) δ 167.68, 154.34, 151.72, 151.06, 140.80, 139.21, 134.98, 129.84, 129.46, 129.03, 128.90 (2C), 126.99, 125.62, 123.38, 121.21, 120.20, 118.73, 115.30 (2C), 57.50, 52.77 (2C), 48.19 (2C), 40.18, 27.25, 23.62. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> 459.2396; found 459.2409 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> [3-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate Hydrochloride (<b>20</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (111 mg, 0.51 mmol), 4-dimethylaminopyridine (53 mg, 0.44 mmol) 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (110 mg, 0.36 mmol), and 3-phenylphenol (68 mg, 0.40 mmol) in acetonitrile (4 mL). The compound was isolated as hydrochloride salt. White solid 52 mg (27%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 3.12 min, <i>m</i>/<i>z</i> 498 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.15 (br s, 1H), 7.89 (t, <i>J</i> = 5.7 Hz, 1H), 7.70–7.63 (m, 2H), 7.53–7.43 (m, 4H), 7.41–7.32 (m, 4H), 7.19 (dd, <i>J</i> = 7.0, 2.6 Hz, 1H), 7.14–7.10 (m, 1H), 3.62–3.55 (m, 2H), 3.47–3.40 (m, 2H), 3.30–3.08 (m, 8H), 1.89–1.73 (m, 2H), 1.55 (p, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 154.43, 151.63, 149.56, 141.46, 139.28, 138.98, 132.76, 129.80, 129.00, 128.67, 127.78, 126.74, 126.08, 125.31, 123.27, 120.82, 119.96, 119.81, 106.96, 55.09, 51.05 (2C), 47.67 (2C), 39.40, 26.44, 20.48 ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>·ClH 498.1722; found 498.1721 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 96%.</div></div><div id="sec5_1_4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propyl]carbamate (<b>21</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (85 mg, 0.39 mmol), 4-dimethylaminopyridine (34 mg, 0.28 mmol), 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propan-1-amine (80 mg, 0.28 mmol), and 3-(4-hydroxyphenyl)benzamide (83 mg, 0.39 mmol) in acetonitrile (4 mL). White solid 34 mg (23%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.34 min; <i>m</i>/<i>z</i> 527 [M – H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ. 8.14 (t, <i>J</i> = 1.8 Hz, 1H), 8.08 (br s, 1H), 7.87–7.83 (m, 1H), 7.82–7.77 (m, 2H), 7.76–7.70 (m, 2H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.40 (br s, 1H), 7.34–7.27 (m, 2H), 7.25–7.19 (m, 2H), 7.15 (dd, <i>J</i> = 6.6, 3.0 Hz, 1H), 3.14 (q, <i>J</i> = 6.6 Hz, 2H), 3.05–2.95 (m, 4H), 2.62–2.52 (m, 4H), 2.42 (t, <i>J</i> = 7.1 Hz, 2H), 1.69 (p, <i>J</i> = 7.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.90, 157.35, 151.18, 134.79, 132.58, 130.25, 129.24, 128.71, 128.58, 128.39, 127.87 (2C), 127.67, 125.49, 124.88, 124.27, 122.20 (2C), 119.49, 115.73, 55.44, 52.83 (2C), 50.91 (2C), 39.07, 27.21. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> 527.1617; found 527.1612 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl]carbamate (<b>22</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method B, starting from <i>p</i>-nitrophenyl chloroformate (104 mg, 0.52 mmol), DIPEA (0.15 mL, 0.84 mmol), 3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-amine (70 mg, 0.47 mmol), and 3-(4-hydroxyphenyl)benzamide (100 mg, 0.47 mmol) in a 1:1 mixture of DMA:DCM (4 mL). White solid 22 mg (10%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.83 min; <i>m</i>/<i>z</i> 489 [M – H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.14 (t, 1H), 8.09 (br s, 1H), 7.88–7.84 (m, 1H), 7.83–7.78 (m, 2H), 7.76–7.70 (m, 2H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.41 (br s, 1H), 7.26–7.20 (m, 2H), 6.97–6.82 (m, 4H), 3.77 (s, 3H), 3.14 (q, <i>J</i> = 6.7 Hz, 2H), 3.04–2.90 (m, 4H), 2.60–2.51 (m, 4H), 2.39 (t, <i>J</i> = 7.1 Hz, 2H), 1.68 (p, <i>J</i> = 7.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 157.54, 154.16, 150.49, 140.92, 140.89, 134.01, 133.02, 129.15, 128.85, 128.82, 126.42, 125.87, 122.36, 120.04, 119.69, 117.71, 114.35, 56.42, 54.54, 52.27, 49.82, 37.82, 24.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub> 489.2502; found 489.2507 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate (<b>23</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method B, starting from <i>p</i>-nitrophenyl chloroformate (84 mg, 0.42 mmol), DIPEA (0.15 mL, 0.84 mmol), 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (100 mg, 0.38 mmol), and 3-(4-hydroxyphenyl)benzamide (101 mg, 0.47 mmol) in a 1:1 mixture of DMA/DCM (4 mL). White solid 50 mg (26%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.86 min; <i>m</i>/<i>z</i> 503 [M – H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.95 (br s, 1H), 8.29–7.99 (m, 2H), 7.95–7.77 (m, 3H), 7.77–7.69 (m, 2H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.41 (br s, 1H), 7.29–7.19 (m, 2H), 7.08–6.87 (m, 4H), 3.79 (s, 3H), 3.51 (dd, <i>J</i> = 18.6, 10.4 Hz, 4H), 3.22–3.04 (m, 8H), 1.89–1.74 (m, 2H), 1.54 (p, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.74, 154.31, 151.82, 150.86, 139.42, 139.29, 136.30, 134.94, 129.27, 128.93, 127.70 (2C), 126.49, 125.57, 123.54, 122.23 (2C), 120.85, 118.28, 111.97, 55.39, 55.08, 51.03 (2C), 46.85 (2C), 39.71, 26.43, 20.48. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub> 503.2658; found 503.2665 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-[4-(<i>o</i>-Tolyl)piperazin-1-yl]butyl]carbamate (<b>24</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (136 mg, 0.62 mmol), 4-dimethylaminopyridine (65 mg, 0.53 mmol) 4-[4-(<i>o</i>-tolyl)piperazin-1-yl]butan-1-amine (110 mg, 0.44 mmol), and 3-(4-hydroxyphenyl)benzamide (83 mg, 0.38 mmol) in acetonitrile (4 mL). White solid 30 mg (14%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.52 min, <i>m</i>/<i>z</i> 418 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ. 8.17–8.12 (m, 1H), 8.10 (br s, 1H), 7.89–7.77 (m, 3H), 7.72 (d, <i>J</i> = 8.2 Hz, 2H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.41 (br s, 1H), 7.21 (d, <i>J</i> = 8.3 Hz, 2H), 7.17–7.09 (m, 2H), 7.00 (d, <i>J</i> = 7.8 Hz, 1H), 6.93 (t, <i>J</i> = 7.4 Hz, 1H), 3.18–3.05 (m, 2H), 2.91–2.76 (m, 4H), 2.61–2.51 (m, 4H), 2.44–2.29 (m, 2H), 2.23 (s, 3H), 1.61–1.43 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.72, 157.35, 154.21, 151.30, 140.13, 136.21, 134.93, 131.66, 130.75, 129.25, 128.91, 127.87, 127.67 (2C), 126.47, 124.89, 122.70, 122.19 (2C), 118.63, 57.52, 53.23 (2C), 51.37 (2C), 40.41, 28.01, 27.21, 23.62. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub> 487.2709; found 487.2707 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-[4-[2-(Trifluoromethyl)phenyl]piperazin-1-yl]butyl]carbamate (<b>25</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (79 mg, 0.36 mmol), 4-dimethylaminopyridine (44 mg, 0.36 mmol) 4-[4-[2-(trifluoromethyl)phenyl]piperazin-1-yl]butan-1-amine (100 mg, 0.33 mmol), and 3-(4-hydroxyphenyl)benzamide (77 mg, 0.36 mmol) in acetonitrile (4 mL). White solid 63 mg (35%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.19 min, <i>m</i>/<i>z</i> 541 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ. 8.19–8.15 (m, 1H), 8.12 (br s, 1H), 7.89–7.83 (m, 1H), 7.82–7.76 (m, 2H), 7.75–7.69 (m, 2H), 7.56–7.45 (m, 1H), 7.38 (br s, 1H), 7.34–7.27 (m, 2H), 7.25–7.19 (m, 2H), 6.92–6.86 (m, 2H), 3.18–3.05 (m, 2H), 2.89–2.81 (m, 4H), 2.50–2.42 (m, 4H), 2.35 (t, <i>J</i> = 6.4 Hz, 2H), 1.59–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.82, 157.49, 154.27, 152.45, 150.96, 140.20, 139.48, 136.25, 134.96, 133.51, 128.93, 128.74, 127.70, 126.87, 125.59, 124.97, 124.33, 122.21 (2C), 115.80 (2C), 57.53, 53.18 (2C), 53.13 (2C), 40.57, 27.24, 23.62. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>31</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> 541.2427; found 541.2423 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[4-(4-Phenylpiperazin-1-yl)butyl]carbamate (<b>26</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method B, starting from <i>p</i>-nitrophenyl chloroformate (42 mg, 0.21 mmol), DIPEA (0.07 mL, 0.42 mmol), 4-(4-phenyl-1-piperidyl)butan-1-amine (45 mg, 0.19 mmol), and 3-(4-hydroxyphenyl)benzamide (45 mg, 0.21 mmol) in a 1:1 mixture of DMA/DCM (4 mL). White solid 14 mg (15%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.92 min, <i>m</i>/<i>z</i> 473 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.17–8.13 (m, 1H), 8.10 br s, 1H), 7.88–7.78 (m, 2H), 7.75–7.69 (m, 2H), 7.54 (t, <i>J</i> = 7.8 Hz, 2H), 7.41 (b. s, 1H), 7.25–7.16 (m, 4H), 6.95–6.89 (m, 2H), 6.76 (t, <i>J</i> = 7.3 Hz, 1H), 3.17–3.06 (m, 6H), 2.51–2.43 (m, 4H), 2.37–2.30 (m, 2H), 1.59–1.48 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 157.54, 154.16, 151.80, 140.89, 134.01, 133.02, 129.40, 129.15, 128.85, 128.82, 126.42, 125.87, 120.04, 117.79, 116.30, 56.72, 51.98, 47.69, 40.36, 27.50, 25.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> 473.2553; found 473.2556 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> [4-(3-Carbamoylphenyl)-3-fluorophenyl] <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>27</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (73 mg, 0.33 mmol), 4-dimethylaminopyridine (41 mg, 0.33 mmol), 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (92 mg, 0.30 mmol), and 3-(2-fluoro-4-hydroxyphenyl)benzamide (77 mg, 0.33 mmol) in acetonitrile (4 mL). White solid 12 mg (7%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.36 min, <i>m</i>/<i>z</i> 559 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.08 (br s, 1H), 8.04–8.01 (m, 1H), 7.98–7.86 (m, 2H), 7.68 (d, <i>J</i> = 6.9 Hz, 1H), 7.63–7.53 (m, 2H), 7.40 (br s, 1H), 7.33–7.24 (m, 2H), 7.18 (dd, <i>J</i> = 11.7, 2.2 Hz, 1H), 7.15–7.05 (m, 2H), 3.16–3.06 (m, 2H), 3.03–2.94 (m, 4H), 2.63–2.51 (m, 4H), 2.40–2.32 (m, 2H), 1.59–1.46 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 160.91 (d, <i>J</i> = 251.8 Hz), 157.54, 154.31 (d, <i>J</i> = 7.7 Hz), 148.43, 133.16, 133.08, 132.47, 130.37 (d, <i>J</i> = 8.6 Hz), 130.02 (d, <i>J</i> = 2.9 Hz), 129.62 (d, <i>J</i> = 2.9 Hz), 129.25, 127.68, 127.01, 126.15, 125.53 (d, <i>J</i> = 20.0 Hz), 125.00, 120.05, 119.56 (d, <i>J</i> = 2.8 Hz), 108.70 (d, <i>J</i> = 20.0 Hz), 56.72, 52.27, 50.49, 40.36, 27.50, 25.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>29</sub>Cl<sub>2</sub>FN<sub>4</sub>O<sub>3</sub> 559.1679; found 559.1673 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> [4-(3-Carbamoylphenyl)-3-methoxyphenyl] <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>28</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (93 mg, 0.43 mmol), 4-dimethylaminopyridine (44 mg, 0.36 mmol) 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (80 mg, 0.26 mmol), and 3-(4-hydroxy-2-methoxyphenyl)benzamide (81 mg, 0.33 mmol) in acetonitrile (4 mL). White solid 35 mg (23%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.91 min, <i>m</i>/<i>z</i> 572 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.98 (br s, 1H), 7.96–7.91 (m, 1H), 7.86–7.78 (m, 2H), 7.61 (d, <i>J</i> = 7.8 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.38–7.32 (m, 2H), 7.29 (dd, <i>J</i> = 6.9, 3.9 Hz, 2H), 7.14 (dd, <i>J</i> = 6.4, 3.1 Hz, 1H), 6.88 (d, <i>J</i> = 2.1 Hz, 1H), 6.79 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 3.75 (s, 3H), 3.16–3.08 (m, 2H), 3.04–2.94 (m, 4H), 2.60–2.52 (m, 4H), 2.42–2.34 (m, 2H), 1.60–1.48 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.97, 156.67, 154.16, 151.95, 151.19, 137.66, 134.31, 132.58, 132.00, 130.64, 128.51, 128.33, 127.85, 125.97, 125.91, 125.88, 124.29, 119.52, 114.06, 105.93, 57.38, 55.79, 52.78 (2C), 50.94 (2C), 40.65, 27.23, 23.55. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub> 571.1879; found 571.1884 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> [4-(3-Carbamoylphenyl)-3-methoxyphenyl] <i>N</i>-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate (<b>29</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (93 mg, 0.43 mmol), 4-dimethylaminopyridine (44 mg, 0.36 mmol), 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (80 mg, 0.30 mmol), and 3-(4-hydroxy-2-methoxyphenyl)benzamide (81 mg, 0.33 mmol) in acetonitrile (4 mL). White solid 35 mg (22%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 1.88 min, <i>m</i>/<i>z</i> 533 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.01 (br s, 1H), 7.96–7.92 (m, 1H), 7.86 (t, <i>J</i> = 5.6 Hz, 1H), 7.81 (d, <i>J</i> = 7.7 Hz, 1H), 7.61 (d, <i>J</i> = 7.8 Hz, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 1H), 7.37 (br s, 1H), 7.31 (d, <i>J</i> = 8.3 Hz, 1H), 6.95–6.91 (m, 2H), 6.89–6.84 (m, 3H), 6.79 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.17–3.05 (m, 2H), 3.03–2.88 (m, 4H), 2.58–2.49 (m, 4H), 2.40–2.29 (m, 2H), 1.59–1.46 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.05, 156.67, 154.28, 152.01, 151.90, 141.31, 137.67, 134.33, 132.14, 130.69, 128.33, 127.97, 126.08, 125.95, 122.40, 120.92, 117.91, 114.05, 111.91, 106.05, 57.65, 55.85, 55.34, 53.09 (2C), 50.12 (2C), 40.68, 27.32, 23.66. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>36</sub>N<sub>4</sub>O<sub>5</sub> 533.2764; found 533.2767 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 97%.</div></div><div id="sec5_1_4_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> [4-(3-Carbamoylphenyl)phenyl] <i>N</i>-[(<i>E</i>)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]carbamate (<b>30</b>)</h3><div class="NLM_p last">The title compound was prepared according to the general procedure 3 method A starting from di-<i>tert</i> butyl carbonate (102 mg, 0.47 mmol), 4-dimethylaminopyridine (49 mg, 0.40 mmol), (<i>E</i>)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-en-1-amine (100 mg, 0.33 mmol), and 3-(4-hydroxyphenyl)benzamide (78 mg, 0.37 mmol) in MeCN (3 mL). White solid 28 mg (16%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.36 min, <i>m</i>/<i>z</i> 539 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.17–8.13 (m, 1H), 8.09 (br s, 1H), 7.99 (t, <i>J</i> = 5.7 Hz, 1H), 7.85 (d, <i>J</i> = 7.7 Hz, 1H), 7.80 (d, <i>J</i> = 7.9 Hz, 1H), 7.73 (d, <i>J</i> = 8.6 Hz, 2H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.41 (br s, 1H), 7.34–7.26 (m, 2H), 7.23 (d, <i>J</i> = 8.6 Hz, 2H), 7.14 (dd, <i>J</i> = 6.6, 2.9 Hz, 1H), 5.75–5.62 (m, 2H), 3.78–3.68 (m, 2H), 3.05–2.91 (m, 6H), 2.61–2.52 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 157.45, 154.16, 148.43, 140.89, 134.01, 133.08, 133.02, 131.95, 129.15, 128.85, 128.82, 128.13, 127.68, 127.01, 126.42, 126.15, 125.87, 120.04, 60.39, 51.71, 50.49, 41.42. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> 539.1617; found 539.1634 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 97%.</div></div><div id="sec5_1_4_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> [4-(3-Carbamoylphenyl)-3-fluorophenyl] <i>N</i>-[(<i>E</i>)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]carbamate (<b>31</b>)</h3><div class="NLM_p last">The title compound was prepared according to the general procedure 3 method A starting from di-<i>tert</i> butyl carbonate (102 mg, 0.47 mmol), 4-dimethylaminopyridine (49 mg, 0.40 mmol), (<i>E</i>)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-en-1-amine (100 mg, 0.33 mmol), and 3-(2-fluoro-4-hydroxyphenyl)benzamide (85 mg, 0.37 mmol) in MeCN (3 mL). White solid 41 mg (22%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.43 min, <i>m</i>/<i>z</i> 557 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12–8.04 (m, 2H), 7.92–7.87 (m, 1H), 7.72–7.67 (m, 1H), 7.64–7.48 (m, 3H), 7.41 (br s, 1H), 7.32–7.26 (m, 2H), 7.21 (dd, <i>J</i> = 11.7, 2.3 Hz, 1H), 7.17–7.08 (m, 2H), 5.72–5.63 (m, 2H), 3.80–3.67 (m, 2H), 3.08–2.91 (m, 6H), 2.62–2.51 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.96, 160.91 (d, <i>J</i> = 251.8 Hz), 157.45, 154.31 (d, <i>J</i> = 7.7 Hz), 148.43, 133.16, 133.08, 132.47, 131.95, 130.37 (d, <i>J</i> = 8.6 Hz), 130.02 (d, <i>J</i> = 2.9 Hz), 129.62 (d, <i>J</i> = 2.9 Hz), 129.25, 128.13, 127.68, 127.01, 126.15, 125.53 (d, <i>J</i> = 20.0 Hz), 125.00, 120.05, 119.56 (d, <i>J</i> = 2.8 Hz), 108.70 (d, <i>J</i> = 20.0 Hz), 60.39, 51.71, 50.49, 41.42. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>27</sub>Cl<sub>2</sub>FN<sub>4</sub>O<sub>3</sub> 557.1522; found 557.1517 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (4-Phenylphenyl) <i>N</i>-[3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propyl]carbamate (<b>32</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (85 mg, 0.39 mmol), DMAP (41 mg, 0.33 mmol), 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propan-1-amine (80 mg, 0.28 mmol), and 4-phenylphenol (52 mg, 0.31 mmol) in CH<sub>3</sub>CN (3 mL). White solid 10 mg (7%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.78 min; <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.80 (t, <i>J</i> = 5.7 Hz, 1H), 7.69–7.62 (m, 4H), 7.51–7.43 (m, 2H), 7.39–7.35 (m, 1H), 7.32–7.27 (m, 2H), 7.22–7.17 (m, 2H), 7.15 (dd, <i>J</i> = 6.6, 3.0 Hz, 1H), 3.14 (q, <i>J</i> = 6.8 Hz, 2H), 3.05–2.92 (m, 4H), 2.62–2.54 (m, 4H), 2.42 (t, <i>J</i> = 7.0 Hz, 2H), 1.68 (p, <i>J</i> = 7.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.25, 151.18, 150.66, 140.44, 139.51, 132.65, 130.65, 128.91 (2C), 128.41, 127.49 (2C), 127.29, 126.57 (2C), 124.30, 122.15 (2C), 119.53, 55.15, 52.78 (2C), 50.94 (2C), 39.87, 26.43. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> 498.1715; found 498.1704 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 96%.</div></div><div id="sec5_1_4_2_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (4-Phenylphenyl) <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>33</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (111 mg, 0.51 mmol), 4-dimethylaminopyridine (53 mg, 0.44 mmol), 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (110 mg, 0.36 mmol), and 4-phenylphenol (68 mg, 0.40 mmol) in acetonitrile (4 mL). White solid 42 mg (23%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 3.12 min, <i>m</i>/<i>z</i> 498 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.83 (t, <i>J</i> = 5.7 Hz, 1H), 7.68–7.61 (m, 4H), 7.50–7.43 (m, 2H), 7.38–7.33 (m, 1H), 7.31–7.26 (m, 2H), 7.21–7.16 (m, 2H), 7.13 (dd, <i>J</i> = 6.5, 3.2 Hz, 1H), 3.15–3.06 (m, 2H), 3.03–2.90 (m, 4H), 2.59–2.51 (m, 4H), 2.41–2.33 (m, 2H), 1.60–1.46 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.33, 150.61, 149.52, 139.48, 136.92, 132.72, 128.92 (2C), 128.64, 127.51 (2C), 127.31, 126.58 (2C), 126.04, 125.28, 122.16 (2C), 119.80, 55.06, 51.04 (2C), 47.68 (2C), 40.17, 26.40, 20.49. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> 498.1715; found 498.1704 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (4-Phenylphenyl) <i>N</i>-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl]carbamate Hydrochloride (<b>34</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (122 mg, 0.56 mmol), 4-dimethylaminopyridine (59 mg, 0.48 mmol), 3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-amine (100 mg, 0.40 mmol), and 4-phenylphenol (75 mg, 0.44 mmol) in acetonitrile (4 mL). The resultant oil was dissolved in a small amount of diethyl ether, to which 2 M HCl in diethyl ether was added. Evaporation of the solvent produced the title compound as yellow solid 64 mg (33%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.52 min, <i>m</i>/<i>z</i> 446 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.22 (br s, 1H), 7.99 (t, <i>J</i> = 5.8 Hz, 1H), 7.69–7.62 (m, 4H), 7.51–7.43 (m, 2H), 7.39–7.33 (m, 1H), 7.25–7.19 (m, 2H), 7.07–6.95 (m, 3H), 6.95–6.89 (m, 1H), 3.79 (s, 3H), 3.63–3.44 (m, 4H), 3.26–3.08 (m, 8H), 2.08–1.92 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.54, 154.16, 150.49, 140.92, 140.50, 133.92, 131.07, 129.17, 128.82, 128.01, 122.36, 120.13, 119.69, 117.71, 114.35, 56.42, 54.54, 52.27, 49.82, 37.82, 24.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub>·ClH 446.2444; found 446.2450 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 98%.</div></div><div id="sec5_1_4_2_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (4-Phenylphenyl) <i>N</i>-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate Hydrochloride (<b>35</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (116 mg, 0.53 mmol), 4-dimethylaminopyridine (56 mg, 0.46 mmol), 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (100 mg, 0.38 mmol), and 4-phenylphenol (71 mg, 0.42 mmol) in acetonitrile (4 mL). The resultant oil was dissolved in a small amount of diethyl ether, to which 2 M HCl in diethyl ether was added. Evaporation of the solvent produced the title compound as yellow solid 54 mg (29%). Mp: 91–95 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.54 min, <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.15 (br s, 1H), 7.91 (t, <i>J</i> = 5.7 Hz, 1H), 7.70–7.61 (m, 4H), 7.49–7.42 (m, 2H), 7.40–7.33 (m, 1H), 7.24–7.17 (m, 2H), 7.06–6.88 (m, 4H), 3.79 (s, 3H), 3.59–3.39 (m, 4H), 3.27–3.06 (m, 8H), 1.89–1.74 (m, 2H), 1.53 (p, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.40, 151.84, 150.66, 139.54, 139.27, 136.98, 129.00 (2C), 127.58 (2C), 127.39, 126.65 (2C), 123.63, 122.27 (2C), 120.88, 118.33, 111.97, 55.42, 55.11, 51.04 (2C), 46.90 (2C), 40.32, 26.48, 20.51. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub>·ClH 460.26; found 460.2602 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (4-Phenylphenyl) <i>N</i>-[4-[4-(<i>o</i>-Tolyl)piperazin-1-yl]butyl]carbamate (<b>36</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (136 mg, 0.62 mmol), 4-dimethylaminopyridine (65 mg, 0.53 mmol), 4-[4-(<i>o</i>-tolyl)piperazin-1-yl]butan-1-amine (110.0 mg, 0.44 mmol), and 4-phenylphenol (83 mg, 0.49 mmol) in acetonitrile (4 mL). White solid 27 mg (14%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.75 min, <i>m</i>/<i>z</i> 444 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.87 (t, <i>J</i> = 5.7 Hz, 1H), 7.68–7.63 (m, 4H), 7.46 (t, <i>J</i> = 7.7 Hz, 2H), 7.38–7.34 (m, 1H), 7.21–7.17 (m, 2H), 7.16–7.10 (m, 2H), 7.02–6.98 (m, 1H), 6.93 (td, <i>J</i> = 7.4, 1.2 Hz, 1H), 3.15–3.06 (m, 2H), 2.86–2.78 (m, 4H), 2.59–2.49 (m, 4H), 2.42–2.33 (m, 2H), 2.23 (s, 3H), 1.57–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 154.31, 151.33, 150.71, 139.54, 136.88, 131.70, 130.80, 128.96 (2C), 127.54 (2C), 127.33, 126.62 (2C), 126.53, 122.75, 122.21 (2C), 118.67, 57.57, 53.27 (2C), 51.39 (2C), 41.01, 27.26, 23.66, 17.60. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> 444.2651; found 444.2658 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (4-Phenylphenyl) <i>N</i>-[4-[4-[2-(Trifluoromethyl)phenyl]piperazin-1-yl]butyl]carbamate (<b>37</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (91 mg, 0.42 mmol), 4-dimethylaminopyridine (44 mg, 0.36 mmol), 4-[4-[2-(trifluoromethyl)phenyl]piperazin-1-yl]butan-1-amine (90 mg, 0.30 mmol), and 4-phenylphenol (56 mg, 0.33 mmol) in acetonitrile (4 mL). White solid 47 mg (32%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.92 min, <i>m</i>/<i>z</i> 498 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91–7.84 (m, 1H), 7.68–7.59 (m, 6H), 7.57–7.50 (m, 1H), 7.49–7.42 (m, 2H), 7.39–7.28 (m, 2H), 7.23–7.16 (m, 2H), 3.15–3.06 (m, 2H), 2.91–2.80 (m, 4H), 2.58–2.43 (m, 4H), 2.40–2.29 (m, 2H), 1.56–1.45 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.30, 152.46, 150.71, 139.54, 136.88, 133.54, 128.94 (2C), 127.53 (2C), 127.31, 126.89, 126.60 (2C), 125.71, 125.43, 125.03, 124.38, 122.18 (2C), 57.52, 53.19 (2C), 53.14 (2C), 40.79, 27.23, 23.61. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>30</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> 498.2368; found 498.2377 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 97%.</div></div><div id="sec5_1_4_2_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 9<i>H</i>-Carbazol-2-yl <i>N</i>-[3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propyl]carbamate (<b>42</b>)</h3><div class="NLM_p last">The title compound was prepared according to the general procedure 3 method A starting from di-<i>tert</i>-butyl carbonate (73 mg, 0.33 mmol). 4-dimethylaminopyridine (34 mg, 0.28 mmol), 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propan-1-amine (80 mg, 0.28 mmol), and 2-hydroxycarbazole (61 mg, 0.33 mmol) in MeCN (3 mL). The title compound (off-white solid) was isolated as free base after chromatographic purification. 14 mg (10%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.88 min, <i>m</i>/<i>z</i> 497 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.24 (s, 1H), 8.13–8.01 (m, 2H), 7.75 (t, <i>J</i> = 5.6 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (ddd, <i>J</i> = 8.1, 7.0, 1.2 Hz, 1H), 7.32–7.27 (m, 2H), 7.20 (d, <i>J</i> = 2.1 Hz, 1H), 7.18–7.11 (m, 2H), 6.88 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 3.16 (q, <i>J</i> = 6.6 Hz, 2H), 3.07–2.95 (m, 4H), 2.66–2.53 (m, 4H), 2.48–2.38 (m, 2H), 1.71 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.54, 152.26, 148.43, 139.00, 138.04, 133.08, 130.70, 127.68, 127.01, 126.15, 123.10, 123.00, 122.43, 120.81, 120.05, 119.56, 117.15, 111.28, 100.85, 54.54, 52.27 (2C), 50.49 (2C), 37.82, 24.56. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> 497.1511; found 497.1496 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 9<i>H</i>-Carbazol-2-yl <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>43</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (121 mg, 0.56 mmol), 4-dimethylaminopyridine (58 mg, 0.48 mmol), 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (120 mg, 0.40 mmol), and 9<i>H</i>-carbazol-2-ol (80 mg, 0.44 mmol) in acetonitrile (4 mL). White solid 43 mg (21%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.82 min, <i>m</i>/<i>z</i> 512 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.25 (br s, 1H), 8.06 (t, <i>J</i> = 8.2 Hz, 2H), 7.78 (t, <i>J</i> = 5.6 Hz, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 7.39–7.32 (m, 1H), 7.32–7.26 (m, 2H), 7.19 (d, <i>J</i> = 2.0 Hz, 1H), 7.18–7.11 (m, 2H), 6.87 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 3.17–3.08 (m, 2H), 3.06–2.96 (m, 4H), 2.72–2.54 (m, 4H), 2.49–2.39 (m, 2H), 1.61–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.75, 151.09, 149.47, 140.24, 139.98, 132.65, 128.62, 126.03, 125.25, 124.50, 122.24, 120.40, 119.97, 119.62, 118.77, 113.12, 111.13, 104.13, 99.57, 57.24, 52.62 (2C), 50.50 (2C), 40.62, 27.18, 23.23. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> 511.1668; found 511.1674 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 95%.</div></div><div id="sec5_1_4_2_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 9<i>H</i>-Carbazol-2-yl <i>N</i>-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate (<b>44</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (116 mg, 0.53 mmol), 4-dimethylaminopyridine (56 mg, 0.46 mmol), 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (100 mg, 0.38 mmol), and 9<i>H</i>-carbazol-2-ol (77 mg, 0.42 mmol) in acetonitrile (4 mL). White solid 89 mg (50%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.31 min, <i>m</i>/<i>z</i> 473 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (s, 1H), 8.07 (t, <i>J</i> = 8.4 Hz, 2H), 7.81 (t, <i>J</i> = 5.6 Hz, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 7.39–7.33 (m, 1H), 7.19 (d, <i>J</i> = 2.0 Hz, 1H), 7.15 (t, <i>J</i> = 7.4 Hz, 1H), 6.96–6.82 (m, 5H), 3.76 (s, 3H), 3.18–3.06 (m, 2H), 3.04–2.88 (m, 4H), 2.57–2.50 (m, 4H), 2.40–2.31 (m, 2H), 1.61–1.45 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.78, 152.02, 149.51, 141.46, 140.26, 139.94, 125.25, 122.46, 122.20, 120.86, 120.51, 119.93, 119.59, 118.77, 117.90, 113.04, 112.06, 111.14, 104.13, 57.66, 55.37, 53.19 (2C), 50.12 (2C), 40.71, 27.44, 23.67. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> 473.2553; found 473.2561 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 96%.</div></div><div id="sec5_1_4_2_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> [3-Methoxy-4-phenylphenyl] <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>45</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (202 mg, 0.93 mmol), DMAP (97 mg, 0.79 mmol), 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (200 mg, 0.66 mmol), and 3-methoxy-4-phenylphenol (172 mg, 0.86 mmol) in CH<sub>3</sub>CN (3 mL). White solid 31 mg (9%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.80 min; <i>m</i>/<i>z</i> 528 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.82 (t, <i>J</i> = 5.6 Hz, 1H), 7.47–7.43 (m, 2H), 7.40 (t, <i>J</i> = 7.6 Hz, 2H), 7.34–7.24 (m, 4H), 7.17–7.11 (m, 1H), 6.85 (d, <i>J</i> = 2.1 Hz, 1H), 6.77 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 3.74 (s, 3H), 3.16–3.07 (m, 2H), 3.04–2.94 (m, 4H), 2.60–2.52 (m, <i>J</i> = 8.7 Hz, 4H), 2.43–2.33 (m, 2H), 1.60–1.47 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.52, 154.36, 151.25, 137.69, 132.76, 132.58, 132.42, 130.46, 129.18, 128.47, 127.99, 126.75, 126.56, 126.46, 125.93, 124.30, 119.66, 114.02, 105.99, 57.39, 55.72, 52.78 (2C), 50.95 (2C), 40.64, 27.18, 23.63. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> 473.2553; found 473.2561 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (3-Fluoro-4-phenylphenyl) <i>N</i>-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]carbamate (<b>46</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (397 mg, 1.20 mmol), DMAP (97 mg, 1.79 mmol), 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butan-1-amine (200 mg, 0.66 mmol), and 3-fluoro-4-phenylphenol (148 mg, 0.78 mmol) in CH<sub>3</sub>CN (3.8 mL). White solid 145 mg (42%). Mp: 176–178 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.80 min; <i>m</i>/<i>z</i> 516 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.93 (t, <i>J</i> = 5.6 Hz, 1H), 7.57–7.45 (m, 5H), 7.44–7.37 (m, 1H), 7.33–7.26 (m, 2H), 7.20–7.12 (m, 2H), 7.07 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 3.11 (q, <i>J</i> = 6.3 Hz, 2H), 3.04–2.93 (m, 4H), 2.54 (s, 4H), 2.42–2.32 (m, 2H), 1.60–1.46 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.93, 157.47, 153.76, 151.19, 134.60, 132.58, 130.81, 130.76, 128.71, 128.67, 128.61, 128.40, 127.76, 125.97, 124.29, 119.51, 118.30, 110.21, 109.95, 57.36, 52.77 (2C), 50.94 (2C), 40.94, 27.10, 23.52. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> 473.2553; found 473.2561 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_1_4_2_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (3-Methoxy-4-phenylphenyl) <i>N-</i>[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl]carbamate (<b>47</b>)</h3><div class="NLM_p last">The title compound was synthesized according to the general procedure 3 method A, starting from di-<i>tert</i>-butyl dicarbonate (139 mg, 0.64 mmol), 4-dimethylaminopyridine (68 mg, 0.55 mmol), 4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-amine (120 mg, 0.46 mmol), and 3-methoxy-4-phenylphenol (100 mg, 0.50 mmol) in acetonitrile (4 mL). Yellow solid 94 mg (42%). Mp: 200–202 °C. UPLC–MS (method A): <i>t</i><sub>R</sub> = 2.52 min, <i>m</i>/<i>z</i> 490 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (t, <i>J</i> = 5.7 Hz, 1H), 7.47–7.43 (m, 2H), 7.39 (t, <i>J</i> = 7.6 Hz, 2H), 7.34–7.28 (m, 1H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 7.04–6.85 (m, 5H), 6.78 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 3.50–3.39 (m, 4H), 3.23–3.02 (m, 8H), 1.86–1.72 (m, 2H), 1.60–1.47 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.63, 154.28, 152.07, 151.56, 141.28, 137.67, 130.53, 129.24 (2C), 128.06 (2C), 126.82, 126.51, 122.56, 120.68, 117.92, 113.97, 111.90, 106.01, 57.48, 55.76, 55.38, 52.96 (2C), 50.01 (2C), 40.47, 27.23, 23.47. ESI+ (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>29</sub>H<sub>35</sub>N<sub>3</sub>O<sub>4</sub> 490.2706; found 490.2689 [M + H]<sup>+</sup>. UPLC–MS purity (UV at 215 nm): 99%.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">b Pharmacology. Cell Culture Conditions</h3><div class="NLM_p last">Hek293 cells stably transfected with human FAAH-1 were used as an enzyme source (membrane enrichment) to evaluate FAAH-1 activity. CHO-K1 stably expressing human D2R-short was used to perform cell-based cAMP assay to determine D2R activation. Cells were maintained in DMEM or DMEM:Ham’s F-12 1:1, respectively, both supplemented with 10% FBS. 500 μg/mL G418 were added to culture medium to maintain selective pressure. Activities on D3R and CB<sub>1</sub>R were assayed on a human D3R and human CB<sub>1</sub>R expressing CHO cells.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Human Recombinant Fatty Acid Amide Hydrolase (FAAH-1) Fluorescent Assay</h3><div class="NLM_p last">The detailed procedure was recently described in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>. Briefly, the assay was run in 96-well microplates (Black OptiPlate-96 F; PerkinElmer, MA, USA) in a total reaction volume of 180 μL. FAAH-1 membrane-enriched lysate (2.5 μg) was preincubated for 50 min with various concentrations of test compounds or vehicle control (2.5% DMSO) in assay buffer (50 mM Tris-HCl, pH 7.4, 0.05% fatty acid free BSA). Then 1 μM substrate (AMC arachidonyl amide; A6855, Sigma) was added and the reaction carried out for 4 h at 37 °C. Fluorescence was measured with EnVision 2014 multilabel reader (PerkinElmer, MA, USA) using an excitation wavelength of 355 nm and an emission of 460 nm. The results are expressed as a percentage of the total enzymatic activity (protein preparation incubated with the vehicle control).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> D3R, D2R-Short Dopamine Receptors, and CB<sub>1</sub>R Cellular Assay</h3><div class="NLM_p last">Activities on D2R-short were tested with an HTRF-cAMP functional assay (cAMP dynamic 2, CISBIO Bioassays). Stably transfected human-DRD2short-expressing CHO-K1 cells were suspended in assay buffer made up of HBSS (Life Technologies) complemented with 20 mM Hepes/NaOH (pH 7.4), 0.1% BSA, and 200 μM IBMX. Cells were seeded at a density of 10<sup>4</sup> cells/well in 384-well microplates (384-well small volume HiBase polystyrene microplates, Greiner) and preincubated for 10 min at room temperature (rt) in the presence of the HBSS (basal control), the reference agonist (stimulated control), or various concentrations of the test compounds. Subsequently, the adenylyl cyclase activator NKH 477 (N3290, Sigma) was added at a final concentration of 0.5 μM. Following 45 min incubation at rt, the fluorescence acceptor (D2-labeled cAMP) and fluorescence donor (anti-cAMP antibody labeled with europium cryptate) were added. After 1 h at rt, the time-resolved fluorescence was measured at λ<sub>ex</sub> = 320 nm and λ<sub>em</sub> = 620 and 665 nm using EnVision 2014 multilabel reader (PerkinElmer, MA, USA). The cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results are expressed as a percentage of the control response to 300 nM dopamine. D3R and CB-1 assays were run by CEREP (Le Bois l’Evêque, FR), as previously described in ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Analysis of the Biological Data</h3><div class="NLM_p last">Dose–response curves were run in at least two independent experiments, performed in three technical replicates. For compounds assayed on D2R-short and FAAH-1, concentrations were corrected by NMR determinations. EC<sub>50</sub> or IC<sub>50</sub> values (concentrations causing half-maximal response or inhibition of control agonist response) were determined by nonlinear regression analysis of the log[concentration]/response curves generated with mean replicate values using a four-parameter Hill equation curve fitting with GraphPad Prism 5 (GraphPad Software Inc., CA, USA).</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62">c PK Studies. In Vitro Plasma Stability Study</h3><div class="NLM_p">10 mM DMSO stock solution of test compound was diluted 20-fold with DMSO–H<sub>2</sub>O (1:1) and incubated at 37 °C for 2 h with rat plasma added 5% DMSO (preheated at 37 °C for 10 min). The final concentration was 2 μM. At each time point (0, 5, 15, 30, 60, 120 min), 50 μL of incubation mixture was diluted with 200 μL of cold CH<sub>3</sub>CN spiked with 200 nM of internal standard, followed by centrifugation at 3500<i>g</i> for 20 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of test compound was quantified by LC/MS–MS. The percentage of test compound remaining at each time point relative to <i>t</i> = 0 was calculated. The half-lives (<i>t</i><sub>1/2</sub>) were determined by a one-phase decay equation using a nonlinear regression of compound concentration versus time and were reported as mean values along with their standard deviations (<i>n</i> = 3).</div><div class="NLM_p last">The analyses were performed on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (triple quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array eλ detector. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> (50 mm × 2.1 mm i.d., particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 mm × 2.1 mm i.d., particle size 1.7 μm) at 40 °C, using 0.1% HCOOH in H<sub>2</sub>O (A) and 0.1% HCOOH in CH<sub>3</sub>CN (B) as mobile phase. Electrospray ionization (ESI) was applied in positive mode. Compound-dependent parameters, such as MRM transitions and collision energy, were developed for each compound.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> In Vitro Microsomal Stability Study</h3><div class="NLM_p">10 mM DMSO stock solution of test compound was preincubated at 37 °C for 15 min with rat liver microsomes added 0.1 M Tris-HCl buffer (pH 7.4). The final concentration was 4.6 μM. After preincubation, the cofactors (NADPH, G6P, G6PDH, and MgCl<sub>2</sub> predissolved in 0.1 M Tris-HCl) were added to the incubation mixture and the incubation was continued at 37 °C for 1 h. At each time point (0, 5, 15, 30, 60 min), 30 μL of incubation mixture was diluted with 200 μL of cold CH<sub>3</sub>CN spiked with 200 nM internal standard, followed by centrifugation at 3500<i>g</i> for 15 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of test compound was quantified by LC/MS–MS. The percentage of test compound remaining at each time point relative to <i>t</i> = 0 was calculated. The half-lives (<i>t</i><sub>1/2</sub>) were determined by a one-phase decay equation using a nonlinear regression of compound concentration versus time and were reported as mean values along with their standard deviations (<i>n</i> = 3).</div><div class="NLM_p last">The analyses were performed on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (triple quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array eλ detector. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> (50 mm × 2.1 mm i.d., particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 mm × 2.1 mm i.d., particle size 1.7 μm) at 40 °C, using 0.1% HCOOH in H<sub>2</sub>O (A) and 0.1% HCOOH in CH<sub>3</sub>CN (B) as mobile phase. Electrospray ionization (ESI) was applied in positive mode. Compound-dependent parameters, such as MRM transitions and collision energy, were developed for each compound.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Animals</h3><div class="NLM_p last">We used male Sprague-Dawley rats, weighing 175–200 g (Charles River, Calco, Italy). Animals were group-housed in ventilated cages and had free access to food and water. They were maintained under a 12 h light/dark cycle (lights on at 8:00 am) at a controlled temperature (21 ± 1 °C) and relative humidity (55 ± 10%). All experiments were carried out in accordance with the guidelines established by the European Communities Council Directive (Directive 2010/63/EU of September 22, 2010) and approved by the National Council on Animal Care of the Italian Ministry of Health. All efforts were made to minimize animal suffering and to use the minimal number of animals required to produce reliable results.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Pharmacokinetics Methods</h3><div class="NLM_p last">Compound <b>33</b> was administered orally (po) and intravenously (iv) to cannulated Sprague-Dawley rats at 3 and 10 mg/kg dose. Vehicle was PEG400/Tween 80/saline solution at 10/10/80% in volume, respectively. Three animals per dose were treated. Blood samples at 0, 15, 30, 60, 120, 240, 480, and 1440 min after administration were collected for po arm. Blood samples at 0, 5, 15, 30, 60, 120, and 240 min after administration were collected for iv arm. Plasma was separated from blood by centrifugation for 15 min at 3500 rpm a 4 °C, collected in an Eppendorf tube, and frozen (−80 °C). Control animals treated with vehicle only were also included in the experimental protocol.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Sample Preparation Brain Exposure Analysis</h3><div class="NLM_p">Three animals per dose were treated. Compound <b>33</b> was dissolved in PEG400/Tween 80/saline solution at 10/10/80% in volume, respectively, and administered orally at the dose of 10 mg kg<sup>–1</sup>. After 1 and 4 h, rats were sacrificed and brains were immediately dissected, frozen on dry ice, and stored at −80 °C until analysis.</div><div class="NLM_p last">Brain samples were homogenized in RIPA buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) and were then split into two aliquots kept at −80 °C until analysis. An aliquot was used for compound brain level evaluations. The second aliquot was kept for protein content evaluation by BCA assay.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Pharmacokinetic Study</h3><div class="NLM_p last">Samples (plasma and brain homogenate) were thawed in an ice bath, then centrifuged for 20 min. An aliquot of each (50 μL) was transferred into a 96-deep-well plate, and to it was added with 150 μL of the extraction solution, consisting of cold acetonitrile spiked with 200 nM of a structural analog of the analyte (compound <b>32</b>, closely eluting with the analyte itself) as internal standard. After agitation (3 min) the plate was centrifuged at 3000<i>g</i> for 20 min at 4 °C. 80 μL of supernatant was then transferred into a 96-well plate, and to it was added with 80 μL of water. Standard compound was spiked in neat solvent (PBS, pH 7.4, added with 20% acetonitrile) to prepare a calibration curve over the 1 nM to 10 μM range. Three quality control samples were also prepared, spiking the compound in blank mouse plasma to final 20, 200, and 2000 nM concentrations. Calibrators and QCs were created with the same extraction solution used for the plasma samples. Dosing solutions, previously diluted 100 000 fold in the neat solvent, were also included in the samples and tested. Plasma and brain levels were monitored on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (triple quadrupole detector) mass spectrometer equipped with an electrospray ionization interface; an amount of 3 μL of each sample was injected on a reversed phase column (Acquity UPLC BEH C18, 2.1 mm × 50 mm, 1.7 μm particle size) and separated with a linear acetonitrile gradient. Column and UPLC–MS system were purchased from Waters Inc., Milford, USA. Flow rate was set to 0.5 mL/min. Eluents were A = water and B = acetonitrile, both added with 0.1% formic acid. After 0.5 min at 10% B, a linear gradient of B was applied from 10% to 100% in 2 min, then held at 100% for 10 s. After the gradient, the system was reconditioned at 10% B for 1 min. Compounds were quantified by monitoring their MRM peak areas (compound <b>33</b>, <i>m</i>/<i>z</i> = 498 → 285 at 38 eV of collision energy and <i>m</i>/<i>z</i> = 498 → 328 at 38 eV of collision energy; compound <b>32</b>, internal standard, <i>m</i>/<i>z</i> = 484→ 254 at 35 eV of collision energy), and the response factors, calculated on the basis of the internal standard peak area, were then plotted over the calibration curve. MS parameters were the following: positive ion mode; capillary 2.5 kV; cone 55 V; source temperature 130 °C; cone gas 100 L/h; desolvation gas 800 L/h; desolvation temperature 400 °C. The time/concentration profiles measured with the above-mentioned system were then analyzed using PK Solutions Excel application (Summit Research Service, USA) to derive the pharmacokinetic data (maximum observed concentration (<i>C</i><sub>max</sub>); maximum time (<i>T</i><sub>max</sub>); cumulative area under curve (AUC) for experimental time points; distribution volume (<i>V</i><sub>d</sub>); and systemic clearance (Cl)).</div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68">d Computational Methods. Three-Dimensional Alignment of the Training Set Molecules</h3><div class="NLM_p last">The starting structural alignment was built based on a rigid template, namely, the 3D structure of <b>33</b> with the aliphatic side chain perpendicular to the plane of the proximal ring in line with the CB<sub>1</sub>R bound conformation of the molecule, which has been consistently hypothesized in previous modeling studies. Compound <b>4</b> was structurally aligned to the template by means of the atomic property fields (APF) procedure developed by Totrov and summarized only briefly here.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> All molecules were assigned MMFF parameters.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Seven continuous 3D grid potentials representing the hydrogen bond donor and acceptor propensity, lipophilicity, size, charge, hybridization, and electronegativity of the template were calculated. Molecule <b>4</b> was globally optimized within the precalculated APF by means of the biased probability Monte Carlo (BPMC) stochastic optimizer implemented in ICM.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The intramolecular force field energy was also considered so as to avoid introducing unrealistic strain into the generated conformations. In turn, compounds <b>2</b>, <b>3</b>, <b>16</b>, <b>17</b>, <b>21</b>–<b>24</b>, <b>27</b>, <b>29</b>–<b>33</b>, and <b>42</b>–<b>44</b> were individually superimposed according to the same procedure as the generated conformation of <b>4</b>.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3D QSAR Model</h3><div class="NLM_p last">The APF 3D QSAR methodology was adopted in order to create a predictive model for CB<sub>1</sub>R activity. For each aligned molecule, the seven-component APF were calculated and pooled together. Each molecule was originally described by its fit, according to the conformation assigned in the alignment, in each of the 126 APF. On the basis of the activity data at CB<sub>1</sub>R, the proper weight for the contributions of each compound to each APF component had to be defined in order to provide quantitative predictions of activity for new compounds. Optimal weights were assigned by the partial least-squares (PLS) methodology. The optimal number of latent vectors for PLS was established by leave-one-out cross-validation on the training set. Then, weighted individual contributions were added together. The new compounds’ activities could thus be estimated by simply calculating their fit within the combined QSAR APF.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01578">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01578" class="ext-link">10.1021/acs.jmedchem.6b01578</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Syntheses of the intermediates and <sup>1</sup>H and <sup>13</sup>C NMR spectra of <b>33</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf">jm6b01578_si_001.pdf (2.57 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_002.csv">jm6b01578_si_002.csv (2.61 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01578" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giovanni Bottegoni</span> - <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1251-583X" title="Orcid link">http://orcid.org/0000-0003-1251-583X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#abccc2c4ddcac5c5c285c9c4dfdfceccc4c5c2ebc3cedbdfcad9ced885c8c4c6"><span class="__cf_email__" data-cfemail="d4b3bdbba2b5bababdfab6bba0a0b1b3bbbabd94bcb1a4a0b5a6b1a7fab7bbb9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessio De Simone</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debora Russo</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gian Filippo Ruda</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandra Micoli</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariarosaria Ferraro</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Maria Concetta Di Martino</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuliana Ottonello</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Summa</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Armirotti</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tiziano Bandiera</span> - <span class="hlFld-Affiliation affiliation">†CompuNet, and ‡PharmaChemistry, Istituto Italiano di Tecnologia, 16163 Genova, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">BiKi
Technologies, 16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2496-2701" title="Orcid link">http://orcid.org/0000-0002-2496-2701</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Cavalli</span> - <span class="hlFld-Affiliation affiliation">FaBit, Università
di Bologna, 40127 Bologna, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): At the time this study was carried out, G.B. was employed by BiKi Technologies, a company that commercializes software solutions for medicinal chemistry. A.D.S., G.B., G.F.R., T.B., and A.C. are inventors in a patent application claiming the compounds described in the study.<br /></br></div></li></ul></div><div class="ack" id="ACK-d45e5128-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge the contribution of Silvia Venzano (compound handling) and Luca Goldoni (NMR). We thank Grace Fox for copyediting and proofreading the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i77" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i77"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i78" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i78"> Abbreviations Used</h2><tr><td class="NLM_term">D3R</td><td class="NLM_def"><p class="first last">dopamine receptor subtype D<sub>3</sub></p></td></tr><tr><td class="NLM_term">FAAH</td><td class="NLM_def"><p class="first last">human fatty acid amide hydrolase</p></td></tr><tr><td class="NLM_term">CB<sub>1</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid receptor CB<sub>1</sub></p></td></tr><tr><td class="NLM_term">MTDL</td><td class="NLM_def"><p class="first last">multitarget-directed ligand</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 54 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lgA41p_L21Yyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Polypharmacology in a single drug: multitarget drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span><span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+multitarget+drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0lgG8IuoTSQrdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lgG8IuoTSQrdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbahce, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loscalzo, J.</span><span> </span><span class="NLM_article-title">Network medicine: a network-based approach to human disease</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1038/nrg2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrg2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21164525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOiu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=56-68&author=A.-L.+Barabasiauthor=N.+Gulbahceauthor=J.+Loscalzo&title=Network+medicine%3A+a+network-based+approach+to+human+disease&doi=10.1038%2Fnrg2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Network medicine: a network-based approach to human disease</span></div><div class="casAuthors">Barabasi, Albert-Laszlo; Gulbahce, Natali; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-68</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Diseases are increasingly being found to reflect the perturbations of complex mol. networks.  The principles of network medicine are being used to identify new disease genes, det. the functional significance of disease-assocd. mutations, and identify new drug targets and biomarkers.  Given the functional interdependencies between the mol. components in a human cell, a disease is rarely a consequence of an abnormality in a single gene, but reflects the perturbations of the complex intracellular and intercellular network that links tissue and organ systems.  The emerging tools of network medicine offer a platform to explore systematically not only the mol. complexity of a particular disease, leading to the identification of disease modules and pathways, but also the mol. relationships among apparently distinct (patho)phenotypes.  Advances in this direction are essential for identifying new disease genes, for uncovering the biol. significance of disease-assocd. mutations identified by genome-wide assocn. studies and full-genome sequencing, and for identifying drug targets and biomarkers for complex diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTINXPcbp-brVg90H21EOLACvtfcHk0lgG8IuoTSQrdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOiu7vM&md5=9ea3a47ba09cf0dca734ec341db507a0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrg2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2918%26sid%3Dliteratum%253Aachs%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DGulbahce%26aufirst%3DN.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DNetwork%2520medicine%253A%2520a%2520network-based%2520approach%2520to%2520human%2520disease%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2011%26volume%3D12%26spage%3D56%26epage%3D68%26doi%3D10.1038%2Fnrg2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Alzheimer’s disease: new approaches to drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2009.04.619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.cbpa.2009.04.619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=19467915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWlur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=303-308&author=M.+L.+Bolognesiauthor=R.+Materaauthor=A.+Minariniauthor=M.+Rosiniauthor=C.+Melchiorre&title=Alzheimer%E2%80%99s+disease%3A+new+approaches+to+drug+discovery&doi=10.1016%2Fj.cbpa.2009.04.619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: new approaches to drug discovery</span></div><div class="casAuthors">Bolognesi, Maria L.; Matera, Riccardo; Minarini, Anna; Rosini, Michela; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-308</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this work, we review and comment upon the challenges and the quo vadis' in Alzheimer's disease drug discovery at the beginning of the new millennium.  We emphasize recent approaches that, moving on from a target-centric approach, have produced innovative mol. probes or drug candidates.  In particular, the discovery of endosome-targeted BACE1 inhibitors and mitochondria-targeted antioxidants represents a significant advance in Alzheimer's research and therapy.  The case study of the development of rasagiline provides an excellent example to support the validity of the multitarget-designed ligand approach to the search for effective medicines for combating Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IG07GjEOtbVg90H21EOLACvtfcHk0liZZ-yu1nqHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWlur0%253D&md5=76b399f0ed60cd43625c7f2217409a2c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.04.619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.04.619%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMatera%26aufirst%3DR.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520new%2520approaches%2520to%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D303%26epage%3D308%26doi%3D10.1016%2Fj.cbpa.2009.04.619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Prati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer’s disease</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466-478&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+chemical+space+of+multitarget-directed+ligands%3A+from+hybrids+to+fragments+in+Alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0liZZ-yu1nqHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520chemical%2520space%2520of%2520multitarget-directed%2520ligands%253A%2520from%2520hybrids%2520to%2520fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D466%26epage%3D478%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+anti-targets+for+cancer+polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0liZZ-yu1nqHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lj_wzoO_o3BCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7339</span><span class="NLM_x">–</span> <span class="NLM_lpage">7359</span><span class="refDoi"> DOI: 10.1021/jm9004835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1ehtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7339-7359&author=A.+Cavalliauthor=M.+L.+Bolognesi&title=Neglected+tropical+diseases%3A+multi-target-directed+ligands+in+the+search+for+novel+lead+candidates+against+Trypanosoma+and+Leishmania&doi=10.1021%2Fjm9004835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against Trypanosoma and Leishmania</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7339-7359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Multi-Target-Directed Ligands in the search for novel lead candidates against neglected tropical diseases like Trypanosomiasis and Leishmaniasis is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA_YvlDGyaUbVg90H21EOLACvtfcHk0lj_wzoO_o3BCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1ehtLg%253D&md5=caf70e02c3d2b9ccc99576678c41d8fa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm9004835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004835%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNeglected%2520tropical%2520diseases%253A%2520multi-target-directed%2520ligands%2520in%2520the%2520search%2520for%2520novel%2520lead%2520candidates%2520against%2520Trypanosoma%2520and%2520Leishmania%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7339%26epage%3D7359%26doi%3D10.1021%2Fjm9004835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Syed, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, K.</span><span> </span><span class="NLM_article-title">Smoking cessation drugs market</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1038/nrd3914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrd3914" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=97-98&author=B.+A.+Syedauthor=K.+Chaudhari&title=Smoking+cessation+drugs+market&doi=10.1038%2Fnrd3914"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3914%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DB.%2BA.%26aulast%3DChaudhari%26aufirst%3DK.%26atitle%3DSmoking%2520cessation%2520drugs%2520market%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D97%26epage%3D98%26doi%3D10.1038%2Fnrd3914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">World Health Organization</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">Report on the global tobacco epidemic: enforcing bans on tobacco advertising, promotion and sponsorship</span>. <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+Report+on+the+global+tobacco+epidemic%3A+enforcing+bans+on+tobacco+advertising%2C+promotion+and+sponsorship.+World+Health+Organization%3A+Geneva%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DReport%2520on%2520the%2520global%2520tobacco%2520epidemic%253A%2520enforcing%2520bans%2520on%2520tobacco%2520advertising%252C%2520promotion%2520and%2520sponsorship%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Benowitz, N. L.</span><span> </span><span class="NLM_article-title">Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.48.113006.094742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1146%2Fannurev.pharmtox.48.113006.094742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18834313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2jsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=57-71&author=N.+L.+Benowitz&title=Pharmacology+of+nicotine%3A+addiction%2C+smoking-induced+disease%2C+and+therapeutics&doi=10.1146%2Fannurev.pharmtox.48.113006.094742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics</span></div><div class="casAuthors">Benowitz, Neal L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-71</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Nicotine sustains tobacco addiction, a major cause of disability and premature death.  Nicotine binds to nicotinic cholinergic receptors, facilitating neurotransmitter release and thereby mediating the complex actions of nicotine in tobacco users.  Dopamine, glutamate, and gamma-aminobutyric acid release are particularly important in the development of nicotine dependence, and corticotropin-releasing factor appears to contribute to nicotine withdrawal.  Nicotine dependence is highly heritable.  Genetic studies indicate roles for nicotinic receptor subtypes, as well as genes involved in neuroplasticity and learning, in the development of dependence.  Nicotine is primarily metabolized by CYP 2A6, and variability in the rate of metab. contributes to vulnerability to tobacco dependence, response to smoking cessation treatment, and lung cancer risk.  Tobacco addiction is much more common in persons with mental illness and substance abuse disorders, representing a high proportion of current smokers.  Pharmacotherapeutic approaches to tobacco addiction include nicotine replacement, bupropion, and Varenicline, the latter a selective nicotine receptor partial agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCj2sDCfVrf7Vg90H21EOLACvtfcHk0lgp3YUgiQIk_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2jsL8%253D&md5=76e0755fa21f9f83c0e7fb38e43242cb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.113006.094742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.113006.094742%26sid%3Dliteratum%253Aachs%26aulast%3DBenowitz%26aufirst%3DN.%2BL.%26atitle%3DPharmacology%2520of%2520nicotine%253A%2520addiction%252C%2520smoking-induced%2520disease%252C%2520and%2520therapeutics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2009%26volume%3D49%26spage%3D57%26epage%3D71%26doi%3D10.1146%2Fannurev.pharmtox.48.113006.094742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">D’Souza, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markou, A.</span><span> </span><span class="NLM_article-title">Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments</span> <span class="citation_source-journal">Addict. Sci. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22003417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A280%3ADC%252BC3Mbhs1Gjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=4-16&author=M.+S.+D%E2%80%99Souzaauthor=A.+Markou&title=Neuronal+mechanisms+underlying+development+of+nicotine+dependence%3A+implications+for+novel+smoking-cessation+treatments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments</span></div><div class="casAuthors">D'Souza Manoranjan S; Markou Athina</div><div class="citationInfo"><span class="NLM_cas:title">Addiction science & clinical practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tobacco smoking causes high rates of mortality and morbidity throughout the world.  Despite the availability of smoking-cessation medications, maintenance of long-term abstinence is difficult, and most individuals who attempt to quit smoking relapse.  Although tobacco smoke contains many substances, researchers and policymakers agree that nicotine is a major cause of tobacco dependence.  Understanding the neural substrates of nicotine dependence is essential for the development of more effective antismoking medications than those currently available.  This article focuses on the neural substrates, especially nicotinic acetylcholine receptors, that mediate the reinforcing effects of nicotine and the development of nicotine dependence.  Neuroadaptations in the function of the neurotransmitters dopamine, glutamate, and gamma-aminobutyric acid (GABA), which have been shown to be critically involved in nicotine dependence, are also reviewed.  Finally, the article discusses progress in the discovery and development of smoking-cessation medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnNF5GDChlcI3yKPtYViAGfW6udTcc2eaAfoLuoruxg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mbhs1Gjtw%253D%253D&md5=45506372d3563c3a8ceeca32a7c3dbd2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DM.%2BS.%26aulast%3DMarkou%26aufirst%3DA.%26atitle%3DNeuronal%2520mechanisms%2520underlying%2520development%2520of%2520nicotine%2520dependence%253A%2520implications%2520for%2520novel%2520smoking-cessation%2520treatments%26jtitle%3DAddict.%2520Sci.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D6%26spage%3D4%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Picciotto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineur, Y. S.</span><span> </span><span class="NLM_article-title">Molecules and circuits involved in nicotine addiction: the many faces of smoking</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">Part B</span><span class="NLM_x">) </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.neuropharm.2013.04.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=545-553&issue=Part+B&author=M.+R.+Picciottoauthor=Y.+S.+Mineur&title=Molecules+and+circuits+involved+in+nicotine+addiction%3A+the+many+faces+of+smoking&doi=10.1016%2Fj.neuropharm.2013.04.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DPicciotto%26aufirst%3DM.%2BR.%26aulast%3DMineur%26aufirst%3DY.%2BS.%26atitle%3DMolecules%2520and%2520circuits%2520involved%2520in%2520nicotine%2520addiction%253A%2520the%2520many%2520faces%2520of%2520smoking%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D76%26issue%3DPart%2520B%26spage%3D545%26epage%3D553%26doi%3D10.1016%2Fj.neuropharm.2013.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Fernandez-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, J. A.</span><span> </span><span class="NLM_article-title">Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders</span> <span class="citation_source-journal">CNS Neurosci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">e72</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00144.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1755-5949.2010.00144.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=e72-91&author=J.+Fernandez-Ruizauthor=M.+Hernandezauthor=J.+A.+Ramos&title=Cannabinoid-dopamine+interaction+in+the+pathophysiology+and+treatment+of+CNS+disorders&doi=10.1111%2Fj.1755-5949.2010.00144.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00144.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00144.x%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DJ.%2BA.%26atitle%3DCannabinoid-dopamine%2520interaction%2520in%2520the%2520pathophysiology%2520and%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2010%26volume%3D16%26spage%3De72%26epage%3D91%26doi%3D10.1111%2Fj.1755-5949.2010.00144.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Melis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muntoni, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillolla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessa, G. L.</span><span> </span><span class="NLM_article-title">Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4503-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1523%2FJNEUROSCI.4503-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=14715937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=53-62&author=M.+Melisauthor=M.+Pistisauthor=S.+Perraauthor=A.+L.+Muntoniauthor=G.+Pillollaauthor=G.+L.+Gessa&title=Endocannabinoids+mediate+presynaptic+inhibition+of+glutamatergic+transmission+in+rat+ventral+tegmental+area+dopamine+neurons+through+activation+of+CB1+receptors&doi=10.1523%2FJNEUROSCI.4503-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors</span></div><div class="casAuthors">Melis, Miriam; Pistis, Marco; Perra, Simona; Muntoni, Anna Lisa; Pillolla, Giuliano; Gessa, Gian Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endogenous cannabinoid system has been shown to play a crucial role in controlling neuronal excitability and synaptic transmission.  In this study the authors investigated the effects of a cannabinoid receptor (CB-R) agonist WIN 55,212-2 (WIN) on excitatory synaptic transmission in the rat ventral tegmental area (VTA).  Whole-cell patch clamp recordings were performed from VTA dopamine (DA) neurons in an in vitro slice prepn.  WIN reduced both NMDA and AMPA EPSCs, as well as miniature EPSCs (mEPSCs), and increased the paired-pulse ratio, indicating a presynaptic locus of its action.  The authors also found that WIN-induced effects were dose-dependent and mimicked by the CB1-R agonist HU210.  Furthermore, two CB1-R antagonists, AM281 and SR141716A, blocked WIN-induced effects, suggesting that WIN modulates excitatory synaptic transmission via activation of CB1-Rs.  The authors' addnl. that both AM281 and SR141716A per se increased NMDA EPSCs suggests that endogenous cannabinoids, released from depolarized postsynaptic neurons, might act retrogradely on presynaptic CB1-Rs to suppress glutamate release.  Hence, the authors report that a type of synaptic modulation, previously termed depolarization-induced suppression of excitation (DSE), is present also in the VTA as a calcium-dependent phenomenon, blocked by both AM281 and SR141716A, and occluded by WIN.  Importantly, DSE was partially blocked by the D2DA antagonist eticlopride and enhanced by the D2DA agonist quinpirole without changing the presynaptic cannabinoid sensitivity.  These results indicate that the two pathways work in a cooperative manner to release endocannabinoids in the VTA, where they play a role as retrograde messengers for DSE via CB1-Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL8pQqBa25HrVg90H21EOLACvtfcHk0lg26GSlKCn-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2ntA%253D%253D&md5=5caa0d3c3d3c61e25bf3911c3dd96182</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4503-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4503-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DPistis%26aufirst%3DM.%26aulast%3DPerra%26aufirst%3DS.%26aulast%3DMuntoni%26aufirst%3DA.%2BL.%26aulast%3DPillolla%26aufirst%3DG.%26aulast%3DGessa%26aufirst%3DG.%2BL.%26atitle%3DEndocannabinoids%2520mediate%2520presynaptic%2520inhibition%2520of%2520glutamatergic%2520transmission%2520in%2520rat%2520ventral%2520tegmental%2520area%2520dopamine%2520neurons%2520through%2520activation%2520of%2520CB1%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D53%26epage%3D62%26doi%3D10.1523%2FJNEUROSCI.4503-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hartmann-Boyce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stead, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, T.</span><span> </span><span class="NLM_article-title">Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews</span> <span class="citation_source-journal">Addiction</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1721</span><span class="refDoi"> DOI: 10.1111/add.12291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fadd.12291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=1711-1721&author=J.+Hartmann-Boyceauthor=L.+F.+Steadauthor=K.+Cahillauthor=T.+Lancaster&title=Efficacy+of+interventions+to+combat+tobacco+addiction%3A+Cochrane+update+of+2012+reviews&doi=10.1111%2Fadd.12291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fadd.12291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadd.12291%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann-Boyce%26aufirst%3DJ.%26aulast%3DStead%26aufirst%3DL.%2BF.%26aulast%3DCahill%26aufirst%3DK.%26aulast%3DLancaster%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520interventions%2520to%2520combat%2520tobacco%2520addiction%253A%2520Cochrane%2520update%2520of%25202012%2520reviews%26jtitle%3DAddiction%26date%3D2013%26volume%3D108%26spage%3D1711%26epage%3D1721%26doi%3D10.1111%2Fadd.12291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mihalak, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetje, C. W.</span><span> </span><span class="NLM_article-title">Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1124/mol.106.025130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1124%2Fmol.106.025130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=801-805&author=K.+B.+Mihalakauthor=F.+I.+Carrollauthor=C.+W.+Luetje&title=Varenicline+is+a+partial+agonist+at+alpha4beta2+and+a+full+agonist+at+alpha7+neuronal+nicotinic+receptors&doi=10.1124%2Fmol.106.025130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025130%26sid%3Dliteratum%253Aachs%26aulast%3DMihalak%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DLuetje%26aufirst%3DC.%2BW.%26atitle%3DVarenicline%2520is%2520a%2520partial%2520agonist%2520at%2520alpha4beta2%2520and%2520a%2520full%2520agonist%2520at%2520alpha7%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D801%26epage%3D805%26doi%3D10.1124%2Fmol.106.025130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Crooks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwoskin, L. P.</span><span> </span><span class="NLM_article-title">Nicotinic receptor antagonists as treatments for nicotine abuse</span> <span class="citation_source-journal">Adv. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span><span class="refDoi"> DOI: 10.1016/B978-0-12-420118-7.00013-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2FB978-0-12-420118-7.00013-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=513-551&author=P.+A.+Crooksauthor=M.+T.+Bardoauthor=L.+P.+Dwoskin&title=Nicotinic+receptor+antagonists+as+treatments+for+nicotine+abuse&doi=10.1016%2FB978-0-12-420118-7.00013-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-420118-7.00013-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-420118-7.00013-5%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26aulast%3DBardo%26aufirst%3DM.%2BT.%26aulast%3DDwoskin%26aufirst%3DL.%2BP.%26atitle%3DNicotinic%2520receptor%2520antagonists%2520as%2520treatments%2520for%2520nicotine%2520abuse%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D513%26epage%3D551%26doi%3D10.1016%2FB978-0-12-420118-7.00013-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Micheli, F.</span><span> </span><span class="NLM_article-title">Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1162</span><span class="refDoi"> DOI: 10.1002/cmdc.201000538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2Fcmdc.201000538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21425240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1152-1162&author=F.+Micheli&title=Recent+advances+in+the+development+of+dopamine+D3+receptor+antagonists%3A+a+medicinal+chemistry+perspective&doi=10.1002%2Fcmdc.201000538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective</span></div><div class="casAuthors">Micheli, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1152-1162</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Dopamine (DA) D3 receptor antagonism might play a significant role in different therapeutic areas.  A high no. of preclin. studies on DA D3 receptor antagonists have shown efficacy in animal models of Parkinson's disease, schizophrenia and drug dependence.  This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compds.  Both primary and patent literature is reviewed here.  Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers.  Examples of advanced leads from academia and industry are described.  The latest potential therapeutic applications are reported too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhYCeq4b9EbVg90H21EOLACvtfcHk0lhUH1Wu-Kk3pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCntbk%253D&md5=61c2b60b5e69df3517421e922b7aa73a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000538%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520dopamine%2520D3%2520receptor%2520antagonists%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1152%26epage%3D1162%26doi%3D10.1002%2Fcmdc.201000538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaylock, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skolnick, P.</span><span> </span><span class="NLM_article-title">Medication discovery for addiction: translating the dopamine D3 receptor hypothesis</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.bcp.2012.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22781742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=882-890&author=A.+H.+Newmanauthor=B.+L.+Blaylockauthor=M.+a.+Naderauthor=J.+Bergmanauthor=D.+R.+Sibleyauthor=P.+Skolnick&title=Medication+discovery+for+addiction%3A+translating+the+dopamine+D3+receptor+hypothesis&doi=10.1016%2Fj.bcp.2012.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis</span></div><div class="casAuthors">Newman, Amy Hauck; Blaylock, Brandi L.; Nader, Michael A.; Bergman, Jack; Sibley, David R.; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine.  Currently, there are no approved medications to treat cocaine and methamphetamine addiction and thus developing pharmacotherapeutics to complement existing behavioral strategies is a fundamental goal.  Novel compds. with high affinity and D3R selectivity have been evaluated in numerous animal models of drug abuse and favorable outcomes in nonhuman primate models of self-administration and relapse have provided compelling evidence to advance these agents into the clinic.  One approach is to repurpose drugs that share the D3R mechanism and already have clin. utility, and to this end buspirone has been identified as a viable candidate for clin. trials.  A second, but substantially more resource intensive and risky approach involves the development of compds. that exclusively target D3R, such as GSK598809 and PG 619.  Clin. investigation of these drugs or other novel D3R-selective agents will provide a better understanding of the role D3R plays in addiction and whether or not antagonists or partial agonists that are D3R selective are effective in achieving abstinence in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_waGudfGt4LVg90H21EOLACvtfcHk0li6qnWaUauENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O&md5=820f1ddd46c9888c687bc0cc8cd3aa96</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBlaylock%26aufirst%3DB.%2BL.%26aulast%3DNader%26aufirst%3DM.%2Ba.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DMedication%2520discovery%2520for%2520addiction%253A%2520translating%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D882%26epage%3D890%26doi%3D10.1016%2Fj.bcp.2012.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. A.</span><span> </span><span class="NLM_article-title">Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3663</span><span class="NLM_x">–</span> <span class="NLM_lpage">3679</span><span class="refDoi"> DOI: 10.1021/jm040190e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040190e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtl2nur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3663-3679&author=A.+H.+Newmanauthor=P.+Grundtauthor=M.+A.+Nader&title=Dopamine+D3+receptor+partial+agonists+and+antagonists+as+potential+drug+abuse+therapeutic+agents&doi=10.1021%2Fjm040190e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents</span></div><div class="casAuthors">Newman, Amy Hauck; Grundt, Peter; Nader, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3663-3679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This report is limited to discussions of potential dopamine D3 receptor agents, currently being developed as medications for drug abuse and other neuropsychiatric disorders, to partial agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqHXSFV83KfLVg90H21EOLACvtfcHk0li6qnWaUauENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtl2nur0%253D&md5=4244539d9e8038e2027dba1e21497cdd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm040190e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040190e%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DNader%26aufirst%3DM.%2BA.%26atitle%3DDopamine%2520D3%2520receptor%2520partial%2520agonists%2520and%2520antagonists%2520as%2520potential%2520drug%2520abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3663%26epage%3D3679%26doi%3D10.1021%2Fjm040190e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Moreira, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalley, J. W.</span><span> </span><span class="NLM_article-title">Dopamine receptor partial agonists and addiction</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">752</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2015.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.ejphar.2015.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=25724788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=752&publication_year=2015&pages=112-115&author=F.+A.+Moreiraauthor=J.+W.+Dalley&title=Dopamine+receptor+partial+agonists+and+addiction&doi=10.1016%2Fj.ejphar.2015.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor partial agonists and addiction</span></div><div class="casAuthors">Moreira, Fabricio A.; Dalley, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">752</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-115</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many drugs abused by humans acutely facilitate, either directly or indirectly, dopamine neurotransmission in the mesolimbic pathway.  As a consequence dopamine receptor agonists and antagonists have been widely investigated as putative pharmacol. therapies for addiction.  This general strategy, however, has had only limited success due in part to poor treatment adherence and efficacy and the significant adverse effects of dopaminergic medications.  In this perspective, we discuss the potential therapeutic use of dopamine receptor partial agonists in addiction, developed initially as antipsychotic agents.  Recent research indicates that the dopamine D2 receptor partial agonists, such as aripiprazole, also shows useful ancillary efficacy in several animal models of psychostimulant and opioid addiction.  Notably, these findings suggest that unlike full dopamine receptor agonists and antagonists these compds. have low abuse liability and are generally well tolerated.  Indeed, partial dopamine agonists attenuate the rewarding properties of opioids without interfering with their analgesic effects.  Herein we discuss the utility and potential of dopamine receptor partial agonists as treatments for both stimulant and non-stimulant drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8T303gZlZT7Vg90H21EOLACvtfcHk0lgZliLUCXTclA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gqu7s%253D&md5=42a1128d4293e5e30963ee7fae789bcf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DMoreira%26aufirst%3DF.%2BA.%26aulast%3DDalley%26aufirst%3DJ.%2BW.%26atitle%3DDopamine%2520receptor%2520partial%2520agonists%2520and%2520addiction%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D752%26spage%3D112%26epage%3D115%26doi%3D10.1016%2Fj.ejphar.2015.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Heidbreder, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1187</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1749-6632.2009.05149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=20201845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=4-34&author=C.+A.+Heidbrederauthor=A.+H.+Newman&title=Current+perspectives+on+selective+dopamine+D%283%29+receptor+antagonists+as+pharmacotherapeutics+for+addictions+and+related+disorders&doi=10.1111%2Fj.1749-6632.2009.05149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders</span></div><div class="casAuthors">Heidbreder, Christian A.; Newman, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">4-34</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Repeated exposure to drugs of abuse produces long-term mol. and neurochem. changes that may explain the core features of addiction, such as the compulsive seeking and taking of the drug, as well as the risk of relapse.  A growing no. of new mol. and cellular targets of addictive drugs have been identified, and rapid advances are being made in relating those targets to specific behavioral phenotypes in animal models of addiction.  In this context, the pattern of expression of the dopamine (DA) D3 receptor in the rodent and human brain and changes in this pattern in response to drugs of abuse have contributed primarily to direct research efforts toward the development of selective DA D3 receptor antagonists.  Growing preclin. evidence indicates that these compds. may actually regulate the motivation to self-administer drugs and disrupt drug-assocd. cue-induced craving.  This report will be divided into three parts.  First, preclin. evidence in support of the efficacy of selective DA D3 receptor antagonists in animal models of drug addiction will be reviewed.  The effects of mixed DA D2/D3 receptor antagonists will not be discussed here because most of these compds. have low selectivity at the D3 vs. D2 receptor, and their efficacy profile is related primarily to functional antagonism at D2 receptors and possibly interactions with other neurotransmitter systems.  Second, major advances in medicinal chem. for the identification and optimization of selective DA D3 receptor antagonists and partial agonists will be analyzed.  Third, translational research from preclin. efficacy studies to so-called proof-of-concept studies for drug addiction indications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarcQYm33s6LVg90H21EOLACvtfcHk0lgZliLUCXTclA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D&md5=48ded12d27f36b8d77717b118ccfa869</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05149.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DCurrent%2520perspectives%2520on%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%2520as%2520pharmacotherapeutics%2520for%2520addictions%2520and%2520related%2520disorders%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D4%26epage%3D34%26doi%3D10.1111%2Fj.1749-6632.2009.05149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Keck, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czoty, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5361</span><span class="NLM_x">–</span> <span class="NLM_lpage">5380</span><span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0lhe7iyK-OPIhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Scherma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panlilio, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamaleddin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Foll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justinova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikics, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medalie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fratta, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1124/jpet.108.142224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1124%2Fjpet.108.142224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18725543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=482-490&author=M.+Schermaauthor=L.+V.+Panlilioauthor=P.+Faddaauthor=L.+Fattoreauthor=I.+Gamaleddinauthor=B.+Le+Follauthor=Z.+Justinovaauthor=E.+Mikicsauthor=J.+Hallerauthor=J.+Medalieauthor=J.+Stroikauthor=C.+Barnesauthor=S.+Yasarauthor=G.+Tandaauthor=D.+Piomelliauthor=W.+Frattaauthor=S.+R.+Goldberg&title=Inhibition+of+anandamide+hydrolysis+by+cyclohexyl+carbamic+acid+3%E2%80%B2-carbamoyl-3-yl+ester+%28URB597%29+reverses+abuse-related+behavioral+and+neurochemical+effects+of+nicotine+in+rats&doi=10.1124%2Fjpet.108.142224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats</span></div><div class="casAuthors">Scherma, Maria; Panlilio, Leigh V.; Fadda, Paola; Fattore, Liana; Gamaleddin, Islam; Le Foll, Bernard; Justinova, Zuzana; Mikics, Eva; Haller, Jozsef; Medalie, Julie; Stroik, Jessica; Barnes, Chanel; Yasar, Sevil; Tanda, Gianluigi; Piomelli, Daniele; Fratta, Walter; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Emerging evidence suggests that the rewarding, abuse-related effects of nicotine are modulated by the endocannabinoid system of the brain.  For example, pharmacol. blockade or genetic deletion of cannabinoid CB1 receptors can reduce or eliminate many abuse-related behavioral and neurochem. effects of nicotine.  Furthermore, doses of Δ9-tetrahydrocannabinol and nicotine that are ineffective when given alone can induce conditioned place preference when given together.  These previous studies have used systemically administered CB1 receptor agonists and antagonists and gene deletion techniques, which affect cannabinoid CB1 receptors throughout the brain.  A more functionally selective way to alter endocannabinoid activity is to inhibit fatty acid amide hydrolase (FAAH), thereby magnifying and prolonging the effects of the endocannabinoid anandamide only when and where it is synthesized and released on demand.  Here, we combined behavioral and neurochem. approaches to evaluate whether the FAAH inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) could alter the abuse-related effects of nicotine in rats.  We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects by itself, prevented development of nicotine-induced conditioned place preference (CPP) and acquisition of nicotine self-administration.  URB597 also reduced nicotine-induced reinstatement in both CPP and self-administration models of relapse.  Furthermore, in vivo microdialysis showed that URB597 reduced nicotine-induced dopamine elevations in the nucleus accumbens shell, the terminal area of the brain's mesolimbic reward system.  These findings suggest that FAAH inhibition can counteract the addictive properties of nicotine and that FAAH may serve as a new target for development of medications for treatment of tobacco dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphdm-HRHpIKLVg90H21EOLACvtfcHk0lhe7iyK-OPIhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7rJ&md5=5391ce52b5d6ce4b27d7af2cd5c2d534</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142224%26sid%3Dliteratum%253Aachs%26aulast%3DScherma%26aufirst%3DM.%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DFadda%26aufirst%3DP.%26aulast%3DFattore%26aufirst%3DL.%26aulast%3DGamaleddin%26aufirst%3DI.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DMikics%26aufirst%3DE.%26aulast%3DHaller%26aufirst%3DJ.%26aulast%3DMedalie%26aufirst%3DJ.%26aulast%3DStroik%26aufirst%3DJ.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DYasar%26aufirst%3DS.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DFratta%26aufirst%3DW.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520of%2520anandamide%2520hydrolysis%2520by%2520cyclohexyl%2520carbamic%2520acid%25203%25E2%2580%25B2-carbamoyl-3-yl%2520ester%2520%2528URB597%2529%2520reverses%2520abuse-related%2520behavioral%2520and%2520neurochemical%2520effects%2520of%2520nicotine%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D482%26epage%3D490%26doi%3D10.1124%2Fjpet.108.142224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Parsons, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, Y. L.</span><span> </span><span class="NLM_article-title">Endocannabinoid signalling in reward and addiction</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1038/nrn4004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrn4004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=26373473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=579-594&author=L.+H.+Parsonsauthor=Y.+L.+Hurd&title=Endocannabinoid+signalling+in+reward+and+addiction&doi=10.1038%2Fnrn4004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling in reward and addiction</span></div><div class="casAuthors">Parsons, Loren H.; Hurd, Yasmin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">579-594</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Brain endocannabinoid (eCB) signaling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs.  Pathol. forms of natural and drug-induced reward are assocd. with dysregulated eCB signaling that may derive from pre-existing genetic factors or from prolonged drug exposure.  Impaired eCB signaling contributes to dysregulated synaptic plasticity, increased stress responsivity, neg. emotional states and cravings that propel addiction.  Understanding the contributions of eCB disruptions to behavioral and physiol. traits provides insight into the eCB influence on addiction vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s5P4XZrYGbVg90H21EOLACvtfcHk0lge79Jnv_1IHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF&md5=0a7180790eba188007435ec107c6a2a9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrn4004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4004%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DHurd%26aufirst%3DY.%2BL.%26atitle%3DEndocannabinoid%2520signalling%2520in%2520reward%2520and%2520addiction%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D579%26epage%3D594%26doi%3D10.1038%2Fnrn4004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Panlilio, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justinova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pharmthera.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=23333350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlamsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=84-102&author=L.+V.+Panlilioauthor=Z.+Justinovaauthor=S.+R.+Goldberg&title=Inhibition+of+FAAH+and+activation+of+PPAR%3A+new+approaches+to+the+treatment+of+cognitive+dysfunction+and+drug+addiction&doi=10.1016%2Fj.pharmthera.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction</span></div><div class="casAuthors">Panlilio, Leigh V.; Justinova, Zuzana; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-102</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Enhancing the effects of endogenously-released cannabinoid ligands in the brain might provide therapeutic effects more safely and effectively than administering drugs that act directly at the cannabinoid receptor.  Inhibitors of fatty acid amide hydrolase (FAAH) prevent the breakdown of endogenous ligands for cannabinoid receptors and peroxisome proliferator-activated receptors (PPAR), prolonging and enhancing the effects of these ligands when they are naturally released.  This review considers recent research on the effects of FAAH inhibitors and PPAR activators in animal models of addiction and cognition (specifically learning and memory).  These studies show that FAAH inhibitors can produce potentially therapeutic effects, some through cannabinoid receptors and some through PPAR.  These effects include enhancing certain forms of learning, counteracting the rewarding effects of nicotine and alc., relieving symptoms of withdrawal from cannabis and other drugs, and protecting against relapse-like reinstatement of drug self-administration.  Since FAAH inhibition might have a wide range of therapeutic actions but might also share some of the adverse effects of cannabis, it is noteworthy that at least one FAAH-inhibiting drug (URB597) has been found to have potentially beneficial effects but no indication of liability for abuse or dependence.  Although these areas of research are new, the preliminary evidence indicates that they might lead to improved therapeutic interventions and a better understanding of the brain mechanisms underlying addiction and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVfd0ns0RUZrVg90H21EOLACvtfcHk0lge79Jnv_1IHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlamsrc%253D&md5=a13bc121f2523849c97c8029d279e8a7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520of%2520FAAH%2520and%2520activation%2520of%2520PPAR%253A%2520new%2520approaches%2520to%2520the%2520treatment%2520of%2520cognitive%2520dysfunction%2520and%2520drug%2520addiction%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D138%26spage%3D84%26epage%3D102%26doi%3D10.1016%2Fj.pharmthera.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Melis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillolla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchicchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muntoni, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistis, M.</span><span> </span><span class="NLM_article-title">Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">13985</span><span class="NLM_x">–</span> <span class="NLM_lpage">13994</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3221-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1523%2FJNEUROSCI.3221-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=19091987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCqtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=13985-13994&author=M.+Melisauthor=G.+Pillollaauthor=A.+Luchicchiauthor=A.+L.+Muntoniauthor=S.+Yasarauthor=S.+R.+Goldbergauthor=M.+Pistis&title=Endogenous+fatty+acid+ethanolamides+suppress+nicotine-induced+activation+of+mesolimbic+dopamine+neurons+through+nuclear+receptors&doi=10.1523%2FJNEUROSCI.3221-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors</span></div><div class="casAuthors">Melis, Miriam; Pillolla, Giuliano; Luchicchi, Antonio; Muntoni, Anna Lisa; Yasar, Sevil; Goldberg, Steven R.; Pistis, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13985-13994</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Nicotine stimulates the activity of mesolimbic dopamine neurons, which is believed to mediate the rewarding and addictive properties of tobacco use.  Accumulating evidence suggests that the endocannabinoid system might play a major role in neuronal mechanisms underlying the rewarding properties of drugs of abuse, including nicotine.  Here, we investigated the modulation of nicotine effects by the endocannabinoid system on dopamine neurons in the ventral tegmental area with electrophysiol. techniques in vivo and in vitro.  We discovered that pharmacol. inhibition of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes fatty acid ethanolamides, among which the endocannabinoid anandamide (AEA) is the best known, suppressed nicotine-induced excitation of dopamine cells.  Importantly, this effect was mimicked by the administration of the FAAH substrates oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), but not methanandamide, the hydrolysis resistant analog of AEA.  OEA and PEA are naturally occurring lipid signaling mols. structurally related to AEA, but devoid of affinity for cannabinoid receptors.  They blocked the effects of nicotine by activation of the peroxisome proliferator-activated receptor-α (PPAR-α), a nuclear receptor transcription factor involved in several aspects of lipid metab. and energy balance.  Activation of PPAR-α triggered a nongenomic stimulation of tyrosine kinases, which might lead to phosphorylation and neg. regulation of neuronal nicotinic acetylcholine receptors.  These data indicate for the first time that the anorexic lipids OEA and PEA possess neuromodulatory properties as endogenous ligands of PPAR-α in the brain and provide a potential new target for the treatment of nicotine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_T8NIOwF2rrVg90H21EOLACvtfcHk0lge79Jnv_1IHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCqtrfO&md5=01da030bc1b18420c7fa15e521aae97c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3221-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3221-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DPillolla%26aufirst%3DG.%26aulast%3DLuchicchi%26aufirst%3DA.%26aulast%3DMuntoni%26aufirst%3DA.%2BL.%26aulast%3DYasar%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26aulast%3DPistis%26aufirst%3DM.%26atitle%3DEndogenous%2520fatty%2520acid%2520ethanolamides%2520suppress%2520nicotine-induced%2520activation%2520of%2520mesolimbic%2520dopamine%2520neurons%2520through%2520nuclear%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D13985%26epage%3D13994%26doi%3D10.1523%2FJNEUROSCI.3221-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaetani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fegley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calignano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giustino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tattoli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Modulation of anxiety through blockade of anandamide hydrolysis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1038/nm803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnm803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=12461523" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=76-81&author=S.+Kathuriaauthor=S.+Gaetaniauthor=D.+Fegleyauthor=F.+Valinoauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=G.+Tarziaauthor=G.+La+Ranaauthor=A.+Calignanoauthor=A.+Giustinoauthor=M.+Tattoliauthor=M.+Palmeryauthor=V.+Cuomoauthor=D.+Piomelli&title=Modulation+of+anxiety+through+blockade+of+anandamide+hydrolysis&doi=10.1038%2Fnm803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnm803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm803%26sid%3Dliteratum%253Aachs%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DFegley%26aufirst%3DD.%26aulast%3DValino%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DGiustino%26aufirst%3DA.%26aulast%3DTattoli%26aufirst%3DM.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DModulation%2520of%2520anxiety%2520through%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D9%26spage%3D76%26epage%3D81%26doi%3D10.1038%2Fnm803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">De Simone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4904</span><span class="NLM_x">–</span> <span class="NLM_lpage">4907</span><span class="refDoi"> DOI: 10.1039/c4cc00967c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1039%2Fc4cc00967c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=4904-4907&author=A.+De+Simoneauthor=G.+F.+Rudaauthor=C.+Albaniauthor=G.+Tarozzoauthor=T.+Bandieraauthor=D.+Piomelliauthor=A.+Cavalliauthor=G.+Bottegoni&title=Applying+a+multitarget+rational+drug+design+strategy%3A+the+first+set+of+modulators+with+potent+and+balanced+activity+toward+dopamine+D3+receptor+and+fatty+acid+amide+hydrolase&doi=10.1039%2Fc4cc00967c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fc4cc00967c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cc00967c%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DAlbani%26aufirst%3DC.%26aulast%3DTarozzo%26aufirst%3DG.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DApplying%2520a%2520multitarget%2520rational%2520drug%2520design%2520strategy%253A%2520the%2520first%2520set%2520of%2520modulators%2520with%2520potent%2520and%2520balanced%2520activity%2520toward%2520dopamine%2520D3%2520receptor%2520and%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D4904%26epage%3D4907%26doi%3D10.1039%2Fc4cc00967c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Micoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Simone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottonello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Aryl and heteroaryl N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates with improved physico-chemical properties as dual modulators of dopamine D3 receptor and fatty acid amide hydrolase</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1039/C5MD00590F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1039%2FC5MD00590F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=537-541&author=A.+Micoliauthor=A.+De+Simoneauthor=D.+Russoauthor=G.+Ottonelloauthor=G.+Colombanoauthor=G.+F.+Rudaauthor=T.+Bandieraauthor=A.+Cavalliauthor=G.+Bottegoni&title=Aryl+and+heteroaryl+N-%5B4-%5B4-%282%2C3-substituted-phenyl%29piperazine-1-yl%5Dalkyl%5Dcarbamates+with+improved+physico-chemical+properties+as+dual+modulators+of+dopamine+D3+receptor+and+fatty+acid+amide+hydrolase&doi=10.1039%2FC5MD00590F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC5MD00590F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00590F%26sid%3Dliteratum%253Aachs%26aulast%3DMicoli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DOttonello%26aufirst%3DG.%26aulast%3DColombano%26aufirst%3DG.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DAryl%2520and%2520heteroaryl%2520N-%255B4-%255B4-%25282%252C3-substituted-phenyl%2529piperazine-1-yl%255Dalkyl%255Dcarbamates%2520with%2520improved%2520physico-chemical%2520properties%2520as%2520dual%2520modulators%2520of%2520dopamine%2520D3%2520receptor%2520and%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D537%26epage%3D541%26doi%3D10.1039%2FC5MD00590F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Del Zotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amoroso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigo, P.</span><span> </span><span class="NLM_article-title">Very fast Suzuki-Miyaura reaction catalyzed by Pd(OAc)2 under aerobic conditions at room temperature in EGME/H2O</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1002/ejoc.200800874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2Fejoc.200800874" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=110-116&author=A.+Del+Zottoauthor=F.+Amorosoauthor=W.+Barattaauthor=P.+Rigo&title=Very+fast+Suzuki-Miyaura+reaction+catalyzed+by+Pd%28OAc%292+under+aerobic+conditions+at+room+temperature+in+EGME%2FH2O&doi=10.1002%2Fejoc.200800874"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200800874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200800874%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BZotto%26aufirst%3DA.%26aulast%3DAmoroso%26aufirst%3DF.%26aulast%3DBaratta%26aufirst%3DW.%26aulast%3DRigo%26aufirst%3DP.%26atitle%3DVery%2520fast%2520Suzuki-Miyaura%2520reaction%2520catalyzed%2520by%2520Pd%2528OAc%25292%2520under%2520aerobic%2520conditions%2520at%2520room%2520temperature%2520in%2520EGME%252FH2O%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26volume%3D2009%26spage%3D110%26epage%3D116%26doi%3D10.1002%2Fejoc.200800874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Moreno-Sanz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestichelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5917</span><span class="NLM_x">–</span> <span class="NLM_lpage">5930</span><span class="refDoi"> DOI: 10.1021/jm4007017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5917-5930&author=G.+Moreno-Sanzauthor=A.+Durantiauthor=L.+Melzigauthor=C.+Fiorelliauthor=G.+F.+Rudaauthor=G.+Colombanoauthor=P.+Mestichelliauthor=S.+Sanchiniauthor=A.+Tontiniauthor=M.+Morauthor=T.+Bandieraauthor=R.+Scarpelliauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+structure-activity+relationship+studies+of+O-biphenyl-3-yl+carbamates+as+peripherally+restricted+fatty+acid+amide+hydrolase+inhibitors&doi=10.1021%2Fjm4007017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm4007017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007017%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Sanz%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DColombano%26aufirst%3DG.%26aulast%3DMestichelli%26aufirst%3DP.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520O-biphenyl-3-yl%2520carbamates%2520as%2520peripherally%2520restricted%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5917%26epage%3D5930%26doi%3D10.1021%2Fjm4007017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Grundt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElveen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0lhiTc-8D6WTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banala, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donthamsetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongetti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBounty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6689</span><span class="NLM_x">–</span> <span class="NLM_lpage">6699</span><span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0lhiTc-8D6WTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2352</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span><span class="refDoi"> DOI: 10.1021/jm021119g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm021119g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2352-2360&author=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Piersantiauthor=M.+Morauthor=S.+Rivaraauthor=P.+V.+Plazziauthor=C.+Parkauthor=S.+Kathuriaauthor=D.+Piomelli&title=Design%2C+synthesis%2C+and+structure-activity+relationships+of+alkylcarbamic+acid+aryl+esters%2C+a+new+class+of+fatty+acid+amide+hydrolase+inhibitors&doi=10.1021%2Fjm021119g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm021119g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021119g%26sid%3Dliteratum%253Aachs%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%2520of%2520alkylcarbamic%2520acid%2520aryl%2520esters%252C%2520a%2520new%2520class%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2352%26epage%3D2360%26doi%3D10.1021%2Fjm021119g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4998</span><span class="NLM_x">–</span> <span class="NLM_lpage">5008</span><span class="refDoi"> DOI: 10.1021/jm031140x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031140x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4998-5008&author=M.+Morauthor=S.+Rivaraauthor=A.+Lodolaauthor=P.+V.+Plazziauthor=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Piersantiauthor=S.+Kathuriaauthor=D.+Piomelli&title=Cyclohexylcarbamic+acid+3%E2%80%B2-+or+4%E2%80%B2-substituted+biphenyl-3-yl+esters+as+fatty+acid+amide+hydrolase+inhibitors%3A+synthesis%2C+quantitative+structure-activity+relationships%2C+and+molecular+modeling+studies&doi=10.1021%2Fjm031140x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm031140x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031140x%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DCyclohexylcarbamic%2520acid%25203%25E2%2580%25B2-%2520or%25204%25E2%2580%25B2-substituted%2520biphenyl-3-yl%2520esters%2520as%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520synthesis%252C%2520quantitative%2520structure-activity%2520relationships%252C%2520and%2520molecular%2520modeling%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4998%26epage%3D5008%26doi%3D10.1021%2Fjm031140x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3487</span><span class="NLM_x">–</span> <span class="NLM_lpage">3498</span><span class="refDoi"> DOI: 10.1021/jm701631z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701631z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3487-3498&author=M.+Morauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Durantiauthor=A.+Tontiniauthor=S.+Sanchiniauthor=G.+Piersantiauthor=J.+R.+Clapperauthor=A.+R.+Kingauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+quantitative+structure-activity+relationship+of+fatty+acid+amide+hydrolase+inhibitors%3A+modulation+at+the+N-portion+of+biphenyl-3-yl+alkylcarbamates&doi=10.1021%2Fjm701631z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm701631z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701631z%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520quantitative%2520structure-activity%2520relationship%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520modulation%2520at%2520the%2520N-portion%2520of%2520biphenyl-3-yl%2520alkylcarbamates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3487%26epage%3D3498%26doi%3D10.1021%2Fjm701631z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgW197C02XyUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Cortes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Ruiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canela, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casado, V.</span><span> </span><span class="NLM_article-title">Targeting the dopamine D3 receptor: an overview of drug design strategies</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cortesauthor=E.+Morenoauthor=M.+Rodriguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casado&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0lgW197C02XyUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasado%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Razdan, R. K.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of classical cannabinoids</span>. In  <span class="citation_source-book">The Cannabinoid Receptors</span>; <span class="NLM_contrib-group">Reggio, P. H.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-19&author=R.+K.+Razdanauthor=P.+H.+Reggio&title=The+Cannabinoid+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRazdan%26aufirst%3DR.%2BK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520classical%2520cannabinoids%26btitle%3DThe%2520Cannabinoid%2520Receptors%26aulast%3DReggio%26aufirst%3DP.%2BH.%26pub%3DHumana%2520Press%26date%3D2008%26spage%3D3%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. E.</span><span> </span><span class="NLM_article-title">Ligand-specific homology modeling of human cannabinoid CB1 receptor</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span><span class="refDoi"> DOI: 10.1016/j.jmgm.2012.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.jmgm.2012.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslaqtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=155-164&author=R.+Aiauthor=C.+E.+Chang&title=Ligand-specific+homology+modeling+of+human+cannabinoid+CB1+receptor&doi=10.1016%2Fj.jmgm.2012.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-specific homology modeling of human cannabinoid (CB1) receptor</span></div><div class="casAuthors">Ai, Rizi; Chang, Chia-en A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cannabinoid (CB1) receptor is a therapeutic drug target, and its structure and conformational changes after ligand binding are of great interest.  To study the protein conformations in ligand bound state and assist in drug discovery, CB1 receptor homol. models are needed for computer-based ligand screening.  The known CB1 ligands are highly diverse structurally, so CB1 receptor may undergo considerable conformational changes to accept different ligands, which is challenging for mol. docking methods.  To account for the flexibility of CB1 receptor, we constructed four CB1 receptor models based on four structurally distinct ligands, HU-210, ACEA, WIN 55212-2 and SR 141716A, using the newest X-ray crystal structures of human β2 adrenergic receptor and adenosine A2A receptor as templates.  The conformations of these four CB1-ligand complexes were optimized by mol. dynamics (MD) simulations.  The models revealed interactions between CB1 receptor and known binders suggested by expts. and could successfully discriminate known ligands and non-binders in our docking assays.  MD simulations were used to study the most flexible ligand, ACEA, in its free and bound states to investigate structural mobility achieved by the rearrangement of the fatty acid chain.  Our models may capture important conformational changes of CB1 receptor to help improve accuracy in future CB1 drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPt7qV7XBubVg90H21EOLACvtfcHk0lhjXvdq36R54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslaqtbvN&md5=8d771466ac91897a401ad57e6256125e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2012.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2012.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DC.%2BE.%26atitle%3DLigand-specific%2520homology%2520modeling%2520of%2520human%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2012%26volume%3D38%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.jmgm.2012.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Fichera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumarra, G.</span><span> </span><span class="NLM_article-title">A 3D-QSAR study on the structural requirements for binding to CB (1) and CB(2) cannabinoid receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2309</span><span class="refDoi"> DOI: 10.1021/jm991074s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991074s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2300-2309&author=M.+Ficheraauthor=G.+Crucianiauthor=A.+Bianchiauthor=G.+Musumarra&title=A+3D-QSAR+study+on+the+structural+requirements+for+binding+to+CB+%281%29+and+CB%282%29+cannabinoid+receptors&doi=10.1021%2Fjm991074s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm991074s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991074s%26sid%3Dliteratum%253Aachs%26aulast%3DFichera%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DMusumarra%26aufirst%3DG.%26atitle%3DA%25203D-QSAR%2520study%2520on%2520the%2520structural%2520requirements%2520for%2520binding%2520to%2520CB%2520%25281%2529%2520and%2520CB%25282%2529%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2300%26epage%3D2309%26doi%3D10.1021%2Fjm991074s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Hua, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shui, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laprairie, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvonok, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.+H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+A.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0lhjXvdq36R54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Totrov, M.</span><span> </span><span class="NLM_article-title">Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00605.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1747-0285.2007.00605.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18069986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvF2lsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=15-27&author=M.+Totrov&title=Atomic+property+fields%3A+generalized+3D+pharmacophoric+potential+for+automated+ligand+superposition%2C+pharmacophore+elucidation+and+3D+QSAR&doi=10.1111%2Fj.1747-0285.2007.00605.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR</span></div><div class="casAuthors">Totrov, Maxim</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The at. property fields (APF) concept is introduced as a continuous, multi-component 3D potential that reflects preferences for various at. properties at each point in space.  At. property field-based approaches to several key problems in the field of ligand structure-based rational drug discovery and design are investigated.  The superposition of ligands on one or multiple mol. templates is performed by Monte-Carlo minimization in the at. property fields potentials combined with std. force-field energy.  The approach is extended to multiple flexible ligand alignments using an iterative procedure, Self-Consistent at. Property Fields by Optimization (SCAPFOld).  The application of at. property fields and SCAPFOld for virtual ligand screening and 3D Quantitive Structure-Activity Relationship (QSAR) is tested on published benchmarks.  The new methods are shown to perform competitively in comparison to current state-of-the-art methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFMXqW3d8ErVg90H21EOLACvtfcHk0lhjXvdq36R54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvF2lsL8%253D&md5=d66ce22225d4d9dfeed56196af4025d1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00605.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00605.x%26sid%3Dliteratum%253Aachs%26aulast%3DTotrov%26aufirst%3DM.%26atitle%3DAtomic%2520property%2520fields%253A%2520generalized%25203D%2520pharmacophoric%2520potential%2520for%2520automated%2520ligand%2520superposition%252C%2520pharmacophore%2520elucidation%2520and%25203D%2520QSAR%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2008%26volume%3D71%26spage%3D15%26epage%3D27%26doi%3D10.1111%2Fj.1747-0285.2007.00605.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodbeck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasley, J. W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurkauf, A.</span><span> </span><span class="NLM_article-title">NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2715</span><span class="NLM_x">–</span> <span class="NLM_lpage">2718</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00469-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2FS0960-894X%2898%2900469-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=9873609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADyaK1cXntV2qs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2715-2718&author=J.+Yuanauthor=X.+Chenauthor=R.+Brodbeckauthor=R.+Primusauthor=J.+Braunauthor=J.+W.+F.+Wasleyauthor=A.+Thurkauf&title=NGB+2904+and+NGB+2849%3A+two+highly+selective+dopamine+D3+receptor+antagonists&doi=10.1016%2FS0960-894X%2898%2900469-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists</span></div><div class="casAuthors">Yuan, Jun; Chen, Xi; Brodbeck, Robbin; Primus, Renee; Braun, Julia; Wasley, Jan W. F.; Thurkauf, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2715-2718</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide and N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-2-biphenylenylcarboxamide were prepd. in several steps from 2,3-dichloroaniline.  These compds. were identified as highly selective dopamine D3 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2unsQE-pTcrVg90H21EOLACvtfcHk0lgebLDWm4yidw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntV2qs7k%253D&md5=1886ea40a0addbbba184c9ad51f47f04</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900469-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900469-7%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBrodbeck%26aufirst%3DR.%26aulast%3DPrimus%26aufirst%3DR.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DWasley%26aufirst%3DJ.%2BW.%2BF.%26aulast%3DThurkauf%26aufirst%3DA.%26atitle%3DNGB%25202904%2520and%2520NGB%25202849%253A%2520two%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2715%26epage%3D2718%26doi%3D10.1016%2FS0960-894X%2898%2900469-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Cherkasov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muratov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourches, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramatica, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todeschini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Consonni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuz’min, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terfloth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasteiger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tropsha, A.</span><span> </span><span class="NLM_article-title">QSAR modeling: where have you been? Where are you going to?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4977</span><span class="NLM_x">–</span> <span class="NLM_lpage">5010</span><span class="refDoi"> DOI: 10.1021/jm4004285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4977-5010&author=A.+Cherkasovauthor=E.+N.+Muratovauthor=D.+Fourchesauthor=A.+Varnekauthor=+Baskinauthor=M.+Croninauthor=J.+Deardenauthor=P.+Gramaticaauthor=Y.+C.+Martinauthor=R.+Todeschiniauthor=V.+Consonniauthor=V.+E.+Kuz%E2%80%99minauthor=R.+Cramerauthor=R.+Benigniauthor=C.+Yangauthor=J.+Rathmanauthor=L.+Terflothauthor=J.+Gasteigerauthor=A.+Richardauthor=A.+Tropsha&title=QSAR+modeling%3A+where+have+you+been%3F+Where+are+you+going+to%3F&doi=10.1021%2Fjm4004285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR Modeling: Where Have You Been? Where Are You Going To?</span></div><div class="casAuthors">Cherkasov, Artem; Muratov, Eugene N.; Fourches, Denis; Varnek, Alexandre; Baskin, Igor I.; Cronin, Mark; Dearden, John; Gramatica, Paola; Martin, Yvonne C.; Todeschini, Roberto; Consonni, Viviana; Kuzmin, Victor E.; Cramer, Richard; Benigni, Romualdo; Yang, Chihae; Rathman, James; Terfloth, Lothar; Gasteiger, Johann; Richard, Ann; Tropsha, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4977-5010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Quant. structure-activity relationship modeling is one of the major computational tools employed in medicinal chem.  However, throughout its entire history it has drawn both praise and criticism concerning its reliability, limitations, successes, and failures.  In this paper, we discuss (i) the development and evolution of QSAR; (ii) the current trends, unsolved problems, and pressing challenges; and (iii) several novel and emerging applications of QSAR modeling.  Throughout this discussion, we provide guidelines for QSAR development, validation, and application, which are summarized in best practices for building rigorously validated and externally predictive QSAR models.  We hope that this Perspective will help communications between computational and exptl. chemists toward collaborative development and use of QSAR models.  We also believe that the guidelines presented here will help journal editors and reviewers apply more stringent scientific stds. to manuscripts reporting new QSAR studies, as well as encourage the use of high quality, validated QSARs for regulatory decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbLWydJbspbLVg90H21EOLACvtfcHk0lgebLDWm4yidw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCrsLnE&md5=a2d371ee33fbecf48ef59ecf914e4aa8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm4004285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004285%26sid%3Dliteratum%253Aachs%26aulast%3DCherkasov%26aufirst%3DA.%26aulast%3DMuratov%26aufirst%3DE.%2BN.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DVarnek%26aufirst%3DA.%26aulast%3DBaskin%26aulast%3DCronin%26aufirst%3DM.%26aulast%3DDearden%26aufirst%3DJ.%26aulast%3DGramatica%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DTodeschini%26aufirst%3DR.%26aulast%3DConsonni%26aufirst%3DV.%26aulast%3DKuz%25E2%2580%2599min%26aufirst%3DV.%2BE.%26aulast%3DCramer%26aufirst%3DR.%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRathman%26aufirst%3DJ.%26aulast%3DTerfloth%26aufirst%3DL.%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DTropsha%26aufirst%3DA.%26atitle%3DQSAR%2520modeling%253A%2520where%2520have%2520you%2520been%253F%2520Where%2520are%2520you%2520going%2520to%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4977%26epage%3D5010%26doi%3D10.1021%2Fjm4004285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Schneider, G.; Baringhaus, K.-H.</span><span> </span><span class="NLM_article-title">De novo design: from models to molecules</span>. In  <span class="citation_source-book">De Novo Molecular Design</span>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2F9783527677016.ch1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1-55&author=G.+Schneider&author=K.-H.+Baringhaus&title=De+Novo+Molecular+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F9783527677016.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527677016.ch1%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520novo%2520design%253A%2520from%2520models%2520to%2520molecules%26btitle%3DDe%2520Novo%2520Molecular%2520Design%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2013%26spage%3D1%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Blankman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0lg_Ej2EYqDJqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Leggio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platania, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drago, F.</span><span> </span><span class="NLM_article-title">Current drug treatments targeting dopamine D3 receptor</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+drug+treatments+targeting+dopamine+D3+receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0lg_Ej2EYqDJqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520drug%2520treatments%2520targeting%2520dopamine%2520D3%2520receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Butini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolic, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbaba, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brogi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindisi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campiani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, H.</span><span> </span><span class="NLM_article-title">Polypharmacology of dopamine receptor ligands</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Bruckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campianiauthor=H.+Stark&title=Polypharmacology+of+dopamine+receptor+ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0lg465iLXETXaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBruckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPolypharmacology%2520of%2520dopamine%2520receptor%2520ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADyaK28XhvVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=490-519&author=T.+A.+Halgren&title=Merck+molecular+force+field.+I.+Basis%2C+form%2C+scope%2C+parameterization%2C+and+performance+of+MMFF94&doi=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">490-519</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">This article introduces MMFF94, the initial published version of the Merck mol. force field (MMFF).  It describes the objectives set for MMFF, the form it takes, and the range of systems to which it applies.  This study also outlines the methodol. employed in parameterizing MMFF94 and summarizes its performance in reproducing computational and exptl. data.  Though similar to MM3 in some respects, MMFF94 differs in ways intended to facilitate application to condensed-phase processes in mol.-dynamics simulations.  Indeed, MMFF94 seeks to achieve MM3-like accuracy for small mols. in a combined "org./protein" force field that is equally applicable to proteins and other systems of biol. significance.  A second distinguishing feature is that the core protion of MMFF94 has primarily been derived from high-quality computational data-ca. 500 mol. structures optimized at the HF/6-31G* level, 475 structures optimized at the MP2/6-31G* level, 380 MP2/6-31* structures evaluated at a defined approxn. to the MP4SDQ/TZP level, and 1450 structures partly derived from MP2/6-31G* geometries and evaluated at the MP2/TZP level.  A third distinguishing feature is that MMFF94 has been parameterized for a wide variety of chem. systems of interest to org. and combinations of functional groups for which little, if any, useful exptl. data are available.  The methodol. used in parameterizing MMFF94 represents a fourth distinguishing feature.  Rather than using the common "functional group" approach, nearly all MMFF parameters have been detd. in a mutually consistent fashion from the full set of available computational data.  MMFF94 reproduces the computational data used in its parameterization very well.  In addn., MMFF94 reproduces exptl. bond lengths (0.014 Å root mean square [rms]), bond angles (1.2° rms), vibrational frequencies (61 cm-1 rms), conformational energies (0.38 kcal/mol rms), and rotational barriers (0.39 kcal/mol rms) very nearly as well as does MM3 for comparable systems.  MMFF94 also describes intermol. interactions in hydrogen-bonded systems in a way that closely parallels that given by the highly regarded OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzCYfKnN83rVg90H21EOLACvtfcHk0lg465iLXETXaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVGmsbk%253D&md5=56fb073477b4f49d1dfbd786fc56a480</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-987X%2528199604%252917%253A5%252F6%253C490%253A%253AAID-JCC1%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMerck%2520molecular%2520force%2520field.%2520I.%2520Basis%252C%2520form%252C%2520scope%252C%2520parameterization%252C%2520and%2520performance%2520of%2520MMFF94%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1996%26volume%3D17%26spage%3D490%26epage%3D519%26doi%3D10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Abagyan, R.; Raush, E.; Totrov, M.</span>ICM Manual, version <span class="NLM_edition">3.7</span>. <a href="http://www.molsoft.com/man/index.html" class="extLink">http://www.molsoft.com/man/index.html</a> (accessed October 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Abagyan&author=E.+Raush&author=M.+Totrov&title=ICM+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DAbagyan%26aufirst%3DR.%26jtitle%3DICM%2520Manual%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sean D. Kodani, Debin Wan, Karen M. Wagner, Sung Hee Hwang, Christophe Morisseau, <span class="NLM_string-name hlFld-ContribAuthor">Bruce D. Hammock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (10)
                                     , 14076-14086. <a href="https://doi.org/10.1021/acsomega.8b01625" title="DOI URL">https://doi.org/10.1021/acsomega.8b01625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b01625%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%252Band%252BPotency%252Bof%252BDual%252BSoluble%252BEpoxide%252BHydrolase%25252FFatty%252BAcid%252BAmide%252BHydrolase%252BInhibitors%26aulast%3DKodani%26aufirst%3DSean%2BD.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D04092018%26volume%3D3%26issue%3D10%26spage%3D14076%26epage%3D14086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gilberto Spadoni, Annalida Bedini, Lucia Furiassi, Michele Mari, Marco Mor, Laura Scalvini, Alessio Lodola, Andrea Ghidini, Valeria Lucini, Silvana Dugnani, Francesco Scaglione, Daniele Piomelli, Kwang-Mook Jung, Claudiu T. Supuran, Laura Lucarini, Mariaconcetta Durante, Silvia Sgambellone, Emanuela Masini, <span class="NLM_string-name hlFld-ContribAuthor">Silvia Rivara</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7902-7916. <a href="https://doi.org/10.1021/acs.jmedchem.8b00893" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00893</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00893%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BBivalent%252BLigands%252Bwith%252BMelatonin%252BReceptor%252BAgonist%252Band%252BFatty%252BAcid%252BAmide%252BHydrolase%252B%252528FAAH%252529%252BInhibitory%252BActivity%252BThat%252BExhibit%252BOcular%252BHypotensive%252BEffect%252Bin%252Bthe%252BRabbit%26aulast%3DSpadoni%26aufirst%3DGilberto%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05062018%26date%3D04092018%26date%3D20082018%26volume%3D61%26issue%3D17%26spage%3D7902%26epage%3D7916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Milica  Elek</span>, <span class="hlFld-ContribAuthor ">Nemanja  Djokovic</span>, <span class="hlFld-ContribAuthor ">Annika  Frank</span>, <span class="hlFld-ContribAuthor ">Slavica  Oljacic</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Zivkovic</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in silico, and in vitro studies of novel dopamine D
              2
              and D
              3
              receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>354 </em>
                                    (6)
                                     , 2000486. <a href="https://doi.org/10.1002/ardp.202000486" title="DOI URL">https://doi.org/10.1002/ardp.202000486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000486%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%25252C%252Bin%252Bsilico%25252C%252Band%252Bin%252Bvitro%252Bstudies%252Bof%252Bnovel%252Bdopamine%252BD%252B2%252Band%252BD%252B3%252Breceptor%252Bligands%26aulast%3DElek%26aufirst%3DMilica%26date%3D2021%26date%3D2021%26volume%3D354%26issue%3D6%26spage%3D2000486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hamed  Haghshenas</span>, <span class="hlFld-ContribAuthor ">Bita  Kaviani</span>, <span class="hlFld-ContribAuthor ">Monireh  Firouzeh</span>, <span class="hlFld-ContribAuthor ">Hossein  Tavakol</span>. </span><span class="cited-content_cbyCitation_article-title">Developing a variation of
              3D‐QSAR
              /
              MD
              method in drug design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2021,</strong> <em>42 </em>
                                    (13)
                                     , 917-929. <a href="https://doi.org/10.1002/jcc.26514" title="DOI URL">https://doi.org/10.1002/jcc.26514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.26514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.26514%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DDeveloping%252Ba%252Bvariation%252Bof%252B3D%2525E2%252580%252590QSAR%252B%25252F%252BMD%252Bmethod%252Bin%252Bdrug%252Bdesign%26aulast%3DHaghshenas%26aufirst%3DHamed%26date%3D2021%26date%3D2021%26volume%3D42%26issue%3D13%26spage%3D917%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin  Butler</span>, <span class="hlFld-ContribAuthor ">Bernard  Le Foll</span>. </span><span class="cited-content_cbyCitation_article-title">Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , 1065-1080. <a href="https://doi.org/10.1080/17460441.2020.1767581" title="DOI URL">https://doi.org/10.1080/17460441.2020.1767581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1767581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1767581%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNovel%252Btherapeutic%252Band%252Bdrug%252Bdevelopment%252Bstrategies%252Bfor%252Btobacco%252Buse%252Bdisorder%25253A%252Bendocannabinoid%252Bmodulation%26aulast%3DButler%26aufirst%3DKevin%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D1065%26epage%3D1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rita Maria Concetta  Di Martino</span>, <span class="hlFld-ContribAuthor ">Giovanni  Bottegoni</span>, <span class="hlFld-ContribAuthor ">Francesca  Seghetti</span>, <span class="hlFld-ContribAuthor ">Debora  Russo</span>, <span class="hlFld-ContribAuthor ">Ilaria  Penna</span>, <span class="hlFld-ContribAuthor ">Alessio  De Simone</span>, <span class="hlFld-ContribAuthor ">Giuliana  Ottonello</span>, <span class="hlFld-ContribAuthor ">Sine  Mandrup Bertozzi</span>, <span class="hlFld-ContribAuthor ">Andrea  Armirotti</span>, <span class="hlFld-ContribAuthor ">Tiziano  Bandiera</span>, <span class="hlFld-ContribAuthor ">Federica  Belluti</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (11)
                                     , 949-954. <a href="https://doi.org/10.1002/cmdc.202000210" title="DOI URL">https://doi.org/10.1002/cmdc.202000210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000210%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMultitarget%252BCompounds%252Bfor%252BBipolar%252BDisorder%25253A%252BFrom%252BRational%252BDesign%252Bto%252BPreliminary%252BPharmacokinetic%252BEvaluation%26aulast%3DDi%2BMartino%26aufirst%3DRita%2BMaria%2BConcetta%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D11%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yilin  Hou</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Highly biodegradable fluoroquinolone derivatives designed using the 3D-QSAR model and biodegradation pathways analysis. </span><span class="cited-content_cbyCitation_journal-name">Ecotoxicology and Environmental Safety</span><span> <strong>2020,</strong> <em>191 </em>, 110186. <a href="https://doi.org/10.1016/j.ecoenv.2020.110186" title="DOI URL">https://doi.org/10.1016/j.ecoenv.2020.110186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ecoenv.2020.110186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ecoenv.2020.110186%26sid%3Dliteratum%253Aachs%26jtitle%3DEcotoxicology%2520and%2520Environmental%2520Safety%26atitle%3DHighly%252Bbiodegradable%252Bfluoroquinolone%252Bderivatives%252Bdesigned%252Busing%252Bthe%252B3D-QSAR%252Bmodel%252Band%252Bbiodegradation%252Bpathways%252Banalysis%26aulast%3DHou%26aufirst%3DYilin%26date%3D2020%26volume%3D191%26spage%3D110186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rati Kailash Prasad  Tripathi</span>. </span><span class="cited-content_cbyCitation_article-title">A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111953. <a href="https://doi.org/10.1016/j.ejmech.2019.111953" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111953</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111953%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bperspective%252Breview%252Bon%252Bfatty%252Bacid%252Bamide%252Bhydrolase%252B%252528FAAH%252529%252Binhibitors%252Bas%252Bpotential%252Btherapeutic%252Bagents%26aulast%3DTripathi%26aufirst%3DRati%2BKailash%2BPrasad%26date%3D2020%26volume%3D188%26spage%3D111953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariarosaria  Ferraro</span>, <span class="hlFld-ContribAuthor ">Sergio  Decherchi</span>, <span class="hlFld-ContribAuthor ">Alessio  De Simone</span>, <span class="hlFld-ContribAuthor ">Maurizio  Recanatini</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>, <span class="hlFld-ContribAuthor ">Giovanni  Bottegoni</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111975. <a href="https://doi.org/10.1016/j.ejmech.2019.111975" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111975</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111975%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMulti-target%252Bdopamine%252BD3%252Breceptor%252Bmodulators%25253A%252BActionable%252Bknowledge%252Bfor%252Bdrug%252Bdesign%252Bfrom%252Bmolecular%252Bdynamics%252Band%252Bmachine%252Blearning%26aulast%3DFerraro%26aufirst%3DMariarosaria%26date%3D2020%26volume%3D188%26spage%3D111975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Yehua  Zhu</span>, <span class="hlFld-ContribAuthor ">Yufang  He</span>, <span class="hlFld-ContribAuthor ">Haohao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yi  Gao</span>, <span class="hlFld-ContribAuthor ">Zhi  Li</span>, <span class="hlFld-ContribAuthor ">Junru  Zhu</span>, <span class="hlFld-ContribAuthor ">Xinjie  Sun</span>, <span class="hlFld-ContribAuthor ">Fang  Fang</span>, <span class="hlFld-ContribAuthor ">Hongmei  Wen</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (2)
                                     , 533-547. <a href="https://doi.org/10.1080/07391102.2019.1590241" title="DOI URL">https://doi.org/10.1080/07391102.2019.1590241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1590241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1590241%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DCombined%252Bpharmacophore%252Bmodeling%25252C%252B3D-QSAR%252Band%252Bdocking%252Bstudies%252Bto%252Bidentify%252Bnovel%252BHDAC%252Binhibitors%252Busing%252Bdrug%252Brepurposing%26aulast%3DLiu%26aufirst%3DJian%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D2%26spage%3D533%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hung-Jin  Huang</span>, <span class="hlFld-ContribAuthor ">Olga A  Kraevaya</span>, <span class="hlFld-ContribAuthor ">Ilya I  Voronov</span>, <span class="hlFld-ContribAuthor ">Pavel A  Troshin</span>, <span class="hlFld-ContribAuthor ">Shan-hui  Hsu</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Fullerene Derivatives as Lung Cancer Cell Inhibitors: Investigation of Potential Descriptors Using QSAR Approaches</p>. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Nanomedicine</span><span> <strong>2020,</strong> <em>Volume 15 </em>, 2485-2499. <a href="https://doi.org/10.2147/IJN.S243463" title="DOI URL">https://doi.org/10.2147/IJN.S243463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/IJN.S243463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FIJN.S243463%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Nanomedicine%26atitle%3D%25253Cp%25253EFullerene%252BDerivatives%252Bas%252BLung%252BCancer%252BCell%252BInhibitors%25253A%252BInvestigation%252Bof%252BPotential%252BDescriptors%252BUsing%252BQSAR%252BApproaches%25253C%25252Fp%25253E%26aulast%3DHuang%26aufirst%3DHung-Jin%26date%3D2020%26date%3D2020%26volume%3DVolume%252015%26spage%3D2485%26epage%3D2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianping  Mao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Kazuo  Koike</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Improved 3D-QSAR prediction by multiple-conformational alignment: A case study on PTP1B inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 107134. <a href="https://doi.org/10.1016/j.compbiolchem.2019.107134" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2019.107134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2019.107134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2019.107134%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DImproved%252B3D-QSAR%252Bprediction%252Bby%252Bmultiple-conformational%252Balignment%25253A%252BA%252Bcase%252Bstudy%252Bon%252BPTP1B%252Binhibitors%26aulast%3DZhang%26aufirst%3DXiangyu%26date%3D2019%26volume%3D83%26spage%3D107134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Grillo</span>, <span class="hlFld-ContribAuthor ">Giulia  Chemi</span>, <span class="hlFld-ContribAuthor ">Simone  Brogi</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Nicola  Relitti</span>, <span class="hlFld-ContribAuthor ">Filomena  Fezza</span>, <span class="hlFld-ContribAuthor ">Domenico  Fazio</span>, <span class="hlFld-ContribAuthor ">Laura  Castelletti</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Perdona</span>, <span class="hlFld-ContribAuthor ">Andrea  Wong</span>, <span class="hlFld-ContribAuthor ">Stefania  Lamponi</span>, <span class="hlFld-ContribAuthor ">Alessandra  Pecorelli</span>, <span class="hlFld-ContribAuthor ">Mascia  Benedusi</span>, <span class="hlFld-ContribAuthor ">Manuela  Fantacci</span>, <span class="hlFld-ContribAuthor ">Massimo  Valoti</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Valacchi</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Micheli</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Campiani</span>, <span class="hlFld-ContribAuthor ">Stefania  Butini</span>, <span class="hlFld-ContribAuthor ">Mauro  Maccarrone</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111674. <a href="https://doi.org/10.1016/j.ejmech.2019.111674" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111674%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252Bmultipotent%252Bcompounds%252Bmodulating%252Bendocannabinoid%252Band%252Bdopaminergic%252Bsystems%26aulast%3DGrillo%26aufirst%3DAlessandro%26date%3D2019%26volume%3D183%26spage%3D111674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diego Alejandro  Rodríguez-Soacha</span>, <span class="hlFld-ContribAuthor ">Matthias  Scheiner</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 690-706. <a href="https://doi.org/10.1016/j.ejmech.2019.07.040" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.040%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMulti-target-directed-ligands%252Bacting%252Bas%252Benzyme%252Binhibitors%252Band%252Breceptor%252Bligands%26aulast%3DRodr%25C3%25ADguez-Soacha%26aufirst%3DDiego%2BAlejandro%26date%3D2019%26volume%3D180%26spage%3D690%26epage%3D706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damian  Kułaga</span>, <span class="hlFld-ContribAuthor ">Jolanta  Jaśkowska</span>, <span class="hlFld-ContribAuthor ">Radomir  Jasiński</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave‐Assisted Solvent‐Free Synthesis of Ipsapirone. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2019,</strong> <em>56 </em>
                                    (5)
                                     , 1498-1504. <a href="https://doi.org/10.1002/jhet.3520" title="DOI URL">https://doi.org/10.1002/jhet.3520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DMicrowave%2525E2%252580%252590Assisted%252BSolvent%2525E2%252580%252590Free%252BSynthesis%252Bof%252BIpsapirone%26aulast%3DKu%25C5%2582aga%26aufirst%3DDamian%26date%3D2019%26date%3D2019%26volume%3D56%26issue%3D5%26spage%3D1498%26epage%3D1504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  De Simone</span>, <span class="hlFld-ContribAuthor ">Charis  Georgiou</span>, <span class="hlFld-ContribAuthor ">Harris  Ioannidis</span>, <span class="hlFld-ContribAuthor ">Arun A.  Gupta</span>, <span class="hlFld-ContribAuthor ">Jordi  Juárez-Jiménez</span>, <span class="hlFld-ContribAuthor ">Dahlia  Doughty-Shenton</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Blackburn</span>, <span class="hlFld-ContribAuthor ">Martin A.  Wear</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  Richards</span>, <span class="hlFld-ContribAuthor ">Paul N.  Barlow</span>, <span class="hlFld-ContribAuthor ">Neil  Carragher</span>, <span class="hlFld-ContribAuthor ">Malcolm D.  Walkinshaw</span>, <span class="hlFld-ContribAuthor ">Alison N.  Hulme</span>, <span class="hlFld-ContribAuthor ">Julien  Michel</span>. </span><span class="cited-content_cbyCitation_article-title">A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 542-547. <a href="https://doi.org/10.1039/C8SC03831G" title="DOI URL">https://doi.org/10.1039/C8SC03831G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8SC03831G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8SC03831G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DA%252Bcomputationally%252Bdesigned%252Bbinding%252Bmode%252Bflip%252Bleads%252Bto%252Ba%252Bnovel%252Bclass%252Bof%252Bpotent%252Btri-vector%252Bcyclophilin%252Binhibitors%26aulast%3DDe%2BSimone%26aufirst%3DAlessio%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D542%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Zhu  Liu</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Wang</span>, <span class="hlFld-ContribAuthor ">Xi  Li</span>, <span class="hlFld-ContribAuthor ">Xue-Yu  Zhao</span>, <span class="hlFld-ContribAuthor ">Ke  Li</span>, <span class="hlFld-ContribAuthor ">Gao-Chao  Lv</span>, <span class="hlFld-ContribAuthor ">Ling  Qiu</span>, <span class="hlFld-ContribAuthor ">Jian-Guo  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2018,</strong> <em>91 </em>
                                    (3)
                                     , 735-746. <a href="https://doi.org/10.1111/cbdd.13134" title="DOI URL">https://doi.org/10.1111/cbdd.13134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13134%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3D3D-QSAR%25252C%252Bmolecular%252Bdocking%25252C%252Band%252BONIOM%252Bstudies%252Bon%252Bthe%252Bstructure-activity%252Brelationships%252Band%252Baction%252Bmechanism%252Bof%252Bnitrogen-containing%252Bbisphosphonates%26aulast%3DLiu%26aufirst%3DQing-Zhu%26date%3D2018%26date%3D2017%26volume%3D91%26issue%3D3%26spage%3D735%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giovanni  Bottegoni</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Methods in Multitarget Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 239-258. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00009-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00009-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00009-X%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BMethods%252Bin%252BMultitarget%252BDrug%252BDiscovery%26aulast%3DBottegoni%26aufirst%3DGiovanni%26date%3D2017%26spage%3D239%26epage%3D258%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported <i>O</i>-biphenyl carbamates with dual D3R and FAAH activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Compounds <b>16</b>–<b>29</b>, <b>32</b>–<b>37</b>, and <b>40</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub>, reflux, 6 h. Yields: 83–99%. (b) Hydrazine monohydrate, MeOH, 80 °C, 2 h, then 2 N HCl, 1 h. Yields: 53–88%. (c) ArOH, (Boc)<sub>2</sub>O, DMAP, CH<sub>3</sub>CN, rt, 23 h. Yields: 7–50%. (d) ArOH, <i>p</i>-nitrophenyl chloroformate, DIPEA, DMA/DCM 1:1, rt, overnight. Yields: 10–26%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Noncommercially Available Phenolic Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, EGME/H<sub>2</sub>O, rt, 5 min. Yields: 58–97%. (b) PdCl<sub>2</sub>(dppf), K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/water 3:1, 90 °C, 3 h. Yield: 48% (average of two attempts).</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to Alkenyl Derivatives <b>30</b> and <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, rt, under nitrogen atmosphere, overnight. Yield: 67%. (b) 1-(2,3-dichlorophenyl)piperazine, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 6 h. Yield: 83%. (c) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, MeOH, then 2 N HCl, reflux, 3 h. Yield: 88%. (d) Boc<sub>2</sub>O, DMAP, MeCN, rt, 20–25 h. Yields: <b>30</b>, 16%; <b>31</b>, 22%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General structure of the newly synthesized dual D3R FAAH modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of the results of SAR studies performed on different regions of the synthesized derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of four CB<sub>1</sub>R agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/medium/jm-2016-01578h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Computational studies to rationalize activity at CB<sub>1</sub>R: (A) APF-based superimposition of <b>4</b> and <b>39</b>, using the putative receptor-bound conformation of the latter as a rigid template; (B) 3D alignment of the 18 molecules included in the training set; (C) equipotential contours of the H-bond acceptor (red) and H-bond donor (blue) APF components; (D) equipotential contours of the sp<sup>2</sup> carbon atom hybridization APF component (white); (E) equipotential contours of the lipophilicity APF component (green); (F) correlation plot between pIC<sub>50exp</sub> and pIC<sub>50pred</sub>. The structures of the predicted compounds (red dots) are reported explicitly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-6/acs.jmedchem.6b01578/20170317/images/large/jm-2016-01578h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01578&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i79">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 54 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lg_8HflrQdoVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Polypharmacology in a single drug: multitarget drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1645</span><span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+multitarget+drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0lg_8HflrQdoVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lg_8HflrQdoVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Barabasi, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbahce, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loscalzo, J.</span><span> </span><span class="NLM_article-title">Network medicine: a network-based approach to human disease</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1038/nrg2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrg2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21164525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOiu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=56-68&author=A.-L.+Barabasiauthor=N.+Gulbahceauthor=J.+Loscalzo&title=Network+medicine%3A+a+network-based+approach+to+human+disease&doi=10.1038%2Fnrg2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Network medicine: a network-based approach to human disease</span></div><div class="casAuthors">Barabasi, Albert-Laszlo; Gulbahce, Natali; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-68</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Diseases are increasingly being found to reflect the perturbations of complex mol. networks.  The principles of network medicine are being used to identify new disease genes, det. the functional significance of disease-assocd. mutations, and identify new drug targets and biomarkers.  Given the functional interdependencies between the mol. components in a human cell, a disease is rarely a consequence of an abnormality in a single gene, but reflects the perturbations of the complex intracellular and intercellular network that links tissue and organ systems.  The emerging tools of network medicine offer a platform to explore systematically not only the mol. complexity of a particular disease, leading to the identification of disease modules and pathways, but also the mol. relationships among apparently distinct (patho)phenotypes.  Advances in this direction are essential for identifying new disease genes, for uncovering the biol. significance of disease-assocd. mutations identified by genome-wide assocn. studies and full-genome sequencing, and for identifying drug targets and biomarkers for complex diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTINXPcbp-brVg90H21EOLACvtfcHk0lj-wD9lML1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOiu7vM&md5=9ea3a47ba09cf0dca734ec341db507a0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrg2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2918%26sid%3Dliteratum%253Aachs%26aulast%3DBarabasi%26aufirst%3DA.-L.%26aulast%3DGulbahce%26aufirst%3DN.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DNetwork%2520medicine%253A%2520a%2520network-based%2520approach%2520to%2520human%2520disease%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2011%26volume%3D12%26spage%3D56%26epage%3D68%26doi%3D10.1038%2Fnrg2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Alzheimer’s disease: new approaches to drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2009.04.619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.cbpa.2009.04.619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=19467915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWlur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=303-308&author=M.+L.+Bolognesiauthor=R.+Materaauthor=A.+Minariniauthor=M.+Rosiniauthor=C.+Melchiorre&title=Alzheimer%E2%80%99s+disease%3A+new+approaches+to+drug+discovery&doi=10.1016%2Fj.cbpa.2009.04.619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease: new approaches to drug discovery</span></div><div class="casAuthors">Bolognesi, Maria L.; Matera, Riccardo; Minarini, Anna; Rosini, Michela; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-308</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this work, we review and comment upon the challenges and the quo vadis' in Alzheimer's disease drug discovery at the beginning of the new millennium.  We emphasize recent approaches that, moving on from a target-centric approach, have produced innovative mol. probes or drug candidates.  In particular, the discovery of endosome-targeted BACE1 inhibitors and mitochondria-targeted antioxidants represents a significant advance in Alzheimer's research and therapy.  The case study of the development of rasagiline provides an excellent example to support the validity of the multitarget-designed ligand approach to the search for effective medicines for combating Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IG07GjEOtbVg90H21EOLACvtfcHk0lj-wD9lML1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWlur0%253D&md5=76b399f0ed60cd43625c7f2217409a2c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.04.619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.04.619%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMatera%26aufirst%3DR.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520new%2520approaches%2520to%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D303%26epage%3D308%26doi%3D10.1016%2Fj.cbpa.2009.04.619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Prati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer’s disease</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466-478&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+chemical+space+of+multitarget-directed+ligands%3A+from+hybrids+to+fragments+in+Alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0lj-wD9lML1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520chemical%2520space%2520of%2520multitarget-directed%2520ligands%253A%2520from%2520hybrids%2520to%2520fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D466%26epage%3D478%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+genetic+discovery+of+targets+and+anti-targets+for+cancer+polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lj-wD9lML1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520genetic%2520discovery%2520of%2520targets%2520and%2520anti-targets%2520for%2520cancer%2520polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lg5gAFmrN1oOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span> </span><span class="NLM_article-title">Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7339</span><span class="NLM_x">–</span> <span class="NLM_lpage">7359</span><span class="refDoi"> DOI: 10.1021/jm9004835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1ehtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7339-7359&author=A.+Cavalliauthor=M.+L.+Bolognesi&title=Neglected+tropical+diseases%3A+multi-target-directed+ligands+in+the+search+for+novel+lead+candidates+against+Trypanosoma+and+Leishmania&doi=10.1021%2Fjm9004835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected Tropical Diseases: Multi-Target-Directed Ligands in the Search for Novel Lead Candidates against Trypanosoma and Leishmania</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7339-7359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Multi-Target-Directed Ligands in the search for novel lead candidates against neglected tropical diseases like Trypanosomiasis and Leishmaniasis is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA_YvlDGyaUbVg90H21EOLACvtfcHk0lg5gAFmrN1oOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1ehtLg%253D&md5=caf70e02c3d2b9ccc99576678c41d8fa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm9004835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004835%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNeglected%2520tropical%2520diseases%253A%2520multi-target-directed%2520ligands%2520in%2520the%2520search%2520for%2520novel%2520lead%2520candidates%2520against%2520Trypanosoma%2520and%2520Leishmania%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7339%26epage%3D7359%26doi%3D10.1021%2Fjm9004835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Syed, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, K.</span><span> </span><span class="NLM_article-title">Smoking cessation drugs market</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1038/nrd3914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrd3914" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=97-98&author=B.+A.+Syedauthor=K.+Chaudhari&title=Smoking+cessation+drugs+market&doi=10.1038%2Fnrd3914"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3914%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DB.%2BA.%26aulast%3DChaudhari%26aufirst%3DK.%26atitle%3DSmoking%2520cessation%2520drugs%2520market%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D97%26epage%3D98%26doi%3D10.1038%2Fnrd3914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">World Health Organization</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">Report on the global tobacco epidemic: enforcing bans on tobacco advertising, promotion and sponsorship</span>. <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+Report+on+the+global+tobacco+epidemic%3A+enforcing+bans+on+tobacco+advertising%2C+promotion+and+sponsorship.+World+Health+Organization%3A+Geneva%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DReport%2520on%2520the%2520global%2520tobacco%2520epidemic%253A%2520enforcing%2520bans%2520on%2520tobacco%2520advertising%252C%2520promotion%2520and%2520sponsorship%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Benowitz, N. L.</span><span> </span><span class="NLM_article-title">Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.48.113006.094742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1146%2Fannurev.pharmtox.48.113006.094742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18834313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2jsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=57-71&author=N.+L.+Benowitz&title=Pharmacology+of+nicotine%3A+addiction%2C+smoking-induced+disease%2C+and+therapeutics&doi=10.1146%2Fannurev.pharmtox.48.113006.094742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics</span></div><div class="casAuthors">Benowitz, Neal L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-71</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Nicotine sustains tobacco addiction, a major cause of disability and premature death.  Nicotine binds to nicotinic cholinergic receptors, facilitating neurotransmitter release and thereby mediating the complex actions of nicotine in tobacco users.  Dopamine, glutamate, and gamma-aminobutyric acid release are particularly important in the development of nicotine dependence, and corticotropin-releasing factor appears to contribute to nicotine withdrawal.  Nicotine dependence is highly heritable.  Genetic studies indicate roles for nicotinic receptor subtypes, as well as genes involved in neuroplasticity and learning, in the development of dependence.  Nicotine is primarily metabolized by CYP 2A6, and variability in the rate of metab. contributes to vulnerability to tobacco dependence, response to smoking cessation treatment, and lung cancer risk.  Tobacco addiction is much more common in persons with mental illness and substance abuse disorders, representing a high proportion of current smokers.  Pharmacotherapeutic approaches to tobacco addiction include nicotine replacement, bupropion, and Varenicline, the latter a selective nicotine receptor partial agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCj2sDCfVrf7Vg90H21EOLACvtfcHk0lizvJpLxlSZUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2jsL8%253D&md5=76e0755fa21f9f83c0e7fb38e43242cb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.113006.094742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.113006.094742%26sid%3Dliteratum%253Aachs%26aulast%3DBenowitz%26aufirst%3DN.%2BL.%26atitle%3DPharmacology%2520of%2520nicotine%253A%2520addiction%252C%2520smoking-induced%2520disease%252C%2520and%2520therapeutics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2009%26volume%3D49%26spage%3D57%26epage%3D71%26doi%3D10.1146%2Fannurev.pharmtox.48.113006.094742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">D’Souza, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markou, A.</span><span> </span><span class="NLM_article-title">Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments</span> <span class="citation_source-journal">Addict. Sci. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22003417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A280%3ADC%252BC3Mbhs1Gjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=4-16&author=M.+S.+D%E2%80%99Souzaauthor=A.+Markou&title=Neuronal+mechanisms+underlying+development+of+nicotine+dependence%3A+implications+for+novel+smoking-cessation+treatments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments</span></div><div class="casAuthors">D'Souza Manoranjan S; Markou Athina</div><div class="citationInfo"><span class="NLM_cas:title">Addiction science & clinical practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tobacco smoking causes high rates of mortality and morbidity throughout the world.  Despite the availability of smoking-cessation medications, maintenance of long-term abstinence is difficult, and most individuals who attempt to quit smoking relapse.  Although tobacco smoke contains many substances, researchers and policymakers agree that nicotine is a major cause of tobacco dependence.  Understanding the neural substrates of nicotine dependence is essential for the development of more effective antismoking medications than those currently available.  This article focuses on the neural substrates, especially nicotinic acetylcholine receptors, that mediate the reinforcing effects of nicotine and the development of nicotine dependence.  Neuroadaptations in the function of the neurotransmitters dopamine, glutamate, and gamma-aminobutyric acid (GABA), which have been shown to be critically involved in nicotine dependence, are also reviewed.  Finally, the article discusses progress in the discovery and development of smoking-cessation medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnNF5GDChlcI3yKPtYViAGfW6udTcc2eaa7o6WtRUCxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mbhs1Gjtw%253D%253D&md5=45506372d3563c3a8ceeca32a7c3dbd2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DM.%2BS.%26aulast%3DMarkou%26aufirst%3DA.%26atitle%3DNeuronal%2520mechanisms%2520underlying%2520development%2520of%2520nicotine%2520dependence%253A%2520implications%2520for%2520novel%2520smoking-cessation%2520treatments%26jtitle%3DAddict.%2520Sci.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D6%26spage%3D4%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Picciotto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineur, Y. S.</span><span> </span><span class="NLM_article-title">Molecules and circuits involved in nicotine addiction: the many faces of smoking</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">Part B</span><span class="NLM_x">) </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.neuropharm.2013.04.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=545-553&issue=Part+B&author=M.+R.+Picciottoauthor=Y.+S.+Mineur&title=Molecules+and+circuits+involved+in+nicotine+addiction%3A+the+many+faces+of+smoking&doi=10.1016%2Fj.neuropharm.2013.04.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DPicciotto%26aufirst%3DM.%2BR.%26aulast%3DMineur%26aufirst%3DY.%2BS.%26atitle%3DMolecules%2520and%2520circuits%2520involved%2520in%2520nicotine%2520addiction%253A%2520the%2520many%2520faces%2520of%2520smoking%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D76%26issue%3DPart%2520B%26spage%3D545%26epage%3D553%26doi%3D10.1016%2Fj.neuropharm.2013.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Fernandez-Ruiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, J. A.</span><span> </span><span class="NLM_article-title">Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders</span> <span class="citation_source-journal">CNS Neurosci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">e72</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00144.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1755-5949.2010.00144.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=e72-91&author=J.+Fernandez-Ruizauthor=M.+Hernandezauthor=J.+A.+Ramos&title=Cannabinoid-dopamine+interaction+in+the+pathophysiology+and+treatment+of+CNS+disorders&doi=10.1111%2Fj.1755-5949.2010.00144.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00144.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00144.x%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DJ.%2BA.%26atitle%3DCannabinoid-dopamine%2520interaction%2520in%2520the%2520pathophysiology%2520and%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2010%26volume%3D16%26spage%3De72%26epage%3D91%26doi%3D10.1111%2Fj.1755-5949.2010.00144.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Melis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muntoni, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillolla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessa, G. L.</span><span> </span><span class="NLM_article-title">Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4503-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1523%2FJNEUROSCI.4503-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=14715937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=53-62&author=M.+Melisauthor=M.+Pistisauthor=S.+Perraauthor=A.+L.+Muntoniauthor=G.+Pillollaauthor=G.+L.+Gessa&title=Endocannabinoids+mediate+presynaptic+inhibition+of+glutamatergic+transmission+in+rat+ventral+tegmental+area+dopamine+neurons+through+activation+of+CB1+receptors&doi=10.1523%2FJNEUROSCI.4503-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors</span></div><div class="casAuthors">Melis, Miriam; Pistis, Marco; Perra, Simona; Muntoni, Anna Lisa; Pillolla, Giuliano; Gessa, Gian Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endogenous cannabinoid system has been shown to play a crucial role in controlling neuronal excitability and synaptic transmission.  In this study the authors investigated the effects of a cannabinoid receptor (CB-R) agonist WIN 55,212-2 (WIN) on excitatory synaptic transmission in the rat ventral tegmental area (VTA).  Whole-cell patch clamp recordings were performed from VTA dopamine (DA) neurons in an in vitro slice prepn.  WIN reduced both NMDA and AMPA EPSCs, as well as miniature EPSCs (mEPSCs), and increased the paired-pulse ratio, indicating a presynaptic locus of its action.  The authors also found that WIN-induced effects were dose-dependent and mimicked by the CB1-R agonist HU210.  Furthermore, two CB1-R antagonists, AM281 and SR141716A, blocked WIN-induced effects, suggesting that WIN modulates excitatory synaptic transmission via activation of CB1-Rs.  The authors' addnl. that both AM281 and SR141716A per se increased NMDA EPSCs suggests that endogenous cannabinoids, released from depolarized postsynaptic neurons, might act retrogradely on presynaptic CB1-Rs to suppress glutamate release.  Hence, the authors report that a type of synaptic modulation, previously termed depolarization-induced suppression of excitation (DSE), is present also in the VTA as a calcium-dependent phenomenon, blocked by both AM281 and SR141716A, and occluded by WIN.  Importantly, DSE was partially blocked by the D2DA antagonist eticlopride and enhanced by the D2DA agonist quinpirole without changing the presynaptic cannabinoid sensitivity.  These results indicate that the two pathways work in a cooperative manner to release endocannabinoids in the VTA, where they play a role as retrograde messengers for DSE via CB1-Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL8pQqBa25HrVg90H21EOLACvtfcHk0lizvJpLxlSZUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2ntA%253D%253D&md5=5caa0d3c3d3c61e25bf3911c3dd96182</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4503-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4503-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DPistis%26aufirst%3DM.%26aulast%3DPerra%26aufirst%3DS.%26aulast%3DMuntoni%26aufirst%3DA.%2BL.%26aulast%3DPillolla%26aufirst%3DG.%26aulast%3DGessa%26aufirst%3DG.%2BL.%26atitle%3DEndocannabinoids%2520mediate%2520presynaptic%2520inhibition%2520of%2520glutamatergic%2520transmission%2520in%2520rat%2520ventral%2520tegmental%2520area%2520dopamine%2520neurons%2520through%2520activation%2520of%2520CB1%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D53%26epage%3D62%26doi%3D10.1523%2FJNEUROSCI.4503-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hartmann-Boyce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stead, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, T.</span><span> </span><span class="NLM_article-title">Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews</span> <span class="citation_source-journal">Addiction</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1721</span><span class="refDoi"> DOI: 10.1111/add.12291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fadd.12291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=1711-1721&author=J.+Hartmann-Boyceauthor=L.+F.+Steadauthor=K.+Cahillauthor=T.+Lancaster&title=Efficacy+of+interventions+to+combat+tobacco+addiction%3A+Cochrane+update+of+2012+reviews&doi=10.1111%2Fadd.12291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fadd.12291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadd.12291%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann-Boyce%26aufirst%3DJ.%26aulast%3DStead%26aufirst%3DL.%2BF.%26aulast%3DCahill%26aufirst%3DK.%26aulast%3DLancaster%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520interventions%2520to%2520combat%2520tobacco%2520addiction%253A%2520Cochrane%2520update%2520of%25202012%2520reviews%26jtitle%3DAddiction%26date%3D2013%26volume%3D108%26spage%3D1711%26epage%3D1721%26doi%3D10.1111%2Fadd.12291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mihalak, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetje, C. W.</span><span> </span><span class="NLM_article-title">Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1124/mol.106.025130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1124%2Fmol.106.025130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=801-805&author=K.+B.+Mihalakauthor=F.+I.+Carrollauthor=C.+W.+Luetje&title=Varenicline+is+a+partial+agonist+at+alpha4beta2+and+a+full+agonist+at+alpha7+neuronal+nicotinic+receptors&doi=10.1124%2Fmol.106.025130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.106.025130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.106.025130%26sid%3Dliteratum%253Aachs%26aulast%3DMihalak%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DLuetje%26aufirst%3DC.%2BW.%26atitle%3DVarenicline%2520is%2520a%2520partial%2520agonist%2520at%2520alpha4beta2%2520and%2520a%2520full%2520agonist%2520at%2520alpha7%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D70%26spage%3D801%26epage%3D805%26doi%3D10.1124%2Fmol.106.025130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Crooks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwoskin, L. P.</span><span> </span><span class="NLM_article-title">Nicotinic receptor antagonists as treatments for nicotine abuse</span> <span class="citation_source-journal">Adv. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span><span class="refDoi"> DOI: 10.1016/B978-0-12-420118-7.00013-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2FB978-0-12-420118-7.00013-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=513-551&author=P.+A.+Crooksauthor=M.+T.+Bardoauthor=L.+P.+Dwoskin&title=Nicotinic+receptor+antagonists+as+treatments+for+nicotine+abuse&doi=10.1016%2FB978-0-12-420118-7.00013-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-420118-7.00013-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-420118-7.00013-5%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26aulast%3DBardo%26aufirst%3DM.%2BT.%26aulast%3DDwoskin%26aufirst%3DL.%2BP.%26atitle%3DNicotinic%2520receptor%2520antagonists%2520as%2520treatments%2520for%2520nicotine%2520abuse%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D513%26epage%3D551%26doi%3D10.1016%2FB978-0-12-420118-7.00013-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Micheli, F.</span><span> </span><span class="NLM_article-title">Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1162</span><span class="refDoi"> DOI: 10.1002/cmdc.201000538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2Fcmdc.201000538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21425240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1152-1162&author=F.+Micheli&title=Recent+advances+in+the+development+of+dopamine+D3+receptor+antagonists%3A+a+medicinal+chemistry+perspective&doi=10.1002%2Fcmdc.201000538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective</span></div><div class="casAuthors">Micheli, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1152-1162</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Dopamine (DA) D3 receptor antagonism might play a significant role in different therapeutic areas.  A high no. of preclin. studies on DA D3 receptor antagonists have shown efficacy in animal models of Parkinson's disease, schizophrenia and drug dependence.  This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compds.  Both primary and patent literature is reviewed here.  Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers.  Examples of advanced leads from academia and industry are described.  The latest potential therapeutic applications are reported too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhYCeq4b9EbVg90H21EOLACvtfcHk0ljW0Y66nbNMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCntbk%253D&md5=61c2b60b5e69df3517421e922b7aa73a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000538%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520dopamine%2520D3%2520receptor%2520antagonists%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1152%26epage%3D1162%26doi%3D10.1002%2Fcmdc.201000538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaylock, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. a.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skolnick, P.</span><span> </span><span class="NLM_article-title">Medication discovery for addiction: translating the dopamine D3 receptor hypothesis</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.bcp.2012.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=22781742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=882-890&author=A.+H.+Newmanauthor=B.+L.+Blaylockauthor=M.+a.+Naderauthor=J.+Bergmanauthor=D.+R.+Sibleyauthor=P.+Skolnick&title=Medication+discovery+for+addiction%3A+translating+the+dopamine+D3+receptor+hypothesis&doi=10.1016%2Fj.bcp.2012.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis</span></div><div class="casAuthors">Newman, Amy Hauck; Blaylock, Brandi L.; Nader, Michael A.; Bergman, Jack; Sibley, David R.; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine.  Currently, there are no approved medications to treat cocaine and methamphetamine addiction and thus developing pharmacotherapeutics to complement existing behavioral strategies is a fundamental goal.  Novel compds. with high affinity and D3R selectivity have been evaluated in numerous animal models of drug abuse and favorable outcomes in nonhuman primate models of self-administration and relapse have provided compelling evidence to advance these agents into the clinic.  One approach is to repurpose drugs that share the D3R mechanism and already have clin. utility, and to this end buspirone has been identified as a viable candidate for clin. trials.  A second, but substantially more resource intensive and risky approach involves the development of compds. that exclusively target D3R, such as GSK598809 and PG 619.  Clin. investigation of these drugs or other novel D3R-selective agents will provide a better understanding of the role D3R plays in addiction and whether or not antagonists or partial agonists that are D3R selective are effective in achieving abstinence in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_waGudfGt4LVg90H21EOLACvtfcHk0ljW0Y66nbNMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O&md5=820f1ddd46c9888c687bc0cc8cd3aa96</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBlaylock%26aufirst%3DB.%2BL.%26aulast%3DNader%26aufirst%3DM.%2Ba.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DMedication%2520discovery%2520for%2520addiction%253A%2520translating%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D882%26epage%3D890%26doi%3D10.1016%2Fj.bcp.2012.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. A.</span><span> </span><span class="NLM_article-title">Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3663</span><span class="NLM_x">–</span> <span class="NLM_lpage">3679</span><span class="refDoi"> DOI: 10.1021/jm040190e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040190e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtl2nur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3663-3679&author=A.+H.+Newmanauthor=P.+Grundtauthor=M.+A.+Nader&title=Dopamine+D3+receptor+partial+agonists+and+antagonists+as+potential+drug+abuse+therapeutic+agents&doi=10.1021%2Fjm040190e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents</span></div><div class="casAuthors">Newman, Amy Hauck; Grundt, Peter; Nader, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3663-3679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This report is limited to discussions of potential dopamine D3 receptor agents, currently being developed as medications for drug abuse and other neuropsychiatric disorders, to partial agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqHXSFV83KfLVg90H21EOLACvtfcHk0ljW0Y66nbNMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtl2nur0%253D&md5=4244539d9e8038e2027dba1e21497cdd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm040190e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040190e%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DNader%26aufirst%3DM.%2BA.%26atitle%3DDopamine%2520D3%2520receptor%2520partial%2520agonists%2520and%2520antagonists%2520as%2520potential%2520drug%2520abuse%2520therapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3663%26epage%3D3679%26doi%3D10.1021%2Fjm040190e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Moreira, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalley, J. W.</span><span> </span><span class="NLM_article-title">Dopamine receptor partial agonists and addiction</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">752</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2015.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.ejphar.2015.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=25724788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=752&publication_year=2015&pages=112-115&author=F.+A.+Moreiraauthor=J.+W.+Dalley&title=Dopamine+receptor+partial+agonists+and+addiction&doi=10.1016%2Fj.ejphar.2015.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor partial agonists and addiction</span></div><div class="casAuthors">Moreira, Fabricio A.; Dalley, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">752</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-115</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many drugs abused by humans acutely facilitate, either directly or indirectly, dopamine neurotransmission in the mesolimbic pathway.  As a consequence dopamine receptor agonists and antagonists have been widely investigated as putative pharmacol. therapies for addiction.  This general strategy, however, has had only limited success due in part to poor treatment adherence and efficacy and the significant adverse effects of dopaminergic medications.  In this perspective, we discuss the potential therapeutic use of dopamine receptor partial agonists in addiction, developed initially as antipsychotic agents.  Recent research indicates that the dopamine D2 receptor partial agonists, such as aripiprazole, also shows useful ancillary efficacy in several animal models of psychostimulant and opioid addiction.  Notably, these findings suggest that unlike full dopamine receptor agonists and antagonists these compds. have low abuse liability and are generally well tolerated.  Indeed, partial dopamine agonists attenuate the rewarding properties of opioids without interfering with their analgesic effects.  Herein we discuss the utility and potential of dopamine receptor partial agonists as treatments for both stimulant and non-stimulant drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8T303gZlZT7Vg90H21EOLACvtfcHk0lg3lIRk8SB9aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gqu7s%253D&md5=42a1128d4293e5e30963ee7fae789bcf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DMoreira%26aufirst%3DF.%2BA.%26aulast%3DDalley%26aufirst%3DJ.%2BW.%26atitle%3DDopamine%2520receptor%2520partial%2520agonists%2520and%2520addiction%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D752%26spage%3D112%26epage%3D115%26doi%3D10.1016%2Fj.ejphar.2015.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Heidbreder, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1187</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05149.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1749-6632.2009.05149.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=20201845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=4-34&author=C.+A.+Heidbrederauthor=A.+H.+Newman&title=Current+perspectives+on+selective+dopamine+D%283%29+receptor+antagonists+as+pharmacotherapeutics+for+addictions+and+related+disorders&doi=10.1111%2Fj.1749-6632.2009.05149.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders</span></div><div class="casAuthors">Heidbreder, Christian A.; Newman, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">4-34</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Repeated exposure to drugs of abuse produces long-term mol. and neurochem. changes that may explain the core features of addiction, such as the compulsive seeking and taking of the drug, as well as the risk of relapse.  A growing no. of new mol. and cellular targets of addictive drugs have been identified, and rapid advances are being made in relating those targets to specific behavioral phenotypes in animal models of addiction.  In this context, the pattern of expression of the dopamine (DA) D3 receptor in the rodent and human brain and changes in this pattern in response to drugs of abuse have contributed primarily to direct research efforts toward the development of selective DA D3 receptor antagonists.  Growing preclin. evidence indicates that these compds. may actually regulate the motivation to self-administer drugs and disrupt drug-assocd. cue-induced craving.  This report will be divided into three parts.  First, preclin. evidence in support of the efficacy of selective DA D3 receptor antagonists in animal models of drug addiction will be reviewed.  The effects of mixed DA D2/D3 receptor antagonists will not be discussed here because most of these compds. have low selectivity at the D3 vs. D2 receptor, and their efficacy profile is related primarily to functional antagonism at D2 receptors and possibly interactions with other neurotransmitter systems.  Second, major advances in medicinal chem. for the identification and optimization of selective DA D3 receptor antagonists and partial agonists will be analyzed.  Third, translational research from preclin. efficacy studies to so-called proof-of-concept studies for drug addiction indications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarcQYm33s6LVg90H21EOLACvtfcHk0lg3lIRk8SB9aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Snurc%253D&md5=48ded12d27f36b8d77717b118ccfa869</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05149.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05149.x%26sid%3Dliteratum%253Aachs%26aulast%3DHeidbreder%26aufirst%3DC.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DCurrent%2520perspectives%2520on%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%2520as%2520pharmacotherapeutics%2520for%2520addictions%2520and%2520related%2520disorders%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D4%26epage%3D34%26doi%3D10.1111%2Fj.1749-6632.2009.05149.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Keck, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czoty, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nader, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5361</span><span class="NLM_x">–</span> <span class="NLM_lpage">5380</span><span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0lg3lIRk8SB9aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Scherma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panlilio, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gamaleddin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Foll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justinova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikics, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medalie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fratta, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1124/jpet.108.142224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1124%2Fjpet.108.142224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18725543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=482-490&author=M.+Schermaauthor=L.+V.+Panlilioauthor=P.+Faddaauthor=L.+Fattoreauthor=I.+Gamaleddinauthor=B.+Le+Follauthor=Z.+Justinovaauthor=E.+Mikicsauthor=J.+Hallerauthor=J.+Medalieauthor=J.+Stroikauthor=C.+Barnesauthor=S.+Yasarauthor=G.+Tandaauthor=D.+Piomelliauthor=W.+Frattaauthor=S.+R.+Goldberg&title=Inhibition+of+anandamide+hydrolysis+by+cyclohexyl+carbamic+acid+3%E2%80%B2-carbamoyl-3-yl+ester+%28URB597%29+reverses+abuse-related+behavioral+and+neurochemical+effects+of+nicotine+in+rats&doi=10.1124%2Fjpet.108.142224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats</span></div><div class="casAuthors">Scherma, Maria; Panlilio, Leigh V.; Fadda, Paola; Fattore, Liana; Gamaleddin, Islam; Le Foll, Bernard; Justinova, Zuzana; Mikics, Eva; Haller, Jozsef; Medalie, Julie; Stroik, Jessica; Barnes, Chanel; Yasar, Sevil; Tanda, Gianluigi; Piomelli, Daniele; Fratta, Walter; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Emerging evidence suggests that the rewarding, abuse-related effects of nicotine are modulated by the endocannabinoid system of the brain.  For example, pharmacol. blockade or genetic deletion of cannabinoid CB1 receptors can reduce or eliminate many abuse-related behavioral and neurochem. effects of nicotine.  Furthermore, doses of Δ9-tetrahydrocannabinol and nicotine that are ineffective when given alone can induce conditioned place preference when given together.  These previous studies have used systemically administered CB1 receptor agonists and antagonists and gene deletion techniques, which affect cannabinoid CB1 receptors throughout the brain.  A more functionally selective way to alter endocannabinoid activity is to inhibit fatty acid amide hydrolase (FAAH), thereby magnifying and prolonging the effects of the endocannabinoid anandamide only when and where it is synthesized and released on demand.  Here, we combined behavioral and neurochem. approaches to evaluate whether the FAAH inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) could alter the abuse-related effects of nicotine in rats.  We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects by itself, prevented development of nicotine-induced conditioned place preference (CPP) and acquisition of nicotine self-administration.  URB597 also reduced nicotine-induced reinstatement in both CPP and self-administration models of relapse.  Furthermore, in vivo microdialysis showed that URB597 reduced nicotine-induced dopamine elevations in the nucleus accumbens shell, the terminal area of the brain's mesolimbic reward system.  These findings suggest that FAAH inhibition can counteract the addictive properties of nicotine and that FAAH may serve as a new target for development of medications for treatment of tobacco dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphdm-HRHpIKLVg90H21EOLACvtfcHk0lhcGngXDrNm4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7rJ&md5=5391ce52b5d6ce4b27d7af2cd5c2d534</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142224%26sid%3Dliteratum%253Aachs%26aulast%3DScherma%26aufirst%3DM.%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DFadda%26aufirst%3DP.%26aulast%3DFattore%26aufirst%3DL.%26aulast%3DGamaleddin%26aufirst%3DI.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DMikics%26aufirst%3DE.%26aulast%3DHaller%26aufirst%3DJ.%26aulast%3DMedalie%26aufirst%3DJ.%26aulast%3DStroik%26aufirst%3DJ.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DYasar%26aufirst%3DS.%26aulast%3DTanda%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DFratta%26aufirst%3DW.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520of%2520anandamide%2520hydrolysis%2520by%2520cyclohexyl%2520carbamic%2520acid%25203%25E2%2580%25B2-carbamoyl-3-yl%2520ester%2520%2528URB597%2529%2520reverses%2520abuse-related%2520behavioral%2520and%2520neurochemical%2520effects%2520of%2520nicotine%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D482%26epage%3D490%26doi%3D10.1124%2Fjpet.108.142224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Parsons, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurd, Y. L.</span><span> </span><span class="NLM_article-title">Endocannabinoid signalling in reward and addiction</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1038/nrn4004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnrn4004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=26373473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=579-594&author=L.+H.+Parsonsauthor=Y.+L.+Hurd&title=Endocannabinoid+signalling+in+reward+and+addiction&doi=10.1038%2Fnrn4004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid signaling in reward and addiction</span></div><div class="casAuthors">Parsons, Loren H.; Hurd, Yasmin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">579-594</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Brain endocannabinoid (eCB) signaling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs.  Pathol. forms of natural and drug-induced reward are assocd. with dysregulated eCB signaling that may derive from pre-existing genetic factors or from prolonged drug exposure.  Impaired eCB signaling contributes to dysregulated synaptic plasticity, increased stress responsivity, neg. emotional states and cravings that propel addiction.  Understanding the contributions of eCB disruptions to behavioral and physiol. traits provides insight into the eCB influence on addiction vulnerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s5P4XZrYGbVg90H21EOLACvtfcHk0lhcGngXDrNm4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWls7%252FF&md5=0a7180790eba188007435ec107c6a2a9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrn4004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4004%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DHurd%26aufirst%3DY.%2BL.%26atitle%3DEndocannabinoid%2520signalling%2520in%2520reward%2520and%2520addiction%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D579%26epage%3D594%26doi%3D10.1038%2Fnrn4004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Panlilio, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justinova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pharmthera.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=23333350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlamsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=84-102&author=L.+V.+Panlilioauthor=Z.+Justinovaauthor=S.+R.+Goldberg&title=Inhibition+of+FAAH+and+activation+of+PPAR%3A+new+approaches+to+the+treatment+of+cognitive+dysfunction+and+drug+addiction&doi=10.1016%2Fj.pharmthera.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction</span></div><div class="casAuthors">Panlilio, Leigh V.; Justinova, Zuzana; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-102</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Enhancing the effects of endogenously-released cannabinoid ligands in the brain might provide therapeutic effects more safely and effectively than administering drugs that act directly at the cannabinoid receptor.  Inhibitors of fatty acid amide hydrolase (FAAH) prevent the breakdown of endogenous ligands for cannabinoid receptors and peroxisome proliferator-activated receptors (PPAR), prolonging and enhancing the effects of these ligands when they are naturally released.  This review considers recent research on the effects of FAAH inhibitors and PPAR activators in animal models of addiction and cognition (specifically learning and memory).  These studies show that FAAH inhibitors can produce potentially therapeutic effects, some through cannabinoid receptors and some through PPAR.  These effects include enhancing certain forms of learning, counteracting the rewarding effects of nicotine and alc., relieving symptoms of withdrawal from cannabis and other drugs, and protecting against relapse-like reinstatement of drug self-administration.  Since FAAH inhibition might have a wide range of therapeutic actions but might also share some of the adverse effects of cannabis, it is noteworthy that at least one FAAH-inhibiting drug (URB597) has been found to have potentially beneficial effects but no indication of liability for abuse or dependence.  Although these areas of research are new, the preliminary evidence indicates that they might lead to improved therapeutic interventions and a better understanding of the brain mechanisms underlying addiction and memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVfd0ns0RUZrVg90H21EOLACvtfcHk0ljHYC7SOzV0Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlamsrc%253D&md5=a13bc121f2523849c97c8029d279e8a7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520of%2520FAAH%2520and%2520activation%2520of%2520PPAR%253A%2520new%2520approaches%2520to%2520the%2520treatment%2520of%2520cognitive%2520dysfunction%2520and%2520drug%2520addiction%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D138%26spage%3D84%26epage%3D102%26doi%3D10.1016%2Fj.pharmthera.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Melis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillolla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchicchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muntoni, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistis, M.</span><span> </span><span class="NLM_article-title">Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">13985</span><span class="NLM_x">–</span> <span class="NLM_lpage">13994</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3221-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1523%2FJNEUROSCI.3221-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=19091987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCqtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=13985-13994&author=M.+Melisauthor=G.+Pillollaauthor=A.+Luchicchiauthor=A.+L.+Muntoniauthor=S.+Yasarauthor=S.+R.+Goldbergauthor=M.+Pistis&title=Endogenous+fatty+acid+ethanolamides+suppress+nicotine-induced+activation+of+mesolimbic+dopamine+neurons+through+nuclear+receptors&doi=10.1523%2FJNEUROSCI.3221-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors</span></div><div class="casAuthors">Melis, Miriam; Pillolla, Giuliano; Luchicchi, Antonio; Muntoni, Anna Lisa; Yasar, Sevil; Goldberg, Steven R.; Pistis, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13985-13994</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Nicotine stimulates the activity of mesolimbic dopamine neurons, which is believed to mediate the rewarding and addictive properties of tobacco use.  Accumulating evidence suggests that the endocannabinoid system might play a major role in neuronal mechanisms underlying the rewarding properties of drugs of abuse, including nicotine.  Here, we investigated the modulation of nicotine effects by the endocannabinoid system on dopamine neurons in the ventral tegmental area with electrophysiol. techniques in vivo and in vitro.  We discovered that pharmacol. inhibition of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes fatty acid ethanolamides, among which the endocannabinoid anandamide (AEA) is the best known, suppressed nicotine-induced excitation of dopamine cells.  Importantly, this effect was mimicked by the administration of the FAAH substrates oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), but not methanandamide, the hydrolysis resistant analog of AEA.  OEA and PEA are naturally occurring lipid signaling mols. structurally related to AEA, but devoid of affinity for cannabinoid receptors.  They blocked the effects of nicotine by activation of the peroxisome proliferator-activated receptor-α (PPAR-α), a nuclear receptor transcription factor involved in several aspects of lipid metab. and energy balance.  Activation of PPAR-α triggered a nongenomic stimulation of tyrosine kinases, which might lead to phosphorylation and neg. regulation of neuronal nicotinic acetylcholine receptors.  These data indicate for the first time that the anorexic lipids OEA and PEA possess neuromodulatory properties as endogenous ligands of PPAR-α in the brain and provide a potential new target for the treatment of nicotine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_T8NIOwF2rrVg90H21EOLACvtfcHk0ljHYC7SOzV0Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCqtrfO&md5=01da030bc1b18420c7fa15e521aae97c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3221-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3221-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMelis%26aufirst%3DM.%26aulast%3DPillolla%26aufirst%3DG.%26aulast%3DLuchicchi%26aufirst%3DA.%26aulast%3DMuntoni%26aufirst%3DA.%2BL.%26aulast%3DYasar%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26aulast%3DPistis%26aufirst%3DM.%26atitle%3DEndogenous%2520fatty%2520acid%2520ethanolamides%2520suppress%2520nicotine-induced%2520activation%2520of%2520mesolimbic%2520dopamine%2520neurons%2520through%2520nuclear%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D13985%26epage%3D13994%26doi%3D10.1523%2FJNEUROSCI.3221-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaetani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fegley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calignano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giustino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tattoli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmery, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Modulation of anxiety through blockade of anandamide hydrolysis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1038/nm803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1038%2Fnm803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=12461523" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=76-81&author=S.+Kathuriaauthor=S.+Gaetaniauthor=D.+Fegleyauthor=F.+Valinoauthor=A.+Durantiauthor=A.+Tontiniauthor=M.+Morauthor=G.+Tarziaauthor=G.+La+Ranaauthor=A.+Calignanoauthor=A.+Giustinoauthor=M.+Tattoliauthor=M.+Palmeryauthor=V.+Cuomoauthor=D.+Piomelli&title=Modulation+of+anxiety+through+blockade+of+anandamide+hydrolysis&doi=10.1038%2Fnm803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnm803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm803%26sid%3Dliteratum%253Aachs%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DGaetani%26aufirst%3DS.%26aulast%3DFegley%26aufirst%3DD.%26aulast%3DValino%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DLa%2BRana%26aufirst%3DG.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DGiustino%26aufirst%3DA.%26aulast%3DTattoli%26aufirst%3DM.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DCuomo%26aufirst%3DV.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DModulation%2520of%2520anxiety%2520through%2520blockade%2520of%2520anandamide%2520hydrolysis%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D9%26spage%3D76%26epage%3D81%26doi%3D10.1038%2Fnm803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">De Simone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4904</span><span class="NLM_x">–</span> <span class="NLM_lpage">4907</span><span class="refDoi"> DOI: 10.1039/c4cc00967c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1039%2Fc4cc00967c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=4904-4907&author=A.+De+Simoneauthor=G.+F.+Rudaauthor=C.+Albaniauthor=G.+Tarozzoauthor=T.+Bandieraauthor=D.+Piomelliauthor=A.+Cavalliauthor=G.+Bottegoni&title=Applying+a+multitarget+rational+drug+design+strategy%3A+the+first+set+of+modulators+with+potent+and+balanced+activity+toward+dopamine+D3+receptor+and+fatty+acid+amide+hydrolase&doi=10.1039%2Fc4cc00967c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fc4cc00967c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cc00967c%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DAlbani%26aufirst%3DC.%26aulast%3DTarozzo%26aufirst%3DG.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DApplying%2520a%2520multitarget%2520rational%2520drug%2520design%2520strategy%253A%2520the%2520first%2520set%2520of%2520modulators%2520with%2520potent%2520and%2520balanced%2520activity%2520toward%2520dopamine%2520D3%2520receptor%2520and%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D4904%26epage%3D4907%26doi%3D10.1039%2Fc4cc00967c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Micoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Simone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottonello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Aryl and heteroaryl N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates with improved physico-chemical properties as dual modulators of dopamine D3 receptor and fatty acid amide hydrolase</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1039/C5MD00590F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1039%2FC5MD00590F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=537-541&author=A.+Micoliauthor=A.+De+Simoneauthor=D.+Russoauthor=G.+Ottonelloauthor=G.+Colombanoauthor=G.+F.+Rudaauthor=T.+Bandieraauthor=A.+Cavalliauthor=G.+Bottegoni&title=Aryl+and+heteroaryl+N-%5B4-%5B4-%282%2C3-substituted-phenyl%29piperazine-1-yl%5Dalkyl%5Dcarbamates+with+improved+physico-chemical+properties+as+dual+modulators+of+dopamine+D3+receptor+and+fatty+acid+amide+hydrolase&doi=10.1039%2FC5MD00590F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC5MD00590F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00590F%26sid%3Dliteratum%253Aachs%26aulast%3DMicoli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DOttonello%26aufirst%3DG.%26aulast%3DColombano%26aufirst%3DG.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DAryl%2520and%2520heteroaryl%2520N-%255B4-%255B4-%25282%252C3-substituted-phenyl%2529piperazine-1-yl%255Dalkyl%255Dcarbamates%2520with%2520improved%2520physico-chemical%2520properties%2520as%2520dual%2520modulators%2520of%2520dopamine%2520D3%2520receptor%2520and%2520fatty%2520acid%2520amide%2520hydrolase%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D537%26epage%3D541%26doi%3D10.1039%2FC5MD00590F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Del Zotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amoroso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigo, P.</span><span> </span><span class="NLM_article-title">Very fast Suzuki-Miyaura reaction catalyzed by Pd(OAc)2 under aerobic conditions at room temperature in EGME/H2O</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1002/ejoc.200800874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2Fejoc.200800874" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=110-116&author=A.+Del+Zottoauthor=F.+Amorosoauthor=W.+Barattaauthor=P.+Rigo&title=Very+fast+Suzuki-Miyaura+reaction+catalyzed+by+Pd%28OAc%292+under+aerobic+conditions+at+room+temperature+in+EGME%2FH2O&doi=10.1002%2Fejoc.200800874"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200800874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200800874%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BZotto%26aufirst%3DA.%26aulast%3DAmoroso%26aufirst%3DF.%26aulast%3DBaratta%26aufirst%3DW.%26aulast%3DRigo%26aufirst%3DP.%26atitle%3DVery%2520fast%2520Suzuki-Miyaura%2520reaction%2520catalyzed%2520by%2520Pd%2528OAc%25292%2520under%2520aerobic%2520conditions%2520at%2520room%2520temperature%2520in%2520EGME%252FH2O%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26volume%3D2009%26spage%3D110%26epage%3D116%26doi%3D10.1002%2Fejoc.200800874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Moreno-Sanz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestichelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5917</span><span class="NLM_x">–</span> <span class="NLM_lpage">5930</span><span class="refDoi"> DOI: 10.1021/jm4007017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5917-5930&author=G.+Moreno-Sanzauthor=A.+Durantiauthor=L.+Melzigauthor=C.+Fiorelliauthor=G.+F.+Rudaauthor=G.+Colombanoauthor=P.+Mestichelliauthor=S.+Sanchiniauthor=A.+Tontiniauthor=M.+Morauthor=T.+Bandieraauthor=R.+Scarpelliauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+structure-activity+relationship+studies+of+O-biphenyl-3-yl+carbamates+as+peripherally+restricted+fatty+acid+amide+hydrolase+inhibitors&doi=10.1021%2Fjm4007017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm4007017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007017%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Sanz%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DColombano%26aufirst%3DG.%26aulast%3DMestichelli%26aufirst%3DP.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520O-biphenyl-3-yl%2520carbamates%2520as%2520peripherally%2520restricted%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5917%26epage%3D5930%26doi%3D10.1021%2Fjm4007017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Grundt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElveen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0liUNAUorai2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banala, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donthamsetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongetti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBounty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6689</span><span class="NLM_x">–</span> <span class="NLM_lpage">6699</span><span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0ljfB7hPoz3V7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2352</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span><span class="refDoi"> DOI: 10.1021/jm021119g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm021119g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2352-2360&author=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Piersantiauthor=M.+Morauthor=S.+Rivaraauthor=P.+V.+Plazziauthor=C.+Parkauthor=S.+Kathuriaauthor=D.+Piomelli&title=Design%2C+synthesis%2C+and+structure-activity+relationships+of+alkylcarbamic+acid+aryl+esters%2C+a+new+class+of+fatty+acid+amide+hydrolase+inhibitors&doi=10.1021%2Fjm021119g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm021119g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm021119g%26sid%3Dliteratum%253Aachs%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%2520of%2520alkylcarbamic%2520acid%2520aryl%2520esters%252C%2520a%2520new%2520class%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2352%26epage%3D2360%26doi%3D10.1021%2Fjm021119g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4998</span><span class="NLM_x">–</span> <span class="NLM_lpage">5008</span><span class="refDoi"> DOI: 10.1021/jm031140x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031140x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4998-5008&author=M.+Morauthor=S.+Rivaraauthor=A.+Lodolaauthor=P.+V.+Plazziauthor=G.+Tarziaauthor=A.+Durantiauthor=A.+Tontiniauthor=G.+Piersantiauthor=S.+Kathuriaauthor=D.+Piomelli&title=Cyclohexylcarbamic+acid+3%E2%80%B2-+or+4%E2%80%B2-substituted+biphenyl-3-yl+esters+as+fatty+acid+amide+hydrolase+inhibitors%3A+synthesis%2C+quantitative+structure-activity+relationships%2C+and+molecular+modeling+studies&doi=10.1021%2Fjm031140x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm031140x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031140x%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DCyclohexylcarbamic%2520acid%25203%25E2%2580%25B2-%2520or%25204%25E2%2580%25B2-substituted%2520biphenyl-3-yl%2520esters%2520as%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520synthesis%252C%2520quantitative%2520structure-activity%2520relationships%252C%2520and%2520molecular%2520modeling%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4998%26epage%3D5008%26doi%3D10.1021%2Fjm031140x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3487</span><span class="NLM_x">–</span> <span class="NLM_lpage">3498</span><span class="refDoi"> DOI: 10.1021/jm701631z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701631z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3487-3498&author=M.+Morauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Durantiauthor=A.+Tontiniauthor=S.+Sanchiniauthor=G.+Piersantiauthor=J.+R.+Clapperauthor=A.+R.+Kingauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+quantitative+structure-activity+relationship+of+fatty+acid+amide+hydrolase+inhibitors%3A+modulation+at+the+N-portion+of+biphenyl-3-yl+alkylcarbamates&doi=10.1021%2Fjm701631z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm701631z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701631z%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520quantitative%2520structure-activity%2520relationship%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520modulation%2520at%2520the%2520N-portion%2520of%2520biphenyl-3-yl%2520alkylcarbamates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3487%26epage%3D3498%26doi%3D10.1021%2Fjm701631z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0ljHEJHSR9DViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Cortes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Ruiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canela, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casado, V.</span><span> </span><span class="NLM_article-title">Targeting the dopamine D3 receptor: an overview of drug design strategies</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1080/17460441.2016.1185413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1080%2F17460441.2016.1185413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27135354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=641-664&author=A.+Cortesauthor=E.+Morenoauthor=M.+Rodriguez-Ruizauthor=E.+I.+Canelaauthor=V.+Casado&title=Targeting+the+dopamine+D3+receptor%3A+an+overview+of+drug+design+strategies&doi=10.1080%2F17460441.2016.1185413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dopamine D3 receptor: an overview of drug design strategies</span></div><div class="casAuthors">Cortes, Antoni; Moreno, Estefania; Rodriguez-Ruiz, Mar; Canela, Enric I.; Casado, Vicent</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">641-664</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter widely distributed in both the periphery and the central nervous system (CNS).  Its physiol. effects are mediated by five closely related G protein-coupled receptors (GPCRs) that are divided into two major subclasses: the D1-like (D1, D5) and the D2-like (D2, D3, D4) receptors.  D3 receptors (D3Rs) have the highest d. in the limbic areas of the brain, which are assocd. with cognitive and emotional functions.  These receptors are therefore attractive targets for therapeutic management.  This review summarizes the functional and pharmacol. characteristics of D3Rs, including the design and clin. relevance of full agonists, partial agonists and antagonists, as well as the capacity of these receptors to form active homodimers, heterodimers or higher order receptor complexes as pharmacol. targets in several neurol. and neurodegenerative disorders.  The high sequence homol. between D3R and the D2-type challenges the development of D3R-selective compds.  The design of new D3R-preferential ligands with improved physicochem. properties should provide a better pharmacokinetic/bioavailability profile and lesser toxicity than is found with existing D3R ligands.  It is also essential to optimize D3R affinity and, esp., D3R vs.  D2-type binding and functional selectivity ratios.  Developing allosteric and bitopic ligands should help to improve the D3R selectivity of these drugs.  As most evidence points to the ability of GPCRs to form homomers and heteromers, the most promising therapeutic strategy in the future is likely to involve the application of heteromer-selective drugs.  These selective ligands would display different affinities for a given receptor depending on the receptor partners within the heteromer.  Therefore, designing novel compds. that specifically target and modulate D1R-D3R heteromers would be an interesting approach for the treatment of levodopa (L-DOPA)-induced dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE412vMxQCZ7Vg90H21EOLACvtfcHk0ljHEJHSR9DViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFOrsL4%253D&md5=eda2d0b52e03bbca2d62f1b27b193360</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1185413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1185413%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DRodriguez-Ruiz%26aufirst%3DM.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DCasado%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520dopamine%2520D3%2520receptor%253A%2520an%2520overview%2520of%2520drug%2520design%2520strategies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D641%26epage%3D664%26doi%3D10.1080%2F17460441.2016.1185413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Razdan, R. K.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of classical cannabinoids</span>. In  <span class="citation_source-book">The Cannabinoid Receptors</span>; <span class="NLM_contrib-group">Reggio, P. H.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3-19&author=R.+K.+Razdanauthor=P.+H.+Reggio&title=The+Cannabinoid+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRazdan%26aufirst%3DR.%2BK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520classical%2520cannabinoids%26btitle%3DThe%2520Cannabinoid%2520Receptors%26aulast%3DReggio%26aufirst%3DP.%2BH.%26pub%3DHumana%2520Press%26date%3D2008%26spage%3D3%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. E.</span><span> </span><span class="NLM_article-title">Ligand-specific homology modeling of human cannabinoid CB1 receptor</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span><span class="refDoi"> DOI: 10.1016/j.jmgm.2012.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.jmgm.2012.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslaqtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=155-164&author=R.+Aiauthor=C.+E.+Chang&title=Ligand-specific+homology+modeling+of+human+cannabinoid+CB1+receptor&doi=10.1016%2Fj.jmgm.2012.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-specific homology modeling of human cannabinoid (CB1) receptor</span></div><div class="casAuthors">Ai, Rizi; Chang, Chia-en A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cannabinoid (CB1) receptor is a therapeutic drug target, and its structure and conformational changes after ligand binding are of great interest.  To study the protein conformations in ligand bound state and assist in drug discovery, CB1 receptor homol. models are needed for computer-based ligand screening.  The known CB1 ligands are highly diverse structurally, so CB1 receptor may undergo considerable conformational changes to accept different ligands, which is challenging for mol. docking methods.  To account for the flexibility of CB1 receptor, we constructed four CB1 receptor models based on four structurally distinct ligands, HU-210, ACEA, WIN 55212-2 and SR 141716A, using the newest X-ray crystal structures of human β2 adrenergic receptor and adenosine A2A receptor as templates.  The conformations of these four CB1-ligand complexes were optimized by mol. dynamics (MD) simulations.  The models revealed interactions between CB1 receptor and known binders suggested by expts. and could successfully discriminate known ligands and non-binders in our docking assays.  MD simulations were used to study the most flexible ligand, ACEA, in its free and bound states to investigate structural mobility achieved by the rearrangement of the fatty acid chain.  Our models may capture important conformational changes of CB1 receptor to help improve accuracy in future CB1 drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryPt7qV7XBubVg90H21EOLACvtfcHk0ljKT5u9O5E6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslaqtbvN&md5=8d771466ac91897a401ad57e6256125e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2012.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2012.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DC.%2BE.%26atitle%3DLigand-specific%2520homology%2520modeling%2520of%2520human%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2012%26volume%3D38%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.jmgm.2012.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Fichera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumarra, G.</span><span> </span><span class="NLM_article-title">A 3D-QSAR study on the structural requirements for binding to CB (1) and CB(2) cannabinoid receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2309</span><span class="refDoi"> DOI: 10.1021/jm991074s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991074s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2300-2309&author=M.+Ficheraauthor=G.+Crucianiauthor=A.+Bianchiauthor=G.+Musumarra&title=A+3D-QSAR+study+on+the+structural+requirements+for+binding+to+CB+%281%29+and+CB%282%29+cannabinoid+receptors&doi=10.1021%2Fjm991074s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm991074s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991074s%26sid%3Dliteratum%253Aachs%26aulast%3DFichera%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DMusumarra%26aufirst%3DG.%26atitle%3DA%25203D-QSAR%2520study%2520on%2520the%2520structural%2520requirements%2520for%2520binding%2520to%2520CB%2520%25281%2529%2520and%2520CB%25282%2529%2520cannabinoid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2300%26epage%3D2309%26doi%3D10.1021%2Fjm991074s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Hua, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shui, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laprairie, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvonok, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.+H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+A.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.+J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0ljKT5u9O5E6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BH.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Totrov, M.</span><span> </span><span class="NLM_article-title">Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00605.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1111%2Fj.1747-0285.2007.00605.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18069986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvF2lsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=15-27&author=M.+Totrov&title=Atomic+property+fields%3A+generalized+3D+pharmacophoric+potential+for+automated+ligand+superposition%2C+pharmacophore+elucidation+and+3D+QSAR&doi=10.1111%2Fj.1747-0285.2007.00605.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR</span></div><div class="casAuthors">Totrov, Maxim</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The at. property fields (APF) concept is introduced as a continuous, multi-component 3D potential that reflects preferences for various at. properties at each point in space.  At. property field-based approaches to several key problems in the field of ligand structure-based rational drug discovery and design are investigated.  The superposition of ligands on one or multiple mol. templates is performed by Monte-Carlo minimization in the at. property fields potentials combined with std. force-field energy.  The approach is extended to multiple flexible ligand alignments using an iterative procedure, Self-Consistent at. Property Fields by Optimization (SCAPFOld).  The application of at. property fields and SCAPFOld for virtual ligand screening and 3D Quantitive Structure-Activity Relationship (QSAR) is tested on published benchmarks.  The new methods are shown to perform competitively in comparison to current state-of-the-art methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQFMXqW3d8ErVg90H21EOLACvtfcHk0ljKT5u9O5E6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvF2lsL8%253D&md5=d66ce22225d4d9dfeed56196af4025d1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00605.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00605.x%26sid%3Dliteratum%253Aachs%26aulast%3DTotrov%26aufirst%3DM.%26atitle%3DAtomic%2520property%2520fields%253A%2520generalized%25203D%2520pharmacophoric%2520potential%2520for%2520automated%2520ligand%2520superposition%252C%2520pharmacophore%2520elucidation%2520and%25203D%2520QSAR%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2008%26volume%3D71%26spage%3D15%26epage%3D27%26doi%3D10.1111%2Fj.1747-0285.2007.00605.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodbeck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Primus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasley, J. W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurkauf, A.</span><span> </span><span class="NLM_article-title">NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2715</span><span class="NLM_x">–</span> <span class="NLM_lpage">2718</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00469-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2FS0960-894X%2898%2900469-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=9873609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADyaK1cXntV2qs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2715-2718&author=J.+Yuanauthor=X.+Chenauthor=R.+Brodbeckauthor=R.+Primusauthor=J.+Braunauthor=J.+W.+F.+Wasleyauthor=A.+Thurkauf&title=NGB+2904+and+NGB+2849%3A+two+highly+selective+dopamine+D3+receptor+antagonists&doi=10.1016%2FS0960-894X%2898%2900469-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists</span></div><div class="casAuthors">Yuan, Jun; Chen, Xi; Brodbeck, Robbin; Primus, Renee; Braun, Julia; Wasley, Jan W. F.; Thurkauf, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2715-2718</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide and N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-2-biphenylenylcarboxamide were prepd. in several steps from 2,3-dichloroaniline.  These compds. were identified as highly selective dopamine D3 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2unsQE-pTcrVg90H21EOLACvtfcHk0ljJ7ymimp2nsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntV2qs7k%253D&md5=1886ea40a0addbbba184c9ad51f47f04</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900469-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900469-7%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBrodbeck%26aufirst%3DR.%26aulast%3DPrimus%26aufirst%3DR.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DWasley%26aufirst%3DJ.%2BW.%2BF.%26aulast%3DThurkauf%26aufirst%3DA.%26atitle%3DNGB%25202904%2520and%2520NGB%25202849%253A%2520two%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2715%26epage%3D2718%26doi%3D10.1016%2FS0960-894X%2898%2900469-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Cherkasov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muratov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourches, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramatica, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todeschini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Consonni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuz’min, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terfloth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasteiger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tropsha, A.</span><span> </span><span class="NLM_article-title">QSAR modeling: where have you been? Where are you going to?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4977</span><span class="NLM_x">–</span> <span class="NLM_lpage">5010</span><span class="refDoi"> DOI: 10.1021/jm4004285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4977-5010&author=A.+Cherkasovauthor=E.+N.+Muratovauthor=D.+Fourchesauthor=A.+Varnekauthor=+Baskinauthor=M.+Croninauthor=J.+Deardenauthor=P.+Gramaticaauthor=Y.+C.+Martinauthor=R.+Todeschiniauthor=V.+Consonniauthor=V.+E.+Kuz%E2%80%99minauthor=R.+Cramerauthor=R.+Benigniauthor=C.+Yangauthor=J.+Rathmanauthor=L.+Terflothauthor=J.+Gasteigerauthor=A.+Richardauthor=A.+Tropsha&title=QSAR+modeling%3A+where+have+you+been%3F+Where+are+you+going+to%3F&doi=10.1021%2Fjm4004285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">QSAR Modeling: Where Have You Been? Where Are You Going To?</span></div><div class="casAuthors">Cherkasov, Artem; Muratov, Eugene N.; Fourches, Denis; Varnek, Alexandre; Baskin, Igor I.; Cronin, Mark; Dearden, John; Gramatica, Paola; Martin, Yvonne C.; Todeschini, Roberto; Consonni, Viviana; Kuzmin, Victor E.; Cramer, Richard; Benigni, Romualdo; Yang, Chihae; Rathman, James; Terfloth, Lothar; Gasteiger, Johann; Richard, Ann; Tropsha, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4977-5010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Quant. structure-activity relationship modeling is one of the major computational tools employed in medicinal chem.  However, throughout its entire history it has drawn both praise and criticism concerning its reliability, limitations, successes, and failures.  In this paper, we discuss (i) the development and evolution of QSAR; (ii) the current trends, unsolved problems, and pressing challenges; and (iii) several novel and emerging applications of QSAR modeling.  Throughout this discussion, we provide guidelines for QSAR development, validation, and application, which are summarized in best practices for building rigorously validated and externally predictive QSAR models.  We hope that this Perspective will help communications between computational and exptl. chemists toward collaborative development and use of QSAR models.  We also believe that the guidelines presented here will help journal editors and reviewers apply more stringent scientific stds. to manuscripts reporting new QSAR studies, as well as encourage the use of high quality, validated QSARs for regulatory decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbLWydJbspbLVg90H21EOLACvtfcHk0ljJ7ymimp2nsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCrsLnE&md5=a2d371ee33fbecf48ef59ecf914e4aa8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm4004285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004285%26sid%3Dliteratum%253Aachs%26aulast%3DCherkasov%26aufirst%3DA.%26aulast%3DMuratov%26aufirst%3DE.%2BN.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DVarnek%26aufirst%3DA.%26aulast%3DBaskin%26aulast%3DCronin%26aufirst%3DM.%26aulast%3DDearden%26aufirst%3DJ.%26aulast%3DGramatica%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DTodeschini%26aufirst%3DR.%26aulast%3DConsonni%26aufirst%3DV.%26aulast%3DKuz%25E2%2580%2599min%26aufirst%3DV.%2BE.%26aulast%3DCramer%26aufirst%3DR.%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRathman%26aufirst%3DJ.%26aulast%3DTerfloth%26aufirst%3DL.%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DTropsha%26aufirst%3DA.%26atitle%3DQSAR%2520modeling%253A%2520where%2520have%2520you%2520been%253F%2520Where%2520are%2520you%2520going%2520to%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4977%26epage%3D5010%26doi%3D10.1021%2Fjm4004285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Schneider, G.; Baringhaus, K.-H.</span><span> </span><span class="NLM_article-title">De novo design: from models to molecules</span>. In  <span class="citation_source-book">De Novo Molecular Design</span>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2F9783527677016.ch1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1-55&author=G.+Schneider&author=K.-H.+Baringhaus&title=De+Novo+Molecular+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F9783527677016.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527677016.ch1%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDe%2520novo%2520design%253A%2520from%2520models%2520to%2520molecules%26btitle%3DDe%2520Novo%2520Molecular%2520Design%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2013%26spage%3D1%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Blankman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0lircwrlvP6SvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Leggio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platania, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drago, F.</span><span> </span><span class="NLM_article-title">Current drug treatments targeting dopamine D3 receptor</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pharmthera.2016.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27343365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=164-177&author=G.+M.+Leggioauthor=C.+Bucoloauthor=C.+B.+Plataniaauthor=S.+Salomoneauthor=F.+Drago&title=Current+drug+treatments+targeting+dopamine+D3+receptor&doi=10.1016%2Fj.pharmthera.2016.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Current drug treatments targeting dopamine D3 receptor</span></div><div class="casAuthors">Leggio, Gian Marco; Bucolo, Claudio; Platania, Chiara Bianca Maria; Salomone, Salvatore; Drago, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">164-177</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dopamine receptors (DR) have been extensively studied, but only in recent years they became object of investigation to elucidate the specific role of different subtypes (D1R, D2R, D3R, D4R, D5R) in neural transmission and circuitry.  D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D2R and D4R) differ in signal transduction, binding profile, localization in the central nervous system and physiol. effects.  D3R is involved in a no. of pathol. conditions, including schizophrenia, Parkinson's disease, addiction, anxiety, depression and glaucoma.  Development of selective D3R ligands has been so far challenging, due to the high sequence identity and homol. shared by D2R and D3R.  As a consequence, despite a rational design of selective DR ligands has been carried out, none of currently available medicines selectively target a given D2-like receptor subtype.  The availability of the D3R ligand [11C]-(+)-PHNO for positron emission tomog. studies in animal models as well as in humans, allows researchers to est. the expression of D3R in vivo; displacement of [11C]-(+)-PHNO binding by concurrent drug treatments is used to est. the in vivo occupancy of D3R.  Here we provide an overview of studies indicating D3R as a target for pharmacol. therapy, and a review of market approved drugs endowed with significant affinity at D3R that are used to treat disorders where D3R plays a relevant role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripJ2xDVYRubVg90H21EOLACvtfcHk0lircwrlvP6SvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbfF&md5=e29dffe5b17b48f68d33ec838ece35dc</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DBucolo%26aufirst%3DC.%26aulast%3DPlatania%26aufirst%3DC.%2BB.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DCurrent%2520drug%2520treatments%2520targeting%2520dopamine%2520D3%2520receptor%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D164%26epage%3D177%26doi%3D10.1016%2Fj.pharmthera.2016.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Butini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolic, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agbaba, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brogi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindisi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campiani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, H.</span><span> </span><span class="NLM_article-title">Polypharmacology of dopamine receptor ligands</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Bruckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campianiauthor=H.+Stark&title=Polypharmacology+of+dopamine+receptor+ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0lircwrlvP6SvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBruckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPolypharmacology%2520of%2520dopamine%2520receptor%2520ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;key=1%3ACAS%3A528%3ADyaK28XhvVGmsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=490-519&author=T.+A.+Halgren&title=Merck+molecular+force+field.+I.+Basis%2C+form%2C+scope%2C+parameterization%2C+and+performance+of+MMFF94&doi=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">490-519</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">This article introduces MMFF94, the initial published version of the Merck mol. force field (MMFF).  It describes the objectives set for MMFF, the form it takes, and the range of systems to which it applies.  This study also outlines the methodol. employed in parameterizing MMFF94 and summarizes its performance in reproducing computational and exptl. data.  Though similar to MM3 in some respects, MMFF94 differs in ways intended to facilitate application to condensed-phase processes in mol.-dynamics simulations.  Indeed, MMFF94 seeks to achieve MM3-like accuracy for small mols. in a combined "org./protein" force field that is equally applicable to proteins and other systems of biol. significance.  A second distinguishing feature is that the core protion of MMFF94 has primarily been derived from high-quality computational data-ca. 500 mol. structures optimized at the HF/6-31G* level, 475 structures optimized at the MP2/6-31G* level, 380 MP2/6-31* structures evaluated at a defined approxn. to the MP4SDQ/TZP level, and 1450 structures partly derived from MP2/6-31G* geometries and evaluated at the MP2/TZP level.  A third distinguishing feature is that MMFF94 has been parameterized for a wide variety of chem. systems of interest to org. and combinations of functional groups for which little, if any, useful exptl. data are available.  The methodol. used in parameterizing MMFF94 represents a fourth distinguishing feature.  Rather than using the common "functional group" approach, nearly all MMFF parameters have been detd. in a mutually consistent fashion from the full set of available computational data.  MMFF94 reproduces the computational data used in its parameterization very well.  In addn., MMFF94 reproduces exptl. bond lengths (0.014 Å root mean square [rms]), bond angles (1.2° rms), vibrational frequencies (61 cm-1 rms), conformational energies (0.38 kcal/mol rms), and rotational barriers (0.39 kcal/mol rms) very nearly as well as does MM3 for comparable systems.  MMFF94 also describes intermol. interactions in hydrogen-bonded systems in a way that closely parallels that given by the highly regarded OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzCYfKnN83rVg90H21EOLACvtfcHk0lircwrlvP6SvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVGmsbk%253D&md5=56fb073477b4f49d1dfbd786fc56a480</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-987X%2528199604%252917%253A5%252F6%253C490%253A%253AAID-JCC1%253E3.0.CO%253B2-P%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMerck%2520molecular%2520force%2520field.%2520I.%2520Basis%252C%2520form%252C%2520scope%252C%2520parameterization%252C%2520and%2520performance%2520of%2520MMFF94%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1996%26volume%3D17%26spage%3D490%26epage%3D519%26doi%3D10.1002%2F%28SICI%291096-987X%28199604%2917%3A5%2F6%3C490%3A%3AAID-JCC1%3E3.0.CO%3B2-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Abagyan, R.; Raush, E.; Totrov, M.</span>ICM Manual, version <span class="NLM_edition">3.7</span>. <a href="http://www.molsoft.com/man/index.html" class="extLink">http://www.molsoft.com/man/index.html</a> (accessed October 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Abagyan&author=E.+Raush&author=M.+Totrov&title=ICM+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DAbagyan%26aufirst%3DR.%26jtitle%3DICM%2520Manual%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01578">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45456"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01578">10.1021/acs.jmedchem.6b01578</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Syntheses of the intermediates and <sup>1</sup>H and <sup>13</sup>C NMR spectra of <b>33</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_001.pdf">jm6b01578_si_001.pdf (2.57 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01578/suppl_file/jm6b01578_si_002.csv">jm6b01578_si_002.csv (2.61 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01578&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01578%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01578" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995806db1d3dbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
